<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td></td><td></td></tr>
<tr><td>Novartis AG (NVS) Q4 2025 Earnings Call February 4, 2026 8:00 AM EST<br><br>Company Participants<br><br>Sloan Simpson - Global Head of Investor Relations<br>Vasant Narasimhan - Chief Executive Officer<br>Harry Kirsch - Chief Financial Officer<br>Mukul Mehta<br><br>Conference Call Participants<br><br>Sachin Jain - BofA Securities, Research Division<br>Simon Baker - Rothschild & Co Redburn, Research Division<br>Matthew Weston - UBS Investment Bank, Research Division<br>Peter Verdult - BNP Paribas, Research Division<br>Steve Scala - TD Cowen, Research Division<br>Richard Vosser - JPMorgan Chase & Co, Research Division<br>Graham Glyn Parry - Citigroup Inc., Research Division<br>Seamus Fernandez - Guggenheim Securities, LLC, Research Division<br>James Gordon - Barclays Bank PLC, Research Division<br>Michael Leuchten - Jefferies LLC, Research Division<br>Thibault Boutherin - Morgan Stanley, Research Division<br>James Quigley - Goldman Sachs Group, Inc., Research Division<br><br>Presentation<br><br>Operator<br><br>Good morning and good afternoon, and welcome to the Novartis Q4 Full Year 2025 Results Release Conference Call and Live Webcast.</td><td>ë…¸ë°”í‹°ìŠ¤ AG (NVS) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 2ì›” 4ì¼ ì˜¤ì „ 8ì‹œ(ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>ìŠ¬ë¡  ì‹¬ìŠ¨ - ê¸€ë¡œë²Œ íˆ¬ìì ê´€ê³„ ì±…ì„ì<br>ë°”ì‚°íŠ¸ ë‚˜ë¼ì‹¬í•œ - ìµœê³ ê²½ì˜ì<br>í•´ë¦¬ í‚¤ë¥´ì‰¬ - ìµœê³ ì¬ë¬´ì±…ì„ì<br>ë¬´ì¿¨ ë©”íƒ€<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì—¬ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>ì‚¬ì¹œ ì œì¸ - BofA ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì‚¬ì´ë¨¼ ë² ì´ì»¤ - ë¡œìŠ¤ì°¨ì¼ë“œ ì•¤ ì½” ë ˆë“œë²ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë§¤íŠœ ì›¨ìŠ¤í„´ - UBS ì¸ë² ìŠ¤íŠ¸ë¨¼íŠ¸ ë±…í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í”¼í„° ë² ë¥´ë‘˜íŠ¸ - BNP íŒŒë¦¬ë°”, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìŠ¤í‹°ë¸Œ ìŠ¤ì¹¼ë¼ - TD ì½”ì›¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë¦¬ì²˜ë“œ ë³´ì„œ - JPëª¨ê±´ ì²´ì´ìŠ¤ ì•¤ ì½”, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ê·¸ë ˆì´ì—„ ê¸€ë¦° íŒ¨ë¦¬ - ì‹œí‹°ê·¸ë£¹, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì‹œë¬´ìŠ¤ í˜ë¥´ë‚œë°ìŠ¤ - êµ¬ê²í•˜ì„ ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì œì„ìŠ¤ ê³ ë“  - ë°”í´ë ˆì´ìŠ¤ ì€í–‰, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë§ˆì´í´ ë¡œì´íˆí… - ì œí”„ë¦¬ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í‹°ë³´ ë¶€í…Œë­ - ëª¨ê±´ ìŠ¤íƒ ë¦¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì œì„ìŠ¤ í€´ê¸€ë¦¬ - ê³¨ë“œë§Œ ì‚­ìŠ¤ ê·¸ë£¹, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ë…¸ë°”í‹°ìŠ¤ 2025ë…„ ì—°ê°„ ë° 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ ë° ë¼ì´ë¸Œ ì›¹ìºìŠ¤íŠ¸ì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>[Operator Instructions] The conference is being recorded. A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends. With that, I would like to hand over to Ms. Sloan Simpson, Head of Investor Relations. Please go ahead, madam. Sloan Simpson<br>Global Head of Investor Relations<br><br>Thank you, Sarah. Good morning and good afternoon, everyone, and welcome to our Q4 2025 Earnings Call. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors.</td><td>[ì§„í–‰ì ì•ˆë‚´] ì»¨í¼ëŸ°ìŠ¤ê°€ ë…¹ìŒë˜ê³  ìˆìŠµë‹ˆë‹¤. Q&A ì„¸ì…˜ì„ í¬í•¨í•œ ì»¨í¼ëŸ°ìŠ¤ ì½œ ë…¹ìŒë³¸ì€ í†µí™” ì¢…ë£Œ ì§í›„ ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ì´ì‚¬ì´ì‹  ìŠ¬ë¡  ì‹¬ìŠ¨ ë‹˜ê»˜ ì§„í–‰ì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ë§ì”€í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ìŠ¬ë¡  ì‹¬ìŠ¨<br>ê¸€ë¡œë²Œ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ì´ì‚¬<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì‚¬ë¼. ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œë˜ëŠ” ì •ë³´ì—ëŠ” ì•Œë ¤ì§„ ìœ„í—˜ê³¼ ì•Œë ¤ì§€ì§€ ì•Šì€ ìœ„í—˜, ë¶ˆí™•ì‹¤ì„± ë° ê¸°íƒ€ ìš”ì¸ë“¤ì„ ìˆ˜ë°˜í•˜ëŠ” ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Please refer to the company's Form 20-F on file with the U.S. Securities and Exchange Commission for a description of some of these factors. The discussion today is not a solicitation of a proxy nor an offer of any kind with respect to the securities of Avidity Biosciences or SpinCo. The parties have filed relevant documents with the U.S. SEC, including a proxy statement for the transactions and a registration statement for the spinoff. We urge you to read these materials that contain important information when they become available.</td><td>ì´ëŸ¬í•œ ì§„ìˆ ë“¤ì€ ì‹¤ì œ ê²°ê³¼ê°€ ëª…ì‹œì  ë˜ëŠ” ë¬µì‹œì ìœ¼ë¡œ í‘œí˜„ëœ ë¯¸ë˜ì˜ ê²°ê³¼, ì„±ê³¼ ë˜ëŠ” ì„±ì·¨ì™€ ì‹¤ì§ˆì ìœ¼ë¡œ ë‹¤ë¥¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì¸ë“¤ì— ëŒ€í•œ ì„¤ëª…ì€ ë¯¸êµ­ ì¦ê¶Œê±°ë˜ìœ„ì›íšŒ(SEC)ì— ì œì¶œëœ íšŒì‚¬ì˜ Form 20-Fë¥¼ ì°¸ì¡°í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤. ì˜¤ëŠ˜ì˜ ë…¼ì˜ëŠ” ìœ„ì„ì¥ ê¶Œìœ ë‚˜ Avidity Biosciences ë˜ëŠ” SpinCoì˜ ì¦ê¶Œê³¼ ê´€ë ¨ëœ ì–´ë– í•œ ì¢…ë¥˜ì˜ ì œì•ˆë„ ì•„ë‹™ë‹ˆë‹¤. ë‹¹ì‚¬ìë“¤ì€ ê±°ë˜ì— ëŒ€í•œ ìœ„ì„ì¥ ì„¤ëª…ì„œì™€ ë¶„í• ìƒì¥ì— ëŒ€í•œ ë“±ë¡ì‹ ê³ ì„œë¥¼ í¬í•¨í•œ ê´€ë ¨ ë¬¸ì„œë“¤ì„ ë¯¸êµ­ SECì— ì œì¶œí–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìë£Œë“¤ì´ ê³µê°œë˜ë©´ ì¤‘ìš”í•œ ì •ë³´ê°€ í¬í•¨ë˜ì–´ ìˆìœ¼ë¯€ë¡œ ë°˜ë“œì‹œ ì½ì–´ë³´ì‹œê¸°ë¥¼ ê¶Œê³ ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Before we get started, I also want to remind our analysts to please limit yourselves to one question at a time, and we'll cycle through the queue as needed. And with that, I will hand over to Vas. Vasant Narasimhan<br>Chief Executive Officer<br><br>Terrific. Thank you, Sloan, and great to be with everyone today. With me in the room are Harry Kirsch, our Chief Financial Officer; and Mukul Mehta, our Chief Financial Officer, Designate, who will be taking over for Harry in mid-March. So let's dive into the results. And when we start on Slide 5, Novartis delivered high single-digit growth, as you saw earlier this morning. And importantly, we achieved our 40% core margin goal 2 years ahead of plan.</td><td>ì‹œì‘í•˜ê¸° ì „ì—, ì• ë„ë¦¬ìŠ¤íŠ¸ ì—¬ëŸ¬ë¶„ê»˜ì„œëŠ” í•œ ë²ˆì— í•œ ê°€ì§€ ì§ˆë¬¸ë§Œ í•´ì£¼ì‹œê¸° ë°”ë¼ë©°, í•„ìš”ì— ë”°ë¼ ì§ˆë¬¸ ìˆœì„œë¥¼ ìˆœí™˜í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ë°”ìŠ¤(Vas)ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ë°”ì‚°íŠ¸ ë‚˜ë¼ì‹¬í•œ(Vasant Narasimhan)<br>ìµœê³ ê²½ì˜ì<br><br>ì¢‹ìŠµë‹ˆë‹¤. ìŠ¬ë¡ (Sloan), ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì—¬ëŸ¬ë¶„ê³¼ í•¨ê»˜í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ì €ì™€ í•¨ê»˜ í•´ë¦¬ ì»¤ì‰¬(Harry Kirsch) ìµœê³ ì¬ë¬´ì±…ì„ìì™€ 3ì›” ì¤‘ìˆœì— í•´ë¦¬ì˜ ì—…ë¬´ë¥¼ ì¸ìˆ˜ë°›ì„ ì˜ˆì •ì¸ ë¬´ì¿¨ ë©”íƒ€(Mukul Mehta) ìµœê³ ì¬ë¬´ì±…ì„ì ì§€ëª…ìê°€ ìë¦¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ê·¸ëŸ¼ ì‹¤ì  ë‚´ìš©ìœ¼ë¡œ ë“¤ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 5í˜ì´ì§€ë¥¼ ë³´ì‹œë©´, ë…¸ë°”í‹°ìŠ¤ëŠ” ì˜¤ëŠ˜ ì•„ì¹¨ ì¼ì° ë°œí‘œí•˜ì‹  ê²ƒì²˜ëŸ¼ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¤‘ìš”í•œ ì ì€, ìš°ë¦¬ê°€ ê³„íšë³´ë‹¤ 2ë…„ ì•ë‹¹ê²¨ í•µì‹¬ ë§ˆì§„(core margin) 40% ëª©í‘œë¥¼ ë‹¬ì„±í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And I think that demonstrates the strong operational performance of the company. On the full year, our sales were up 8%. Core OpInc was up 14%, as I mentioned, the 40.1% core margin, $21.9 billion now on Core OpInc. I think significant growth over the years. On quarter 4, sales did decline impacted by both the gross to net, which we'll talk about a bit more as well as the Entresto LOE and Core OpInc is up 1%. We did have some important pipeline highlights, which we'll cover over the course of the call, but I think a few I wanted to highlight upfront.</td><td>ì´ëŠ” íšŒì‚¬ì˜ ê°•ë ¥í•œ ì˜ì—… ì‹¤ì ì„ ë³´ì—¬ì£¼ëŠ” ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ë§¤ì¶œì€ 8% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. í•µì‹¬ ì˜ì—…ì´ìµ(Core OpInc)ì€ ì œê°€ ì–¸ê¸‰í•œ ëŒ€ë¡œ 14% ì¦ê°€í–ˆìœ¼ë©°, í•µì‹¬ ë§ˆì§„ì€ 40.1%, í•µì‹¬ ì˜ì—…ì´ìµì€ 219ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ìˆ˜ë…„ê°„ ìƒë‹¹í•œ ì„±ì¥ì„ ì´ë¤„ì™”ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. 4ë¶„ê¸°ì—ëŠ” ë§¤ì¶œì´ ê°ì†Œí–ˆëŠ”ë°, ì´ëŠ” ì´ì•¡ ëŒ€ë¹„ ìˆœì•¡(gross to net) ì˜í–¥ê³¼ ì—”íŠ¸ë ˆìŠ¤í† (Entresto) íŠ¹í—ˆë§Œë£Œ(LOE) ë•Œë¬¸ì´ë©°, ì´ì— ëŒ€í•´ì„œëŠ” ì¡°ê¸ˆ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í•µì‹¬ ì˜ì—…ì´ìµì€ 1% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ëª‡ ê°€ì§€ ì¤‘ìš”í•œ íŒŒì´í”„ë¼ì¸ í•˜ì´ë¼ì´íŠ¸ê°€ ìˆì—ˆëŠ”ë°, ì´ëŠ” í†µí™” ê³¼ì •ì—ì„œ ë‹¤ë£¨ê² ì§€ë§Œ, ëª‡ ê°€ì§€ëŠ” ë¯¸ë¦¬ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>First, remibrutinib, we achieved the submission in the most common type of CIndU that was based on positive Phase III results as well as interactions with the FDA. And we'll have the remaining readouts for the 2 other subtypes of chronic inducible urticaria over the first half of this year. And with pelabresib, we now have a path forward for both the EU and the U.S. I'll go through that data and the path forward on a future slide. So overall, we met our upgraded full year 2025 guidance. We expect to grow in 2026 through the largest patent expiry in Novartis' history, which I think demonstrates the strong performance we have on our key growth brands as well as our pipeline replacement power.</td><td>ë¨¼ì € ë ˆë¯¸ë¸Œë£¨í‹°ë‹™ì˜ ê²½ìš°, ê¸ì •ì ì¸ 3ìƒ ì„ìƒ ê²°ê³¼ì™€ FDAì™€ì˜ í˜‘ì˜ë¥¼ ë°”íƒ•ìœ¼ë¡œ ê°€ì¥ í”í•œ ìœ í˜•ì˜ ë§Œì„±ìœ ë„ë‘ë“œëŸ¬ê¸°(CIndU)ì— ëŒ€í•œ ì‹ ì²­ì„ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¬í•´ ìƒë°˜ê¸° ì¤‘ ë§Œì„±ìœ ë„ë‘ë“œëŸ¬ê¸°ì˜ ë‚˜ë¨¸ì§€ 2ê°€ì§€ í•˜ìœ„ ìœ í˜•ì— ëŒ€í•œ ê²°ê³¼ë¥¼ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤. í ë¼ë¸Œë ˆì‹­ì˜ ê²½ìš°, ì´ì œ EUì™€ ë¯¸êµ­ ëª¨ë‘ì—ì„œ ì§„í–‰í•  ìˆ˜ ìˆëŠ” ê²½ë¡œë¥¼ í™•ë³´í–ˆìŠµë‹ˆë‹¤. í•´ë‹¹ ë°ì´í„°ì™€ í–¥í›„ ê³„íšì— ëŒ€í•´ì„œëŠ” ë‹¤ìŒ ìŠ¬ë¼ì´ë“œì—ì„œ ìì„¸íˆ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” ìƒí–¥ ì¡°ì •ëœ 2025ë…„ ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë…¸ë°”í‹°ìŠ¤ ì—­ì‚¬ìƒ ìµœëŒ€ ê·œëª¨ì˜ íŠ¹í—ˆ ë§Œë£Œë¥¼ ë§ì´í•˜ëŠ” 2026ë…„ì—ë„ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ”ë°, ì´ëŠ” ìš°ë¦¬ì˜ ì£¼ìš” ì„±ì¥ ë¸Œëœë“œë“¤ì˜ ê°•ë ¥í•œ ì‹¤ì ê³¼ íŒŒì´í”„ë¼ì¸ ëŒ€ì²´ ëŠ¥ë ¥ì„ ì˜ ë³´ì—¬ì¤€ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Now moving to Slide 6. The growth drivers in the quarter continued their strong trajectory as well as on the full year. Here, you see the full year numbers. You can see Kisqali was up 57% on the full year. Kesimpta was up 36%. Scemblix up 85%; Pluvicto on the PSMAfore launch, having dynamic growth as well. We'll talk about each of these brands in turn. Overall, a 35% growth in this portfolio, and this is a portfolio that will carry us through the end of the decade as well with many of these brands taking us into the mid-2030s. Now moving to Slide 7. On Kisqali, we grew 57% in the quarter -- on the year to $4.8 billion, outpacing the market for CDK4/6.</td><td>ì´ì œ ìŠ¬ë¼ì´ë“œ 6ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë¶„ê¸°ì™€ ì—°ê°„ ëª¨ë‘ì—ì„œ ì„±ì¥ ë™ë ¥ë“¤ì´ ê°•ë ¥í•œ ê¶¤ì ì„ ì´ì–´ê°”ìŠµë‹ˆë‹¤. ì—¬ê¸° ë³´ì‹œëŠ” ê²ƒì€ ì—°ê°„ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. KisqaliëŠ” ì—°ê°„ ê¸°ì¤€ 57% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. KesimptaëŠ” 36% ì¦ê°€í–ˆê³ , ScemblixëŠ” 85% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. PSMAfore ì¶œì‹œ ì´í›„ Pluvictoë„ ì—­ë™ì ì¸ ì„±ì¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê° ë¸Œëœë“œì— ëŒ€í•´ì„œëŠ” ì°¨ë¡€ë¡œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì „ì²´ì ìœ¼ë¡œ ì´ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” 35% ì„±ì¥í–ˆìœ¼ë©°, ì´ëŠ” 2030ë…„ëŒ€ ì¤‘ë°˜ê¹Œì§€ ì´ì–´ì§ˆ ë§ì€ ë¸Œëœë“œë“¤ê³¼ í•¨ê»˜ ìš°ë¦¬ë¥¼ ì´ë²ˆ 10ë…„ëŒ€ ë§ê¹Œì§€ ì´ëŒì–´ê°ˆ í¬íŠ¸í´ë¦¬ì˜¤ì…ë‹ˆë‹¤.<br><br>ì´ì œ ìŠ¬ë¼ì´ë“œ 7ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. KisqaliëŠ” ì—°ê°„ ê¸°ì¤€ 57% ì„±ì¥í•˜ì—¬ 48ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, CDK4/6 ì‹œì¥ ì„±ì¥ë¥ ì„ ìƒíšŒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Now when you look at the chart on the lower left, our growth was 44% in Q4. When you remove the U.S. RD adjustments, our global sales grew at 54% and our U.S. sales growth was at 62%. So in our view versus the consensus, the entire miss really came from these onetime RD adjustments. We remain fully confident on the $10 billion peak sales outlook for the brand. And what's underpinning that confidence is the very strong volume growth we're seeing across geographies. When you look at the middle panel, U.S. eBC NBRx is now above 60% and holding steady. I think that really demonstrates the strong preference providers have for Kisqali, particularly in settings where we are uniquely positioned.</td><td>ì´ì œ ì™¼ìª½ í•˜ë‹¨ì˜ ì°¨íŠ¸ë¥¼ ë³´ì‹œë©´, 4ë¶„ê¸° ì„±ì¥ë¥ ì€ 44%ì˜€ìŠµë‹ˆë‹¤. ë¯¸êµ­ RD(Research & Development, ì—°êµ¬ê°œë°œ) ì¡°ì •ë¶„ì„ ì œì™¸í•˜ë©´, ê¸€ë¡œë²Œ ë§¤ì¶œì€ 54% ì„±ì¥í–ˆê³  ë¯¸êµ­ ë§¤ì¶œ ì„±ì¥ë¥ ì€ 62%ì˜€ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ê°€ ë³´ê¸°ì— ì»¨ì„¼ì„œìŠ¤ ëŒ€ë¹„ ë¯¸ë‹¬ë¶„ì€ ì „ì ìœ¼ë¡œ ì´ëŸ¬í•œ ì¼íšŒì„± RD ì¡°ì •ì—ì„œ ë¹„ë¡¯ëœ ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ ë¸Œëœë“œì˜ í”¼í¬ ë§¤ì¶œ 100ì–µ ë‹¬ëŸ¬ ì „ë§ì— ëŒ€í•´ ì—¬ì „íˆ í™•ì‹ ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í™•ì‹ ì˜ ê·¼ê±°ëŠ” ì „ ì§€ì—­ì—ì„œ ë‚˜íƒ€ë‚˜ê³  ìˆëŠ” ë§¤ìš° ê°•ë ¥í•œ ë¬¼ëŸ‰ ì„±ì¥ì…ë‹ˆë‹¤. ì¤‘ê°„ íŒ¨ë„ì„ ë³´ì‹œë©´, ë¯¸êµ­ eBC(early Breast Cancer, ì¡°ê¸° ìœ ë°©ì•”) NBRx(New-to-Brand Prescriptions, ì‹ ê·œ ë¸Œëœë“œ ì²˜ë°©)ê°€ í˜„ì¬ 60%ë¥¼ ìƒíšŒí•˜ë©° ì•ˆì •ì ìœ¼ë¡œ ìœ ì§€ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” íŠ¹íˆ ì €í¬ê°€ ë…ë³´ì ì¸ ìœ„ì¹˜ë¥¼ ì°¨ì§€í•˜ê³  ìˆëŠ” ì¹˜ë£Œ í™˜ê²½ì—ì„œ ì˜ë£Œì§„ë“¤ì´ Kisqaliì— ëŒ€í•´ ê°–ê³  ìˆëŠ” ê°•ë ¥í•œ ì„ í˜¸ë„ë¥¼ ë³´ì—¬ì¤€ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And in Germany, we have over 80% NBRx share in the early breast cancer setting, which I think shows again this early strong performance for the launch in Germany, which we hope to carry over now to other ex U.S. markets. So going to the last panel, I already went through many of the key elements, but I think I wanted to also note that eBC NBRx share is leading in both the overlapping and the exclusive population. Outside of the U.S., we have important launches in Italy and Spain coming up in 2026. And finally, we continue to bolster the data profile for Kisqali, both with data that we recently presented at San Antonio and ESMO.</td><td>ë…ì¼ì—ì„œëŠ” ì¡°ê¸° ìœ ë°©ì•” í™˜ê²½ì—ì„œ 80% ì´ìƒì˜ ì‹ ê·œì²˜ë°© ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ë…ì¼ ì¶œì‹œì˜ ì´ˆê¸° ê°•ë ¥í•œ ì„±ê³¼ë¥¼ ë‹¤ì‹œ í•œë²ˆ ë³´ì—¬ì£¼ëŠ” ê²ƒìœ¼ë¡œ, ì´ì œ ì´ë¥¼ ë¯¸êµ­ ì™¸ ë‹¤ë¥¸ ì‹œì¥ìœ¼ë¡œë„ í™•ëŒ€í•´ ë‚˜ê°€ê¸°ë¥¼ í¬ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ íŒ¨ë„ë¡œ ë„˜ì–´ê°€ì„œ, ì´ë¯¸ ë§ì€ í•µì‹¬ ìš”ì†Œë“¤ì„ ì„¤ëª…ë“œë ¸ì§€ë§Œ, ì¡°ê¸° ìœ ë°©ì•”ì—ì„œì˜ ì‹ ê·œì²˜ë°© ì ìœ ìœ¨ì´ ì¤‘ë³µ í™˜ìêµ°ê³¼ ë…ì  í™˜ìêµ° ëª¨ë‘ì—ì„œ ì„ ë„ì ì´ë¼ëŠ” ì ë„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” 2026ë…„ ì´íƒˆë¦¬ì•„ì™€ ìŠ¤í˜ì¸ì—ì„œ ì¤‘ìš”í•œ ì¶œì‹œê°€ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìµœê·¼ ìƒŒì•ˆí† ë‹ˆì˜¤ì™€ ESMOì—ì„œ ë°œí‘œí•œ ë°ì´í„°ë¥¼ í†µí•´ Kisqaliì˜ ë°ì´í„° í”„ë¡œíŒŒì¼ì„ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We'll continue to follow up these patients over the long run, and that should allow us to continue to have mature OS data over time, which we think will continue to bolster the portfolio. So very excited. Kisqali continues to be -- have the outlook to be the largest brand in Novartis' history. Now moving to Slide 8. Kesimpta grew 36% to $4.4 billion on the year. You can see the continued steady performance of this brand, driven by the continued expansion of the B-cell class within MS. In the U.S., we had 27% growth in quarter 4. Importantly, we see increasing adoption in naive patients, which are now 50% of our NBRx is now in first line.</td><td>ì´ í™˜ìë“¤ì„ ì¥ê¸°ì ìœ¼ë¡œ ê³„ì† ì¶”ì  ê´€ì°°í•  ê²ƒì´ë©°, ì´ë¥¼ í†µí•´ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ì„±ìˆ™í•œ OS(ì „ì²´ ìƒì¡´ìœ¨) ë°ì´í„°ë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ë³´í•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê³„ì†í•´ì„œ ê°•í™”í•  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ë§¤ìš° ê¸°ëŒ€ê°€ ë©ë‹ˆë‹¤. KisqaliëŠ” ë…¸ë°”í‹°ìŠ¤ ì—­ì‚¬ìƒ ìµœëŒ€ ê·œëª¨ì˜ ë¸Œëœë“œê°€ ë  ì „ë§ì„ ê³„ì† ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì´ì œ ìŠ¬ë¼ì´ë“œ 8ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. KesimptaëŠ” ì—°ê°„ 36% ì„±ì¥í•˜ì—¬ 44ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. MS(ë‹¤ë°œì„± ê²½í™”ì¦) ë‚´ì—ì„œ B-ì„¸í¬ ê³„ì—´ì˜ ì§€ì†ì ì¸ í™•ëŒ€ì— í˜ì…ì–´ ì´ ë¸Œëœë“œì˜ ê¾¸ì¤€í•œ ì„±ê³¼ê°€ ê³„ì†ë˜ê³  ìˆìŒì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œëŠ” 4ë¶„ê¸°ì— 27% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€ ì¹˜ë£Œ ê²½í—˜ì´ ì—†ëŠ” í™˜ìë“¤ì˜ ì±„íƒì´ ì¦ê°€í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì¸ë°, í˜„ì¬ ì‹ ê·œ ì²˜ë°©ì˜ 50%ê°€ 1ì°¨ ì¹˜ë£Œì—ì„œ ë°œìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Outside of the U.S., we are leading now with NBRx share in 9 out of the 10 of the major markets that we track. And the core opportunity we see ex U.S. going forward is to continue to expand B-cell therapies in the 67% of patients who are not on B-cell therapies and receiving disease-modifying therapies in MS. So we continue to generate additional value for Kesimpta. We continue to progress also our every 2-month formulation for Kesimpta. So I think we're on a solid track with this brand to fully achieve our peak sales guidance of $6 billion plus. Now moving to the next slide. Pluvicto now really showing dynamic performance with the PSMAfore launch, 42% constant currency growth.</td><td>ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” í˜„ì¬ ì €í¬ê°€ ì¶”ì í•˜ëŠ” 10ê°œ ì£¼ìš” ì‹œì¥ ì¤‘ 9ê°œ ì‹œì¥ì—ì„œ ì‹ ê·œ ì²˜ë°©(NBRx) ì ìœ ìœ¨ 1ìœ„ë¥¼ ê¸°ë¡í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ ì•ìœ¼ë¡œ ë³´ê³  ìˆëŠ” í•µì‹¬ ê¸°íšŒëŠ” ë‹¤ë°œì„±ê²½í™”ì¦(MS) ì§ˆí™˜ì¡°ì ˆì¹˜ë£Œë¥¼ ë°›ê³  ìˆì§€ë§Œ Bì„¸í¬ ì¹˜ë£Œì œë¥¼ ì‚¬ìš©í•˜ì§€ ì•ŠëŠ” 67%ì˜ í™˜ìë“¤ì—ê²Œ Bì„¸í¬ ì¹˜ë£Œì œë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì¼€ì‹¬íƒ€(Kesimpta)ì— ëŒ€í•œ ì¶”ê°€ ê°€ì¹˜ë¥¼ ê³„ì† ì°½ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì¼€ì‹¬íƒ€ì˜ 2ê°œì›”ë§ˆë‹¤ íˆ¬ì—¬í•˜ëŠ” ì œí˜• ê°œë°œë„ ê³„ì† ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ë¸Œëœë“œë¡œ 60ì–µ ë‹¬ëŸ¬ ì´ìƒì´ë¼ëŠ” ìµœê³  ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ë¥¼ ì™„ì „íˆ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” íƒ„íƒ„í•œ ê¶¤ë„ì— ì˜¬ë¼ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. <br><br>ì´ì œ ë‹¤ìŒ ìŠ¬ë¼ì´ë“œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. í”Œë£¨ë¹…í† (Pluvicto)ëŠ” ì´ì œ PSMAfore ì¶œì‹œì™€ í•¨ê»˜ ì •ë§ ì—­ë™ì ì¸ ì‹¤ì ì„ ë³´ì—¬ì£¼ê³  ìˆìœ¼ë©°, ê³ ì •í™˜ìœ¨ ê¸°ì¤€ 42% ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We reached $2 billion in sales now overall globally. And that strong performance was driven primarily in the U.S., where we continue to see strong uptake in the pre-taxane setting. Sales grew 75%. We saw a 4x increase in our PSMA share since approval, now reaching 16% in that setting. We also see continued growth on provider set, across provider settings, including the highest growth in community, where we now have over 790 treatment sites. Outside of the U.S., importantly, we've secured approvals in Japan and China, which also allowed us to continue to drive that ex U.S. strong growth. And we expect that growth to accelerate now with the Japan and China launches upcoming.</td><td>ì €í¬ëŠ” í˜„ì¬ ì „ ì„¸ê³„ì ìœ¼ë¡œ ë§¤ì¶œ 20ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê°•ë ¥í•œ ì‹¤ì ì€ ì£¼ë¡œ ë¯¸êµ­ì—ì„œ ì£¼ë„ë˜ì—ˆìœ¼ë©°, pre-taxane ì„¸íŒ…ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ì±„íƒë¥ ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë§¤ì¶œì€ 75% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ìŠ¹ì¸ ì´í›„ PSMA ì ìœ ìœ¨ì´ 4ë°° ì¦ê°€í•˜ì—¬ í˜„ì¬ í•´ë‹¹ ì„¸íŒ…ì—ì„œ 16%ì— ë„ë‹¬í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ì˜ë£Œê¸°ê´€ ì„¸íŒ… ì „ë°˜ì— ê±¸ì³ ì§€ì†ì ì¸ ì„±ì¥ì„ ë³´ê³  ìˆìœ¼ë©°, íŠ¹íˆ ì§€ì—­ì‚¬íšŒ(ì»¤ë®¤ë‹ˆí‹°) ë¶€ë¬¸ì—ì„œ ê°€ì¥ ë†’ì€ ì„±ì¥ì„ ë³´ì´ê³  ìˆëŠ”ë°, í˜„ì¬ 790ê°œ ì´ìƒì˜ ì¹˜ë£Œ ì‹œì„¤ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” ì¤‘ìš”í•˜ê²Œë„ ì¼ë³¸ê³¼ ì¤‘êµ­ì—ì„œ ìŠ¹ì¸ì„ í™•ë³´í–ˆìœ¼ë©°, ì´ë¥¼ í†µí•´ ë¯¸êµ­ ì™¸ ì§€ì—­ì˜ ê°•ë ¥í•œ ì„±ì¥ì„ ì§€ì†ì ìœ¼ë¡œ ê²¬ì¸í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í–¥í›„ ì¼ë³¸ê³¼ ì¤‘êµ­ ì¶œì‹œë¡œ ì¸í•´ ì´ëŸ¬í•œ ì„±ì¥ì´ ê°€ì†í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Now the next phase for Pluvicto as we expect to kind of get to the peak of the PSMAfore population over the course of this year will be the launch in the hormone-sensitive setting, which adds about 75% additional patients to the patients we already have from the VISION and PSMAfore population. That sNDA has been submitted to the FDA as well as the NMPA in China and PMDA in Japan. We have the right foundation for that launch to be, we think, a rapid uptake with 2/3 of eligible hormone-sensitive patients already with existing treaters or providers. So the capacity is well established.</td><td>ì´ì œ Pluvictoì˜ ë‹¤ìŒ ë‹¨ê³„ëŠ” ì˜¬í•´ ì¤‘ PSMAfore í™˜ìêµ°ì˜ ì •ì ì— ë„ë‹¬í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ê°€ìš´ë°, í˜¸ë¥´ëª¬ ë¯¼ê°ì„±(hormone-sensitive) ì ì‘ì¦ ì¶œì‹œê°€ ë  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ê¸°ì¡´ VISION ë° PSMAfore í™˜ìêµ°ì—ì„œ ì•½ 75%ì˜ ì¶”ê°€ í™˜ìë¥¼ ë”í•˜ê²Œ ë©ë‹ˆë‹¤. í•´ë‹¹ ì¶”ê°€ ì‹ ì•½ ìŠ¹ì¸ ì‹ ì²­ì„œ(sNDA)ëŠ” FDAëŠ” ë¬¼ë¡  ì¤‘êµ­ NMPAì™€ ì¼ë³¸ PMDAì— ì œì¶œëœ ìƒíƒœì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë²ˆ ì¶œì‹œê°€ ë¹ ë¥¸ ì‹œì¥ ì¹¨íˆ¬ë¥¼ ì´ë£° ìˆ˜ ìˆëŠ” ì ì ˆí•œ ê¸°ë°˜ì„ ê°–ì¶”ê³  ìˆë‹¤ê³  ìƒê°í•˜ëŠ”ë°, í˜¸ë¥´ëª¬ ë¯¼ê°ì„± ì ê²© í™˜ìì˜ 2/3ê°€ ì´ë¯¸ ê¸°ì¡´ ì¹˜ë£Œ ì˜ì‚¬ë‚˜ ì˜ë£Œ ì œê³µìì™€ ì—°ê²°ë˜ì–´ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì¹˜ë£Œ ì—­ëŸ‰ì€ ì´ë¯¸ ì˜ êµ¬ì¶•ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I did want to flag as well that we have new manufacturing sites that are coming online in California, in Florida as well as in Japan and China. We have over 440 treatment sites now outside of the U.S. as well. So we've really taken this to scale, which positions us well for the Pluvicto launches, ongoing Lutathera business as well as our future RLT portfolio. Now moving to Slide 10. Leqvio reached blockbuster status in the quarter, an important milestone for this brand as we continue that steady trajectory that we often see for cardiovascular launches, 57% growth on the full year, 46% on the quarter. In the U.S., we continue to outpace the overall advanced lipid lowering market.</td><td>ë˜í•œ ìº˜ë¦¬í¬ë‹ˆì•„, í”Œë¡œë¦¬ë‹¤, ì¼ë³¸, ì¤‘êµ­ì— ìƒˆë¡œìš´ ìƒì‚° ì‹œì„¤ì´ ê°€ë™ë˜ê³  ìˆë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. í˜„ì¬ ë¯¸êµ­ ì™¸ ì§€ì—­ì— 440ê°œ ì´ìƒì˜ ì¹˜ë£Œ ì‹œì„¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê·œëª¨ í™•ëŒ€ëŠ” Pluvicto ì¶œì‹œ, ì§€ì†ì ì¸ Lutathera ì‚¬ì—…, ê·¸ë¦¬ê³  í–¥í›„ RLT í¬íŠ¸í´ë¦¬ì˜¤ì— ìœ ë¦¬í•œ ì…ì§€ë¥¼ ì œê³µí•©ë‹ˆë‹¤. <br><br>ì´ì œ ìŠ¬ë¼ì´ë“œ 10ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. LeqvioëŠ” ì´ë²ˆ ë¶„ê¸°ì— ë¸”ë¡ë²„ìŠ¤í„° ì§€ìœ„ì— ë„ë‹¬í–ˆìœ¼ë©°, ì´ëŠ” ì‹¬í˜ˆê´€ ì œí’ˆ ì¶œì‹œì—ì„œ í”íˆ ë³¼ ìˆ˜ ìˆëŠ” ê¾¸ì¤€í•œ ì„±ì¥ ê¶¤ì ì„ ì´ì–´ê°€ëŠ” ì´ ë¸Œëœë“œì— ìˆì–´ ì¤‘ìš”í•œ ì´ì •í‘œì…ë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ 57% ì„±ì¥, ë¶„ê¸° ê¸°ì¤€ 46% ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œëŠ” ì „ì²´ ê³ ê¸‰ ì§€ì§ˆ ì €í•˜ì œ ì‹œì¥ì„ ì§€ì†ì ìœ¼ë¡œ ì•ì„œê°€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And our real focus is increasing depth in the health systems we prioritize where there's strong capabilities within the buy-and-bill setting, strong interest in getting patients to goal, also focusing more on specialty areas as we've guided in the past. We saw a 33% growth in the setting versus the prior year. Now a key milestone for us outside of the U.S. will be the NRDL listing, which we achieved in China and is now already now started in the first part of January. As you have heard on previous calls, we have had very strong uptake in China in the private setting. And now with the NRDL listing, the early signals are very strong for a rapid uptake in the China market for Leqvio.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ì˜ ì‹¤ì§ˆì ì¸ ì´ˆì ì€ buy-and-bill í™˜ê²½ ë‚´ì—ì„œ ê°•ë ¥í•œ ì—­ëŸ‰ì„ ê°–ì¶”ê³  ìˆê³ , í™˜ìë“¤ì„ ëª©í‘œì¹˜ì— ë„ë‹¬ì‹œí‚¤ëŠ” ë° ê°•í•œ ê´€ì‹¬ì„ ë³´ì´ëŠ” ìš°ì„ ìˆœìœ„ ì˜ë£Œ ì‹œìŠ¤í…œì—ì„œì˜ ì¹¨íˆ¬ë„ë¥¼ ë†’ì´ëŠ” ê²ƒì´ë©°, ê³¼ê±° ê°€ì´ë˜ìŠ¤ì—ì„œ ë°íŒ ë°”ì™€ ê°™ì´ ì „ë¬¸ ì˜ì—­ì— ë”ìš± ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” í•´ë‹¹ ì˜ì—­ì—ì„œ ì „ë…„ ëŒ€ë¹„ 33% ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ ìš°ë¦¬ì˜ ì£¼ìš” ì´ì •í‘œëŠ” ì¤‘êµ­ì—ì„œ ë‹¬ì„±í•œ NRDL(êµ­ê°€ì˜ì•½í’ˆëª©ë¡) ë“±ì¬ê°€ ë  ê²ƒì´ë©°, ì´ëŠ” ì´ë¯¸ 1ì›” ì´ˆë¶€í„° ì‹œì‘ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ì „ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ë“¤ìœ¼ì…¨ë“¯ì´, ìš°ë¦¬ëŠ” ì¤‘êµ­ ë¯¼ê°„ ë¶€ë¬¸ì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì±„íƒë¥ ì„ ë³´ì—¬ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ NRDL ë“±ì¬ì™€ í•¨ê»˜, ì¤‘êµ­ ì‹œì¥ì—ì„œ Leqvioì˜ ë¹ ë¥¸ ì±„íƒì— ëŒ€í•œ ì´ˆê¸° ì‹ í˜¸ê°€ ë§¤ìš° ê°•ë ¥í•˜ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So we're quite excited about that, and it's a key focus area for us in 2026. We continue to build the evidence base for Leqvio, important publications in various journals, mostly focused on adherence rates as well as our ability to drive LDL-C down to goal regardless of which background therapy patients are on. Now moving to Slide 11. Scemblix had another strong quarter. We've reached again blockbuster status with this brand, and we have NBRx leadership in the U.S. and Japan. 87% growth in Q4. Now if I could focus your attention on the middle panel in the U.S., we've reached 41% NBRx share now across all lines of therapy, and we plan to continue to grow that.</td><td>ì´ì— ëŒ€í•´ ìš°í¬ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, 2026ë…„ í•µì‹¬ ì§‘ì¤‘ ì˜ì—­ì…ë‹ˆë‹¤. Leqvioì— ëŒ€í•œ ê·¼ê±° ê¸°ë°˜ì„ ê³„ì† êµ¬ì¶•í•˜ê³  ìˆìœ¼ë©°, ì£¼ë¡œ ìˆœì‘ë„ì™€ í™˜ìê°€ ì–´ë–¤ ê¸°ì € ì¹˜ë£Œë¥¼ ë°›ê³  ìˆë“  ê´€ê³„ì—†ì´ LDL-Cë¥¼ ëª©í‘œì¹˜ê¹Œì§€ ë‚®ì¶œ ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì— ì´ˆì ì„ ë§ì¶˜ ì¤‘ìš”í•œ ë…¼ë¬¸ë“¤ì´ ì—¬ëŸ¬ í•™ìˆ ì§€ì— ê²Œì¬ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 11ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ScemblixëŠ” ë˜ í•œ ë²ˆ ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ ì œí’ˆìœ¼ë¡œ ë‹¤ì‹œ ë¸”ë¡ë²„ìŠ¤í„° ì§€ìœ„ì— ë„ë‹¬í–ˆìœ¼ë©°, ë¯¸êµ­ê³¼ ì¼ë³¸ì—ì„œ ì‹ ê·œ ì²˜ë°©(NBRx) ì„ ë‘ë¥¼ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— 87% ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì¤‘ê°„ íŒ¨ë„ì˜ ë¯¸êµ­ ì‹œì¥ì— ì£¼ëª©í•´ ì£¼ì‹œë©´, í˜„ì¬ ì „ì²´ ì¹˜ë£Œ ë¼ì¸ì—ì„œ 41%ì˜ ì‹ ê·œ ì²˜ë°© ì ìœ ìœ¨ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ë¥¼ ê³„ì† í™•ëŒ€í•  ê³„íšì…ë‹ˆë‹¤.</td></tr>
<tr><td>But the most important thing for us now is to drive the growth in the first-line setting where we're trending ahead of our plan. We're already now in the mid-20% range in the frontline setting. We want to drive that up. And I think as we get -- as we've now secured broad access, we have the opportunity now to continue to make Scemblix the medicine of choice on the front line for patients with TML. And now outside of the U.S., we also continue to have our leadership in the third-line setting with 72% share across the major markets that we track.</td><td>í•˜ì§€ë§Œ í˜„ì¬ ìš°ë¦¬ì—ê²Œ ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ 1ì°¨ ì¹˜ë£Œ í™˜ê²½ì—ì„œì˜ ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ê²ƒì´ë©°, ì´ëŠ” ìš°ë¦¬ì˜ ê³„íšë³´ë‹¤ ì•ì„œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë¯¸ 1ì°¨ ì¹˜ë£Œ í™˜ê²½ì—ì„œ 20% ì¤‘ë°˜ëŒ€ì˜ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë¥¼ ë”ìš± ëŒì–´ì˜¬ë¦¬ê³ ì í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ ê´‘ë²”ìœ„í•œ ì ‘ê·¼ì„±ì„ í™•ë³´í–ˆê¸° ë•Œë¬¸ì—, TML í™˜ìë“¤ì„ ìœ„í•œ 1ì°¨ ì¹˜ë£Œì œë¡œì„œ Scemblixë¥¼ ì„ íƒë°›ëŠ” ì•½ë¬¼ë¡œ ê³„ì† ë§Œë“¤ì–´ê°ˆ ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê°–ê²Œ ë˜ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë˜í•œ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œë„ ìš°ë¦¬ê°€ ì¶”ì í•˜ëŠ” ì£¼ìš” ì‹œì¥ì—ì„œ 72%ì˜ ì ìœ ìœ¨ë¡œ 3ì°¨ ì¹˜ë£Œ í™˜ê²½ì—ì„œì˜ ë¦¬ë”ì‹­ì„ ê³„ì† ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The early line indication is now approved in 60 countries, and we've already just launched in Germany, and we expect to get other EU markets online in the front line with launches expected in 2027. I think one ex U.S. market to note, which I think shows the ability we have to drive Scemblix outside of the U.S. is in Japan, where we already have 45% frontline market share -- NBRx share and 74% second-line NBRx share. So really strong outlook, confident in the $4 billion-plus outlook for this medicine. Now moving to Slide 12. Cosentyx grew 8% overall in the year, getting to $6.7 billion on the steady march up to our $8 billion peak sales guidance. You can see the 11% growth on the quarter.</td><td>1ì°¨ ì¹˜ë£Œ ì ì‘ì¦ì€ í˜„ì¬ 60ê°œêµ­ì—ì„œ ìŠ¹ì¸ë˜ì—ˆìœ¼ë©°, ë…ì¼ì—ì„œ ì´ë¯¸ ì¶œì‹œí–ˆê³ , 2027ë…„ ì¶œì‹œ ì˜ˆì •ìœ¼ë¡œ ë‹¤ë¥¸ EU ì‹œì¥ì—ì„œë„ 1ì°¨ ì¹˜ë£Œì œë¡œ ì§„ì…í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì™¸ ì‹œì¥ ì¤‘ ì£¼ëª©í•  ë§Œí•œ ê³³ì€ ì¼ë³¸ì¸ë°, ì´ëŠ” ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ Scemblixë¥¼ ì„±ì¥ì‹œí‚¬ ìˆ˜ ìˆëŠ” ìš°ë¦¬ì˜ ì—­ëŸ‰ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ì¼ë³¸ì—ì„œëŠ” ì´ë¯¸ 1ì°¨ ì¹˜ë£Œ ì‹œì¥ì ìœ ìœ¨(ì‹ ê·œì²˜ë°© ê¸°ì¤€) 45%, 2ì°¨ ì¹˜ë£Œ ì‹ ê·œì²˜ë°© ì ìœ ìœ¨ 74%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ì˜ì•½í’ˆì— ëŒ€í•œ 40ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ì „ë§ì— ëŒ€í•´ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì´ì œ ìŠ¬ë¼ì´ë“œ 12ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. CosentyxëŠ” ì—°ê°„ 8% ì„±ì¥í•˜ì—¬ 67ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ìµœê³  ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ì¸ 80ì–µ ë‹¬ëŸ¬ë¥¼ í–¥í•´ ê¾¸ì¤€íˆ ë‚˜ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. ë¶„ê¸° ê¸°ì¤€ìœ¼ë¡œëŠ” 11% ì„±ì¥í•œ ê²ƒì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In the U.S., we had 9% growth. That was driven by higher demand we saw both in hidradenitis and in IV. Right now, we're the #1 prescribed IL-17 across indications, and that's really because of the strong access that we have frontline access. In HS now, we are the NBRx leader in naive patients with 51% share and 47% overall. And the naive market is 2.5x the switch market. Certainly, we've seen our competitor get traction in the switch market, but we're very much focused on that naive market where we have a really strong position. And the IV is also steadily advancing 8% a steady growth, 200 new accounts, and we expect that to continue over the coming years.</td><td>ë¯¸êµ­ì—ì„œëŠ” 9% ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” í™”ë†ì„± í•œì„ ì—¼(HS)ê³¼ í¬ë„ë§‰ì—¼(IV) ëª¨ë‘ì—ì„œ ë†’ì€ ìˆ˜ìš”ë¥¼ ë³´ì˜€ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ëŠ” ëª¨ë“  ì ì‘ì¦ì—ì„œ ê°€ì¥ ë§ì´ ì²˜ë°©ë˜ëŠ” IL-17 ì œì œ 1ìœ„ì´ë©°, ì´ëŠ” ìš°ë¦¬ê°€ ë³´ìœ í•œ ê°•ë ¥í•œ 1ì°¨ ì¹˜ë£Œì œ ì ‘ê·¼ì„± ë•ë¶„ì…ë‹ˆë‹¤. í™”ë†ì„± í•œì„ ì—¼ì—ì„œ ìš°ë¦¬ëŠ” ì¹˜ë£Œ ê²½í—˜ì´ ì—†ëŠ” í™˜ìë“¤ì˜ ì‹ ê·œ ì²˜ë°©(NBRx)ì—ì„œ 51%ì˜ ì ìœ ìœ¨ë¡œ ì„ ë‘ë¥¼ ë‹¬ë¦¬ê³  ìˆìœ¼ë©°, ì „ì²´ì ìœ¼ë¡œëŠ” 47%ë¥¼ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¹˜ë£Œ ê²½í—˜ì´ ì—†ëŠ” ì‹œì¥ì€ ì•½ì œ ì „í™˜ ì‹œì¥ì˜ 2.5ë°° ê·œëª¨ì…ë‹ˆë‹¤. ë¬¼ë¡  ê²½ìŸì‚¬ê°€ ì•½ì œ ì „í™˜ ì‹œì¥ì—ì„œ ê²¬ì¸ë ¥ì„ ì–»ê³  ìˆëŠ” ê²ƒì„ í™•ì¸í–ˆì§€ë§Œ, ìš°ë¦¬ëŠ” ê°•ë ¥í•œ ì…ì§€ë¥¼ ê°€ì§„ ì¹˜ë£Œ ê²½í—˜ì´ ì—†ëŠ” í™˜ì ì‹œì¥ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. í¬ë„ë§‰ì—¼ë„ 8%ì˜ ê¾¸ì¤€í•œ ì„±ì¥ìœ¼ë¡œ ì•ˆì •ì ìœ¼ë¡œ ë°œì „í•˜ê³  ìˆìœ¼ë©°, 200ê°œì˜ ì‹ ê·œ ê±°ë˜ì²˜ë¥¼ í™•ë³´í–ˆê³ , í–¥í›„ ëª‡ ë…„ê°„ ì´ëŸ¬í•œ ì„±ì¥ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Outside of the U.S., no major changes, continued very strong growth, leading originator biologics in the EU and China. And overall, we would forecast Cosentyx to have, on average, mid-single-digit growth over the coming years as we get to that $8 billion peak sales potential. I did want to also flag that we have completed the submission with the U.S. FDA for polymyalgia rheumatica. And so we're excited about that as an additional launch now for Cosentyx. And we've also are on track. We're also on track to file in the EU and Japan in the first half. So moving to Slide 13. Our renal portfolio has continued its rollout, I think, with steady progress.</td><td>ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” í° ë³€í™” ì—†ì´ ì§€ì†ì ìœ¼ë¡œ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, EUì™€ ì¤‘êµ­ì—ì„œ ì„ ë„ì ì¸ ë°”ì´ì˜¤ì˜ì•½í’ˆ ì˜¤ë¦¬ì§€ë„¤ì´í„°ë¡œ ìë¦¬ë§¤ê¹€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” Cosentyxê°€ 80ì–µ ë‹¬ëŸ¬ì˜ í”¼í¬ ë§¤ì¶œ ì ì¬ë ¥ì— ë„ë‹¬í•˜ëŠ” ê³¼ì •ì—ì„œ í–¥í›„ ìˆ˜ë…„ê°„ í‰ê· ì ìœ¼ë¡œ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í•  ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë‹¤ë°œì„±ê·¼ìœ¡í†µ(polymyalgia rheumatica)ì— ëŒ€í•œ ë¯¸êµ­ FDA ì œì¶œì„ ì™„ë£Œí–ˆë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” Cosentyxì˜ ì¶”ê°€ ì ì‘ì¦ ì¶œì‹œì— ëŒ€í•´ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ìˆœì¡°ë¡­ê²Œ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. EUì™€ ì¼ë³¸ì—ì„œë„ ìƒë°˜ê¸° ì¤‘ ì‹ ì²­ì„ ì§„í–‰í•  ì˜ˆì •ì…ë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 13ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ì‹ ì¥ì§ˆí™˜ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ê¾¸ì¤€í•œ ì§„ì „ì„ ë³´ì´ë©° ì¶œì‹œë¥¼ ì§€ì†í•´ì™”ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And separate from that, we also have amended our zigakibart Phase III protocol, which I wanted to talk about in a bit more detail. Starting with our renal portfolio, our IgAN portfolio contributed 50% of the NBRx market growth versus prior year, driven equally by Vanrafia and Fabhalta. So I think we see steady uptake across these 2 brands. Also in C3G, also continued steady adoption across the top accounts. So we hope to see that accelerate now over the course of 2026. And outside of the U.S., Fabhalta is now approved in C3G in 45 countries. Vanrafia had its EU submission. So I think across these 3 brands, we have the opportunity to continue to build out a strong position.</td><td>ê·¸ë¦¬ê³  ì´ì™€ ë³„ë„ë¡œ, ì €í¬ëŠ” ì§€ê°€í‚¤ë°”íŠ¸(zigakibart) 3ìƒ í”„ë¡œí† ì½œì„ ìˆ˜ì •í–ˆìœ¼ë©°, ì´ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤. ë¨¼ì € ì‹ ì¥ í¬íŠ¸í´ë¦¬ì˜¤ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì €í¬ IgAN í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ì „ë…„ ëŒ€ë¹„ NBRx(ì‹ ê·œ ì²˜ë°©) ì‹œì¥ ì„±ì¥ì˜ 50%ë¥¼ ê¸°ì—¬í–ˆìœ¼ë©°, ì´ëŠ” ë°˜ë¼í”¼ì•„(Vanrafia)ì™€ íŒŒë°œíƒ€(Fabhalta)ê°€ ë™ë“±í•˜ê²Œ ê²¬ì¸í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ë‘ ë¸Œëœë“œ ì „ë°˜ì— ê±¸ì³ ê¾¸ì¤€í•œ ì‹œì¥ ì¹¨íˆ¬ë¥¼ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ C3Gì—ì„œë„ ì£¼ìš” ê³„ì •ë“¤ì—ì„œ ì§€ì†ì ì´ê³  ê¾¸ì¤€í•œ ì±„íƒì´ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ 2026ë…„ ë™ì•ˆ ì´ëŸ¬í•œ ì¶”ì„¸ê°€ ê°€ì†í™”ë˜ê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” íŒŒë°œíƒ€ê°€ í˜„ì¬ 45ê°œêµ­ì—ì„œ C3G ì ì‘ì¦ìœ¼ë¡œ ìŠ¹ì¸ë˜ì—ˆìŠµë‹ˆë‹¤. ë°˜ë¼í”¼ì•„ëŠ” EU ì œì¶œì„ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ 3ê°œ ë¸Œëœë“œë¥¼ í†µí•´ ê°•ë ¥í•œ ì…ì§€ë¥¼ ì§€ì†ì ìœ¼ë¡œ êµ¬ì¶•í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We do expect to be able to provide the full data set on the Fabhalta eGFR readout in IgAN soon and also move forward with the filing for a full approval in IgAN for Fabhalta. Now on -- and we also expect, I should also note the Vanrafia full eGFR data set in the first half. On zigakibart, we have made the decision in order to optimize the overall label positioning and the competitive positioning to align our UPCR readout with the interim eGFR readout, which we expect in the first half of 2027. And we expect that to support our BLA for a full approval. This was a decision based on our analysis of the Phase I and II data.</td><td>ì €í¬ëŠ” ê³§ IgANì—ì„œ Fabhaltaì˜ eGFR ê²°ê³¼ì— ëŒ€í•œ ì „ì²´ ë°ì´í„°ì…‹ì„ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, IgANì— ëŒ€í•œ Fabhaltaì˜ ì •ì‹ ìŠ¹ì¸ì„ ìœ„í•œ ì‹ ì²­ë„ ì§„í–‰í•  ê³„íšì…ë‹ˆë‹¤. ë˜í•œ Vanrafiaì˜ ì „ì²´ eGFR ë°ì´í„°ì…‹ì€ ìƒë°˜ê¸° ì¤‘ì— ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒëœë‹¤ëŠ” ì ë„ ë§ì”€ë“œë ¤ì•¼ê² ìŠµë‹ˆë‹¤. zigakibartì˜ ê²½ìš°, ì „ë°˜ì ì¸ ë¼ë²¨ í¬ì§€ì…”ë‹ê³¼ ê²½ìŸë ¥ ìˆëŠ” í¬ì§€ì…”ë‹ì„ ìµœì í™”í•˜ê¸° ìœ„í•´ UPCR ê²°ê³¼ ë°œí‘œ ì‹œì ì„ ì¤‘ê°„ eGFR ê²°ê³¼ ë°œí‘œ ì‹œì ê³¼ ì¼ì¹˜ì‹œí‚¤ê¸°ë¡œ ê²°ì •í–ˆìœ¼ë©°, ì´ëŠ” 2027ë…„ ìƒë°˜ê¸°ì— ì˜ˆìƒë©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì •ì‹ ìŠ¹ì¸ì„ ìœ„í•œ BLA ì‹ ì²­ì„ ë’·ë°›ì¹¨í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ì´ëŠ” 1ìƒ ë° 2ìƒ ë°ì´í„° ë¶„ì„ì„ ë°”íƒ•ìœ¼ë¡œ ë‚´ë¦° ê²°ì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>We think we have the opportunity to be second to market with both proteinuria and the eGFR benefit. And so that, I think, is going to hopefully position us well to have a fourth renal agent in our portfolio. We also have combination trials underway because we certainly see the opportunity in having a hemodynamic agent, having a Fabhalta and having zigakibart, the opportunity to use combination to optimize care for these patients. Now moving to Slide 14. Rhapsido's U.S. launch, which is obviously something we're very closely tracking is delivering encouraging results. We are optimistic with already what we're seeing in the early days for this launch.</td><td>ì €í¬ëŠ” ë‹¨ë°±ë‡¨ì™€ eGFR ê°œì„  íš¨ê³¼ ëª¨ë‘ì—ì„œ ì‹œì¥ 2ìœ„ ì§„ì… ê¸°íšŒë¥¼ ê°€ì§€ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì´ ì €í¬ í¬íŠ¸í´ë¦¬ì˜¤ì— ë„¤ ë²ˆì§¸ ì‹ ì¥ ì¹˜ë£Œì œë¥¼ ë³´ìœ í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ë¥¼ ì°¨ì§€í•˜ê²Œ í•´ì¤„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” ë³‘ìš©ìš”ë²• ì„ìƒì‹œí—˜ë„ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ í˜ˆì—­í•™ì  ì œì œ, Fabhalta, ê·¸ë¦¬ê³  zigakibartë¥¼ ë³´ìœ í•¨ìœ¼ë¡œì¨ ì´ëŸ¬í•œ í™˜ìë“¤ì˜ ì¹˜ë£Œë¥¼ ìµœì í™”í•˜ê¸° ìœ„í•´ ë³‘ìš©ìš”ë²•ì„ ì‚¬ìš©í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ë¶„ëª…íˆ ìˆë‹¤ê³  ë³´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <br><br>ì´ì œ ìŠ¬ë¼ì´ë“œ 14ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. Rhapsidoì˜ ë¯¸êµ­ ì‹œì¥ ì¶œì‹œëŠ” ì €í¬ê°€ ë§¤ìš° ë©´ë°€íˆ ì¶”ì í•˜ê³  ìˆëŠ” ì‚¬ì•ˆìœ¼ë¡œ, ê³ ë¬´ì ì¸ ê²°ê³¼ë¥¼ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ ì¶œì‹œ ì´ˆê¸° ë‹¨ê³„ì—ì„œ ì´ë¯¸ ë³´ì´ê³  ìˆëŠ” ì„±ê³¼ì— ëŒ€í•´ ë‚™ê´€ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>We see strong demand with an encouraging mix of patients, both patients who are post antihistamines as well as post a biologic failure. We have a strong and positive response from allergists and dermatologists. The sampling and bridge program has over 2,000 HCP starts. And I think that when we benchmark that versus other highly successful dermatology launches, it's right in line with some of the most successful dermatology launches. We're also seeing early access wins. I think access will be now the gating factor. Every few months, we expect to bring on additional access on board.</td><td>í•­íˆìŠ¤íƒ€ë¯¼ì œ íˆ¬ì—¬ í›„ í™˜ìì™€ ìƒë¬¼í•™ì ì œì œ ì‹¤íŒ¨ í›„ í™˜ì ëª¨ë‘ë¥¼ í¬í•¨í•œ ê³ ë¬´ì ì¸ í™˜ì êµ¬ì„±ìœ¼ë¡œ ê°•ë ¥í•œ ìˆ˜ìš”ë¥¼ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•Œë ˆë¥´ê¸° ì „ë¬¸ì˜ì™€ í”¼ë¶€ê³¼ ì „ë¬¸ì˜ë¡œë¶€í„° ê°•ë ¥í•˜ê³  ê¸ì •ì ì¸ ë°˜ì‘ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ìƒ˜í”Œë§ ë° ë¸Œë¦¿ì§€ í”„ë¡œê·¸ë¨ì€ 2,000ëª… ì´ìƒì˜ ì˜ë£Œ ì „ë¬¸ê°€(HCP)ê°€ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ë‹¤ë¥¸ ë§¤ìš° ì„±ê³µì ì¸ í”¼ë¶€ê³¼ ì œí’ˆ ì¶œì‹œì™€ ë¹„êµí•´ ë³¼ ë•Œ, ê°€ì¥ ì„±ê³µì ì¸ í”¼ë¶€ê³¼ ì œí’ˆ ì¶œì‹œ ì‚¬ë¡€ë“¤ê³¼ ë™ì¼í•œ ìˆ˜ì¤€ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë˜í•œ ì´ˆê¸° ë³´í—˜ ì ìš© ì„±ê³¼ë„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ë³´í—˜ ì ìš©ì´ ì œí•œ ìš”ì¸ì´ ë  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ëª‡ ê°œì›”ë§ˆë‹¤ ì¶”ê°€ì ì¸ ë³´í—˜ ì ìš©ì„ í™•ë³´í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>That will allow a steady pickup in sales over the course of the year with more of a steady pickup in the second half of the year. And I think for that second half, I would encourage everyone to watch as we get that access together. And as a reminder, I think you all know well, clean safety, no box warnings, no contraindication, no required routine lab monitoring, no liver safety issues in the label, fast relief across a broad population as fast as 2 weeks. Anecdotally, we hear reports as fast as a day or 2 days, patients are starting to see benefit. And it's the only oral therapy approved by FDA who remain symptomatic despite antihistamine therapy. Now moving to Slide 15.</td><td>ì´ë¥¼ í†µí•´ ì—°ì¤‘ ë§¤ì¶œì´ ê¾¸ì¤€íˆ ì¦ê°€í•  ê²ƒì´ë©°, íŠ¹íˆ í•˜ë°˜ê¸°ì— ë”ìš± ì•ˆì •ì ì¸ ì„±ì¥ì„¸ë¥¼ ë³´ì¼ ê²ƒì…ë‹ˆë‹¤. í•˜ë°˜ê¸°ì— ëŒ€í•´ì„œëŠ” ì €í¬ê°€ ì´ëŸ¬í•œ ì ‘ê·¼ì„±ì„ í™•ë³´í•´ ë‚˜ê°€ëŠ” ê³¼ì •ì„ ì§€ì¼œë´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ìë©´, ì—¬ëŸ¬ë¶„ ëª¨ë‘ ì˜ ì•Œê³  ê³„ì‹œê² ì§€ë§Œ, ê¹¨ë—í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼, ë°•ìŠ¤ ê²½ê³  ì—†ìŒ, ê¸ˆê¸°ì‚¬í•­ ì—†ìŒ, ì •ê¸°ì ì¸ í˜ˆì•¡ê²€ì‚¬ ëª¨ë‹ˆí„°ë§ ë¶ˆí•„ìš”, ë¼ë²¨ì— ê°„ ì•ˆì „ì„± ë¬¸ì œ ì—†ìŒ, ê´‘ë²”ìœ„í•œ í™˜ìêµ°ì—ì„œ ë¹ ë¥´ë©´ 2ì£¼ ë§Œì— ë¹ ë¥¸ ì¦ìƒ ì™„í™” íš¨ê³¼ë¥¼ ë³´ì…ë‹ˆë‹¤. ì¼í™”ì ìœ¼ë¡œëŠ” 1~2ì¼ ë§Œì— í™˜ìë“¤ì´ íš¨ê³¼ë¥¼ ë³´ê¸° ì‹œì‘í–ˆë‹¤ëŠ” ë³´ê³ ë„ ë“£ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” í•­íˆìŠ¤íƒ€ë¯¼ì œ ì¹˜ë£Œì—ë„ ë¶ˆêµ¬í•˜ê³  ì¦ìƒì´ ì§€ì†ë˜ëŠ” í™˜ìë“¤ì„ ëŒ€ìƒìœ¼ë¡œ FDA ìŠ¹ì¸ì„ ë°›ì€ ìœ ì¼í•œ ê²½êµ¬ ì¹˜ë£Œì œì…ë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 15ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Now Rhapsido is one of these brands that we hope over time could become one of the largest brands in Novartis' history. This is an opportunity over multiple indications. I mentioned CSU launch, the CIndU now positive data that we have in hand for type, 2 more types coming, an HS readout in 2028. We have positive food allergy data, which we'll be presenting in Q1 of this year, and that's leading us to now initiate a broad Phase III program in food allergy. We are on track for the RMS readout second half of this year, but really mid of this year is the opportunity that we have to read out the RMS -- 2 RMS studies, SPMS and myasthenia gravis ongoing.</td><td>ì´ì œ RhapsidoëŠ” ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ë…¸ë°”í‹°ìŠ¤ ì—­ì‚¬ìƒ ê°€ì¥ í° ë¸Œëœë“œ ì¤‘ í•˜ë‚˜ê°€ ë  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•˜ëŠ” ë¸Œëœë“œì…ë‹ˆë‹¤. ì´ëŠ” ì—¬ëŸ¬ ì ì‘ì¦ì— ê±¸ì¹œ ê¸°íšŒì…ë‹ˆë‹¤. CSU ì¶œì‹œë¥¼ ì–¸ê¸‰í–ˆê³ , í˜„ì¬ ë³´ìœ í•˜ê³  ìˆëŠ” CIndU ê¸ì •ì  ë°ì´í„°, 2ê°€ì§€ ìœ í˜•ì´ ë” ë‚˜ì˜¬ ì˜ˆì •ì´ë©°, 2028ë…„ì— HS ê²°ê³¼ê°€ ë‚˜ì˜µë‹ˆë‹¤. ê¸ì •ì ì¸ ì‹í’ˆ ì•Œë ˆë¥´ê¸° ë°ì´í„°ë¥¼ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì˜¬í•´ 1ë¶„ê¸°ì— ë°œí‘œí•  ì˜ˆì •ì´ê³ , ì´ë¥¼ í†µí•´ ì‹í’ˆ ì•Œë ˆë¥´ê¸°ì— ëŒ€í•œ ê´‘ë²”ìœ„í•œ 3ìƒ í”„ë¡œê·¸ë¨ì„ ì‹œì‘í•˜ê²Œ ë©ë‹ˆë‹¤. RMS ê²°ê³¼ëŠ” ì˜¬í•´ í•˜ë°˜ê¸°ì— ë‚˜ì˜¬ ì˜ˆì •ì´ì§€ë§Œ, ì‹¤ì œë¡œëŠ” ì˜¬í•´ ì¤‘ë°˜ì´ RMS 2ê±´ì˜ ì—°êµ¬, SPMS ë° ì¤‘ì¦ ê·¼ë¬´ë ¥ì¦ ì—°êµ¬ê°€ ì§„í–‰ ì¤‘ì¸ ìƒí™©ì—ì„œ ê²°ê³¼ë¥¼ í™•ì¸í•  ìˆ˜ ìˆëŠ” ê¸°íšŒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So when you take that together, you clearly have an opportunity with a medicine with a clean safety profile. and strong efficacy with an oral -- as an oral option to have a significant long-term sales potential. Now moving to Slide 16. Now Itvisma, which we haven't had as much attention, but it's something we continue to believe has a significant overall sales potential, total potential for this brand across the IV and IT of $3 billion plus. This is a U.S. approval that brings the onetime gene therapy in children 2 years and older. It's a broad label across patients who are non-sitters, sitters and walkers, no AAV9 antibody titer limit for this treatment.</td><td>ìŠ¬ë¼ì´ë“œ 16ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì´ì œ Itvismaì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ëŠ”ë°, ê·¸ë™ì•ˆ ë§ì€ ì£¼ëª©ì„ ë°›ì§€ëŠ” ëª»í–ˆì§€ë§Œ, ì €í¬ëŠ” ì—¬ì „íˆ ì´ ì œí’ˆì´ ìƒë‹¹í•œ ì „ì²´ ë§¤ì¶œ ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆë‹¤ê³  ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. IVì™€ ITë¥¼ í•©ì³ ì´ ë¸Œëœë“œì˜ ì´ ì ì¬ë ¥ì€ 30ì–µ ë‹¬ëŸ¬ ì´ìƒì…ë‹ˆë‹¤. ì´ëŠ” 2ì„¸ ì´ìƒ ì†Œì•„ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ì¼íšŒì„± ìœ ì „ì ì¹˜ë£Œì œì— ëŒ€í•œ ë¯¸êµ­ ìŠ¹ì¸ì…ë‹ˆë‹¤. ì•‰ì§€ ëª»í•˜ëŠ” í™˜ì, ì•‰ì„ ìˆ˜ ìˆëŠ” í™˜ì, ê±¸ì„ ìˆ˜ ìˆëŠ” í™˜ì ëª¨ë‘ë¥¼ í¬ê´„í•˜ëŠ” ê´‘ë²”ìœ„í•œ ì ì‘ì¦ì„ ê°€ì§€ê³  ìˆìœ¼ë©°, ì´ ì¹˜ë£Œì œì—ëŠ” AAV9 í•­ì²´ ì—­ê°€ ì œí•œì´ ì—†ìŠµë‹ˆë‹¤.<br><br>ì´ë¥¼ ì¢…í•©í•´ ë³´ë©´, ê¹¨ë—í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ê³¼ ê°•ë ¥í•œ íš¨ëŠ¥ì„ ê°€ì§„ ê²½êµ¬ìš© ì˜µì…˜ìœ¼ë¡œì„œ ìƒë‹¹í•œ ì¥ê¸° ë§¤ì¶œ ì ì¬ë ¥ì„ ê°€ì§„ ì˜ì•½í’ˆì˜ ê¸°íšŒê°€ ëª…í™•íˆ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>There's a strong value proposition, single administration, durable efficacy, solid safety profile. So we see a multi-blockbuster opportunity for this brand. 7,500 children, teens and adults have not been treated yet with Zolgensma IV. We also have an extensive experience in the U.S. and ex U.S. with this medicine. Outside of the U.S., we've already been approved in the UAE 1 day after the FDA approval and Europe and Japan submissions are completed. And as a reminder, for Zolgensma, actually, our sales are larger outside of the U.S. than in the U.S. So there's certainly a significant opportunity ex U.S. for Itvisma. Now moving to Slide 17.</td><td>ê°•ë ¥í•œ ê°€ì¹˜ ì œì•ˆ, ë‹¨íšŒ íˆ¬ì—¬, ì§€ì†ì ì¸ íš¨ëŠ¥, ê²¬ê³ í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì´ ë¸Œëœë“œê°€ ë‹¤ì¤‘ ë¸”ë¡ë²„ìŠ¤í„° ê¸°íšŒë¥¼ ê°€ì§€ê³  ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. 7,500ëª…ì˜ ì–´ë¦°ì´, ì²­ì†Œë…„ ë° ì„±ì¸ì´ ì•„ì§ Zolgensma IVë¡œ ì¹˜ë£Œë°›ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ëŠ” ë¯¸êµ­ ë‚´ì™¸ì—ì„œ ì´ ì˜ì•½í’ˆì— ëŒ€í•œ ê´‘ë²”ìœ„í•œ ê²½í—˜ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” FDA ìŠ¹ì¸ 1ì¼ í›„ UAEì—ì„œ ì´ë¯¸ ìŠ¹ì¸ì„ ë°›ì•˜ìœ¼ë©°, ìœ ëŸ½ê³¼ ì¼ë³¸ ì œì¶œë„ ì™„ë£Œë˜ì—ˆìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ Zolgensmaì˜ ê²½ìš°, ì‹¤ì œë¡œ ë¯¸êµ­ ì™¸ ì§€ì—­ ë§¤ì¶œì´ ë¯¸êµ­ ë‚´ ë§¤ì¶œë³´ë‹¤ í½ë‹ˆë‹¤. ë”°ë¼ì„œ Itvismaì˜ ê²½ìš° ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ í™•ì‹¤íˆ ìƒë‹¹í•œ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 17ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As I mentioned on the first slide, for pelabresib, we read out in the quarter 4, the 96-week data from the Phase III MANIFEST program, which both on safety and efficacy has now given us a path forward to, we believe, get this medicine registered, assuming successful regulatory and clinical trial Phase III trials. In that study, we showed deep and durable responses and a comparable safety profile to ruxolitinib in myelofibrosis. You can see the data here on the left in terms of the spleen response. When you look at the data that we presented, we had a deep and durable spleen volume reduction for the spleen volume, 35% reduction landmark, 91.5% versus 57.6%.</td><td>ì²« ë²ˆì§¸ ìŠ¬ë¼ì´ë“œì—ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, pelabresibì˜ ê²½ìš° 4ë¶„ê¸°ì— 3ìƒ MANIFEST í”„ë¡œê·¸ë¨ì˜ 96ì£¼ì°¨ ë°ì´í„°ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì•ˆì „ì„±ê³¼ ìœ íš¨ì„± ì¸¡ë©´ì—ì„œ ì´ ë°ì´í„°ëŠ” ì„±ê³µì ì¸ ê·œì œ ìŠ¹ì¸ê³¼ 3ìƒ ì„ìƒì‹œí—˜ì„ ì „ì œë¡œ, ì´ ì˜ì•½í’ˆì˜ í—ˆê°€ë¥¼ ë°›ì„ ìˆ˜ ìˆëŠ” ê²½ë¡œë¥¼ ì œì‹œí–ˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ì—ì„œ ìš°ë¦¬ëŠ” ê³¨ìˆ˜ì„¬ìœ ì¦ì—ì„œ ë£©ì†Œë¦¬í‹°ë‹™(ruxolitinib)ê³¼ ë¹„êµ ê°€ëŠ¥í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ê³¼ í•¨ê»˜ ê¹Šê³  ì§€ì†ì ì¸ ë°˜ì‘ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ì™¼ìª½ì—ì„œ ë¹„ì¥ ë°˜ì‘ì— ëŒ€í•œ ë°ì´í„°ë¥¼ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì œì‹œí•œ ë°ì´í„°ë¥¼ ë³´ë©´, ë¹„ì¥ ìš©ì  35% ê°ì†Œ ê¸°ì¤€ì (landmark)ì—ì„œ ê¹Šê³  ì§€ì†ì ì¸ ë¹„ì¥ ìš©ì  ê°ì†Œë¥¼ ë³´ì˜€ìœ¼ë©°, 91.5% ëŒ€ 57.6%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We also saw sustained improvements in symptom scores and anemia. We had 2x as many patients reaching goal with the spleen volume reduction and the TSS50. So we believe this medicine has disease-modifying potential. We saw improvements in bone marrow pathology on the anemia. There was importantly now from a mortality standpoint, fewer deaths and progressions observed with pelabresib and ruxolitinib versus ruxolitinib alone. And the overall safety now has proven comparable with ruxolitinib, including comparable leukemic transformation rates, which was one of the topics that was holding this program back.</td><td>ë˜í•œ ì¦ìƒ ì ìˆ˜ì™€ ë¹ˆí˜ˆì—ì„œ ì§€ì†ì ì¸ ê°œì„ ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë¹„ì¥ ìš©ì  ê°ì†Œì™€ TSS50 ëª©í‘œì— ë„ë‹¬í•œ í™˜ìê°€ 2ë°° ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì´ ì•½ë¬¼ì´ ì§ˆë³‘ ì¡°ì ˆ(disease-modifying) ê°€ëŠ¥ì„±ì„ ê°€ì§€ê³  ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ë¹ˆí˜ˆê³¼ ê´€ë ¨í•˜ì—¬ ê³¨ìˆ˜ ë³‘ë¦¬í•™ì  ê°œì„ ì´ ê´€ì°°ë˜ì—ˆìŠµë‹ˆë‹¤. ì‚¬ë§ë¥  ê´€ì ì—ì„œ ì¤‘ìš”í•œ ì ì€, í ë¼ë¸Œë ˆì‹­ê³¼ ë£©ì†”ë¦¬í‹°ë‹™ ë³‘ìš©ìš”ë²•ì´ ë£©ì†”ë¦¬í‹°ë‹™ ë‹¨ë…ìš”ë²• ëŒ€ë¹„ ì‚¬ë§ ë° ì§ˆë³‘ ì§„í–‰ ì‚¬ë¡€ê°€ ë” ì ì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ë°˜ì ì¸ ì•ˆì „ì„±ì€ ì´ì œ ë£©ì†”ë¦¬í‹°ë‹™ê³¼ ë¹„êµ ê°€ëŠ¥í•œ ìˆ˜ì¤€ìœ¼ë¡œ ì…ì¦ë˜ì—ˆìœ¼ë©°, ë°±í˜ˆë³‘ ì „í™˜ìœ¨ë„ ìœ ì‚¬í•œ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ë°±í˜ˆë³‘ ì „í™˜ìœ¨ì€ ì´ í”„ë¡œê·¸ë¨ì„ ì§€ì—°ì‹œì¼°ë˜ ì£¼ìš” ì´ìŠˆ ì¤‘ í•˜ë‚˜ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So with this data set, we have now an agreement with the EU to file in 2026 based on this data. And in the U.S., China and Japan, we'll be starting a new Phase III study focused on patients who have high TSS50 at baseline, where we believe we have the data set now to show we can achieve the regulatory milestone to ultimately get approval. Now moving to Slide 18. I did want to also take a moment to mention our impact on global health. As I think many of you know, Novartis has been in global health for nearly 100 years, working on malaria and other neglected tropical diseases.</td><td>ì´ ë°ì´í„°ì…‹ì„ ë°”íƒ•ìœ¼ë¡œ í˜„ì¬ EUì™€ 2026ë…„ ì œì¶œì— ëŒ€í•œ í•©ì˜ë¥¼ ë§ˆì³¤ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­, ì¤‘êµ­, ì¼ë³¸ì—ì„œëŠ” ê¸°ì €ì„ ì—ì„œ ë†’ì€ TSS50ì„ ë³´ì´ëŠ” í™˜ìë“¤ì„ ëŒ€ìƒìœ¼ë¡œ í•œ ìƒˆë¡œìš´ 3ìƒ ì„ìƒì‹œí—˜ì„ ì‹œì‘í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ëŠ” ê¶ê·¹ì ìœ¼ë¡œ ìŠ¹ì¸ì„ ë°›ê¸° ìœ„í•œ ê·œì œ ë§ˆì¼ìŠ¤í†¤ì„ ë‹¬ì„±í•  ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ì¤„ ë°ì´í„°ì…‹ì„ í™•ë³´í–ˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 18ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ê¸€ë¡œë²Œ í—¬ìŠ¤ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì˜í–¥ì— ëŒ€í•´ì„œë„ ì ì‹œ ì–¸ê¸‰í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ë§ì€ ë¶„ë“¤ì´ ì•„ì‹œë‹¤ì‹œí”¼, ë…¸ë°”í‹°ìŠ¤ëŠ” ê±°ì˜ 100ë…„ ë™ì•ˆ ë§ë¼ë¦¬ì•„ì™€ ê¸°íƒ€ ì†Œì™¸ ì—´ëŒ€ì§ˆí™˜ì— ëŒ€í•œ ì—°êµ¬ë¥¼ ì§„í–‰í•˜ë©° ê¸€ë¡œë²Œ í—¬ìŠ¤ ë¶„ì•¼ì—ì„œ í™œë™í•´ ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With our Coartem medicine 25 years ago, we started a real sea change in the treatment of malaria, reaching now well over 1 billion patients with Coartem. And now with the recent data we presented in November, we have the opportunity to bring the first new malaria medicine, novel medicines so in 25 years. This is KLU156, ganaplacide plus lumefantrine. It disrupts the parasites internal protein system, very positive data here. You see on the adjusted basis, 99.2% cure rates versus 96.4% versus a 5-day course, a 3-day course, opportunity to block transmission, very solid safety profile. So we're quite excited to bring this forward as part of our mission in global health. So moving to Slide 19.</td><td>25ë…„ ì „ ì½”ì•„ë¥´í…œ(Coartem) ì˜ì•½í’ˆìœ¼ë¡œ ë§ë¼ë¦¬ì•„ ì¹˜ë£Œì— ìˆì–´ ì§„ì •í•œ ëŒ€ë³€í˜ì„ ì‹œì‘í–ˆìœ¼ë©°, í˜„ì¬ ì½”ì•„ë¥´í…œìœ¼ë¡œ 10ì–µ ëª… ì´ìƒì˜ í™˜ìë“¤ì—ê²Œ ë„ë‹¬í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ 11ì›”ì— ë°œí‘œí•œ ìµœê·¼ ë°ì´í„°ë¥¼ í†µí•´ 25ë…„ ë§Œì— ìµœì´ˆì˜ ì‹ ê·œ ë§ë¼ë¦¬ì•„ ì¹˜ë£Œì œ, í˜ì‹ ì ì¸ ì˜ì•½í’ˆì„ ì¶œì‹œí•  ê¸°íšŒë¥¼ ê°–ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ KLU156, ê°€ë‚˜í”Œë¼ì‚¬ì´ë“œì™€ ë£¨ë©”íŒíŠ¸ë¦° ë³µí•©ì œì…ë‹ˆë‹¤. ì´ ì•½ë¬¼ì€ ê¸°ìƒì¶©ì˜ ë‚´ë¶€ ë‹¨ë°±ì§ˆ ì‹œìŠ¤í…œì„ íŒŒê´´í•˜ë©°, ë§¤ìš° ê¸ì •ì ì¸ ë°ì´í„°ë¥¼ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ë³´ì • ê¸°ì¤€ìœ¼ë¡œ 5ì¼ ìš”ë²• ëŒ€ë¹„ 3ì¼ ìš”ë²•ì—ì„œ 96.4% ëŒ€ë¹„ 99.2%ì˜ ì¹˜ë£Œìœ¨ì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìœ¼ë©°, ì „íŒŒ ì°¨ë‹¨ ê¸°íšŒì™€ ë§¤ìš° ê²¬ê³ í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ê¸€ë¡œë²Œ í—¬ìŠ¤ ë¯¸ì…˜ì˜ ì¼í™˜ìœ¼ë¡œ ì´ ì•½ë¬¼ì„ ì¶œì‹œí•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ìŠ¬ë¼ì´ë“œ 19ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Now taken together, a very good year for us from a pipeline standpoint in 2025. You can see we met the vast majority of our milestones and trial starts. And I think that really shows the strong execution machinery we have now in R&D at the company, very aligned across research and development and strong execution across our global development organization. And turning to Slide 20. For 2026, we're on track for 7 pivotal readouts with the potential to strengthen the midterm outlook that we're guiding to, including the mid-single-digit sales growth we expect in the 2030s. A few particular readouts, which I haven't mentioned, which I'll call out.</td><td>ì´ì œ ì „ì²´ì ìœ¼ë¡œ ë³´ë©´, 2025ë…„ì€ íŒŒì´í”„ë¼ì¸ ê´€ì ì—ì„œ ìš°ë¦¬ì—ê²Œ ë§¤ìš° ì¢‹ì€ í•œ í•´ì˜€ìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ ìš°ë¦¬ëŠ” ëŒ€ë¶€ë¶„ì˜ ë§ˆì¼ìŠ¤í†¤ê³¼ ì„ìƒì‹œí—˜ ê°œì‹œ ëª©í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” í˜„ì¬ íšŒì‚¬ì˜ R&D ë¶€ë¬¸ì—ì„œ ê°•ë ¥í•œ ì‹¤í–‰ ì²´ê³„ë¥¼ ê°–ì¶”ê³  ìˆìŒì„ ë³´ì—¬ì¤€ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì—°êµ¬ê°œë°œ ë¶€ë¬¸ ì „ë°˜ì— ê±¸ì³ ë§¤ìš° ì˜ ì •ë ¬ë˜ì–´ ìˆê³ , ê¸€ë¡œë²Œ ê°œë°œ ì¡°ì§ ì „ì²´ì—ì„œ ê°•ë ¥í•œ ì‹¤í–‰ë ¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 20ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 2026ë…„ì—ëŠ” 7ê±´ì˜ í”¼ë³´íƒˆ ì„ìƒê²°ê³¼ ë°œí‘œê°€ ì˜ˆì •ë˜ì–´ ìˆìœ¼ë©°, ì´ëŠ” ìš°ë¦¬ê°€ ê°€ì´ë˜ìŠ¤ë¡œ ì œì‹œí•œ ì¤‘ê¸° ì „ë§, íŠ¹íˆ 2030ë…„ëŒ€ì— ì˜ˆìƒí•˜ëŠ” ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ë§¤ì¶œ ì„±ì¥ë¥ ì„ ê°•í™”í•  ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì œê°€ ì•„ì§ ì–¸ê¸‰í•˜ì§€ ì•Šì€ ëª‡ ê°€ì§€ íŠ¹ì • ì„ìƒê²°ê³¼ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And on the left side, you can see pelacarsen for CVRR. We do expect to read out middle of this year. It will be second half, but it will be middle of this year, which, if positive, would allow us for a U.S. submission this year. We also are on track for our submissions for Ianalumab in Sjogren's disease. and as well as the Del-zota DMD U.S. submission, which assuming the closure of the Avidity deal would also happen in the first half of this year. Number of pivotal readouts. I mentioned pelacarsen. There will be the Ianalumab readouts in hematology, which could have significant potential to drive that brand to very large long-term potential.</td><td>ì™¼ìª½ì„ ë³´ì‹œë©´ CVRR ì ì‘ì¦ì˜ pelacarsenì´ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ì¤‘ë°˜ì— ê²°ê³¼ê°€ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ë°˜ê¸°ê°€ ë˜ê² ì§€ë§Œ ì˜¬í•´ ì¤‘ë°˜ì´ ë  ê²ƒì´ë©°, ê¸ì •ì ì¸ ê²°ê³¼ê°€ ë‚˜ì˜¨ë‹¤ë©´ ì˜¬í•´ ë¯¸êµ­ í—ˆê°€ ì‹ ì²­ì´ ê°€ëŠ¥í•  ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ì‡¼ê·¸ë Œë³‘ ì ì‘ì¦ì˜ Ianalumab í—ˆê°€ ì‹ ì²­ë„ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Del-zota DMDì˜ ë¯¸êµ­ í—ˆê°€ ì‹ ì²­ë„ ìˆëŠ”ë°, Avidity ì¸ìˆ˜ê°€ ì™„ë£Œëœë‹¤ëŠ” ê°€ì • í•˜ì— ì˜¬í•´ ìƒë°˜ê¸°ì— ì´ë£¨ì–´ì§ˆ ê²ƒì…ë‹ˆë‹¤. <br><br>ì—¬ëŸ¬ ê±´ì˜ í”¼ë²— ì„ìƒ ê²°ê³¼ ë°œí‘œê°€ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì•ì„œ ì–¸ê¸‰í•œ pelacarsenì´ ìˆê³ , í˜ˆì•¡í•™ ë¶„ì•¼ì˜ Ianalumab ê²°ê³¼ ë°œí‘œë„ ìˆì„ ì˜ˆì •ì¸ë°, ì´ëŠ” í•´ë‹¹ ë¸Œëœë“œë¥¼ ì¥ê¸°ì ìœ¼ë¡œ ë§¤ìš° í° ì ì¬ë ¥ì„ ê°€ì§„ ì œí’ˆìœ¼ë¡œ ì„±ì¥ì‹œí‚¬ ìˆ˜ ìˆëŠ” ì¤‘ìš”í•œ ê³„ê¸°ê°€ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Of course, remibrutinib as well as the Del-desiran DM1 Phase III readout, again, assuming the closure of the Avidity. We also have the additional readout of the DUX4 interim data readout as well, which could support accelerated launch in FSHD. However, that we would characterize as an upside case. And then a number of key study initiations you can see on the right-hand side of the chart. So another exciting pipeline year to continue to bolster our long-term growth profile. Now moving to Slide 21. I will hand it over now to Harry. Harry Kirsch<br>Chief Financial Officer<br><br>Yes. Thank you, Vas. Good morning, good afternoon, everybody.</td><td>ë¬¼ë¡  remibrutinibê³¼ Del-desiran DM1 3ìƒ ê²°ê³¼ ë°œí‘œë„ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” Avidity ì¸ìˆ˜ ì™„ë£Œë¥¼ ì „ì œë¡œ í•©ë‹ˆë‹¤. ë˜í•œ DUX4 ì¤‘ê°„ ë°ì´í„° ë°œí‘œë„ ìˆì„ ì˜ˆì •ì´ë©°, ì´ëŠ” FSHDì—ì„œì˜ ì‹ ì† ì¶œì‹œë¥¼ ë’·ë°›ì¹¨í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŠ” ìƒí–¥ ì‹œë‚˜ë¦¬ì˜¤ë¡œ ë¶„ë¥˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì°¨íŠ¸ ì˜¤ë¥¸ìª½ì—ì„œ ë³´ì‹œëŠ” ê²ƒì²˜ëŸ¼ ì—¬ëŸ¬ ì£¼ìš” ì„ìƒì‹œí—˜ ê°œì‹œê°€ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë˜ í•œ í•´ ë™ì•ˆ í¥ë¯¸ì§„ì§„í•œ íŒŒì´í”„ë¼ì¸ ì§„í–‰ìœ¼ë¡œ ì¥ê¸° ì„±ì¥ ì „ë§ì„ ê³„ì† ê°•í™”í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 21ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. Harryì—ê²Œ ë°œí‘œë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Harry Kirsch<br>ìµœê³ ì¬ë¬´ì±…ì„ì<br><br>ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Vas. ì—¬ëŸ¬ë¶„ ì¢‹ì€ ì•„ì¹¨, ì¢‹ì€ ì˜¤í›„ì…ë‹ˆë‹¤.</td></tr>
<tr><td>I now walk you through our financial results for the fourth quarter and the full year of 2025, which, as Vas mentioned, was very strong despite midyear significant U.S. generic entries. And as always, my comments refer to growth rates in constant currencies, unless otherwise noted. So on Slide 22, 2025 marked another year of excellent execution. So over the last 5 years, as you can see here, we delivered an 8% sales average growth rate and a 15% core operating income average growth rate, driven by strong commercial execution, a great late-stage readout and disciplined productivity programs.</td><td>ì´ì œ 2025ë…„ 4ë¶„ê¸°ì™€ ì—°ê°„ ì¬ë¬´ ì‹¤ì ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Vasê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì—°ì¤‘ ë¯¸êµ­ ì œë„¤ë¦­ ì§„ì…ì´ ìƒë‹¹í–ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  ë§¤ìš° ê°•ë ¥í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í•­ìƒ ê·¸ë ‡ë“¯ì´, ë³„ë„ë¡œ ì–¸ê¸‰í•˜ì§€ ì•ŠëŠ” í•œ ì œ ì„¤ëª…ì€ ê³ ì •í™˜ìœ¨ ê¸°ì¤€ ì„±ì¥ë¥ ì„ ê¸°ì¤€ìœ¼ë¡œ í•©ë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 22ë¥¼ ë³´ì‹œë©´, 2025ë…„ì€ ë˜ í•œ ë²ˆ íƒì›”í•œ ì‹¤í–‰ë ¥ì„ ë³´ì—¬ì¤€ í•œ í•´ì˜€ìŠµë‹ˆë‹¤. ì§€ë‚œ 5ë…„ê°„ ë³´ì‹œëŠ” ë°”ì™€ ê°™ì´, ê°•ë ¥í•œ ì˜ì—… ì‹¤í–‰ë ¥, í›Œë¥­í•œ í›„ê¸° ì„ìƒ ê²°ê³¼, ê·¸ë¦¬ê³  ì²´ê³„ì ì¸ ìƒì‚°ì„± í”„ë¡œê·¸ë¨ì— í˜ì…ì–´ í‰ê·  8%ì˜ ë§¤ì¶œ ì„±ì¥ë¥ ê³¼ 15%ì˜ í•µì‹¬ ì˜ì—…ì´ìµ í‰ê·  ì„±ì¥ë¥ ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This translated on the right side into more than 1,000 basis points of core margin expansion in constant currencies. And as you can see, in reported currencies, allowed us to reach our midterm core margin target of 40% 2 years earlier than planned. As you may recall, we initially planned for 2027. Now we have achieved it in 2025. With these results, I hope you agree, but I believe we have really elevated the company to a new level of sales performance, margin profile and as I'll discuss later, free cash flow generation. On Slide 23, just a quick summary.</td><td>ì˜¤ë¥¸ìª½ì— ë³´ì‹œëŠ” ê²ƒì²˜ëŸ¼ ì´ëŠ” ê³ ì •í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ 1,000bp ì´ìƒì˜ í•µì‹¬ ë§ˆì§„ í™•ëŒ€ë¡œ ì´ì–´ì¡ŒìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë³´ê³ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œëŠ” ë‹¹ì´ˆ ê³„íšë³´ë‹¤ 2ë…„ ì•ë‹¹ê²¨ ì¤‘ê¸° í•µì‹¬ ë§ˆì§„ ëª©í‘œì¸ 40%ë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ê¸°ì–µí•˜ì‹œê² ì§€ë§Œ, ìš°ë¦¬ëŠ” ì²˜ìŒì— 2027ë…„ì„ ëª©í‘œë¡œ í–ˆì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ì´ì œ 2025ë…„ì— ì´ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ìœ¼ë¡œ, ì—¬ëŸ¬ë¶„ë„ ë™ì˜í•˜ì‹œë¦¬ë¼ ë¯¿ìŠµë‹ˆë‹¤ë§Œ, ìš°ë¦¬ëŠ” ë§¤ì¶œ ì„±ê³¼, ë§ˆì§„ í”„ë¡œíŒŒì¼, ê·¸ë¦¬ê³  ë‚˜ì¤‘ì— ë…¼ì˜í•˜ê² ì§€ë§Œ ì‰ì—¬í˜„ê¸ˆíë¦„ ì°½ì¶œ ì¸¡ë©´ì—ì„œ íšŒì‚¬ë¥¼ ì •ë§ë¡œ ìƒˆë¡œìš´ ìˆ˜ì¤€ìœ¼ë¡œ ëŒì–´ì˜¬ë ¸ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. 23í˜ì´ì§€ëŠ” ê°„ë‹¨í•œ ìš”ì•½ì…ë‹ˆë‹¤.</td></tr>
<tr><td>You see that we have delivered our full year guidance in 2025 after upgrading twice throughout the year, and we guided to high single-digit sales growth, and we delivered 8%. For core operating income, we guided to low teens. and achieved 14%. And this is a strong result in the year, as I mentioned, where U.S. generic entries for Entresto, Promacta and Tasigna happened, and it speaks really for the momentum of our priority brands, as Vas already laid out, as well as disciplined cost management. Turning to Slide 24. So here, a few more details. For the full year, we delivered the described solid top and bottom line growth, record core margin and record free cash flow, almost $18 billion.</td><td>ë³´ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” ì—°ì¤‘ ë‘ ì°¨ë¡€ ìƒí–¥ ì¡°ì •í•œ í›„ 2025ë…„ ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë§¤ì¶œ ì„±ì¥ë¥ ì€ ë†’ì€ í•œ ìë¦¿ìˆ˜ë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí–ˆê³ , 8%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í•µì‹¬ ì˜ì—…ì´ìµì˜ ê²½ìš° ë‚®ì€ ë‘ ìë¦¿ìˆ˜ë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí–ˆê³ , 14%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì œê°€ ì–¸ê¸‰í–ˆë“¯ì´ Entresto, Promacta, Tasignaì˜ ë¯¸êµ­ ì œë„¤ë¦­ ì§„ì…ì´ ìˆì—ˆë˜ í•´ì— ê±°ë‘” ê°•ë ¥í•œ ì‹¤ì ì´ë©°, Vasê°€ ì´ë¯¸ ì„¤ëª…í•œ ë°”ì™€ ê°™ì´ ìš°ì„ ìˆœìœ„ ë¸Œëœë“œë“¤ì˜ ëª¨ë©˜í…€ê³¼ ì—„ê²©í•œ ë¹„ìš© ê´€ë¦¬ë¥¼ ì…ì¦í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ìŠ¬ë¼ì´ë“œ 24ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì—¬ê¸° ì¢€ ë” ìì„¸í•œ ë‚´ìš©ì´ ìˆìŠµë‹ˆë‹¤. ì—°ê°„ ì‹¤ì ìœ¼ë¡œ ì•ì„œ ì„¤ëª…ë“œë¦° ê²¬ê³ í•œ ë§¤ì¶œ ë° ìˆœì´ìµ ì„±ì¥, ê¸°ë¡ì ì¸ í•µì‹¬ ë§ˆì§„, ê·¸ë¦¬ê³  ê±°ì˜ 180ì–µ ë‹¬ëŸ¬ì— ë‹¬í•˜ëŠ” ê¸°ë¡ì ì¸ ì‰ì—¬í˜„ê¸ˆíë¦„ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The core margin in the year improved by 210 basis points to 40.1% and core EPS rose 17% to $8.98. Free cash flow grew 8% to $17.6 billion. Now for the quarter, on the right side here, as expected, the U.S. generics had an impact, which we see in quarter 4, and then Mukul will lay it out first half of next year or 2026, but then again, back to growth. Anyway, sales declined 1%, whilst core operating income increased by 1%. And the results were a little bit noisy due to some U.S.</td><td>í•µì‹¬ ë§ˆì§„ì€ ì „ë…„ ëŒ€ë¹„ 210bp ê°œì„ ë˜ì–´ 40.1%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, í•µì‹¬ ì£¼ë‹¹ìˆœì´ìµ(Core EPS)ì€ 17% ì¦ê°€í•œ $8.98ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì‰ì—¬í˜„ê¸ˆíë¦„(Free Cash Flow)ì€ 8% ì¦ê°€í•˜ì—¬ $176ì–µì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ì œ ë¶„ê¸° ì‹¤ì ì„ ë³´ì‹œë©´, ì˜¤ë¥¸ìª½ì— ë‚˜ì™€ ìˆë“¯ì´ ì˜ˆìƒëŒ€ë¡œ ë¯¸êµ­ ì œë„¤ë¦­ ì˜ì•½í’ˆì´ 4ë¶„ê¸°ì— ì˜í–¥ì„ ë¯¸ì³¤ìœ¼ë©°, Mukulì´ 2026ë…„ ìƒë°˜ê¸° ì „ë§ì„ ì„¤ëª…ë“œë¦´ ì˜ˆì •ì´ì§€ë§Œ, ì´í›„ ë‹¤ì‹œ ì„±ì¥ì„¸ë¡œ ëŒì•„ì„¤ ê²ƒì…ë‹ˆë‹¤. ì–´ì¨Œë“  ë§¤ì¶œì€ 1% ê°ì†Œí•œ ë°˜ë©´, í•µì‹¬ ì˜ì—…ì´ìµì€ 1% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì‹¤ì ì€ ì¼ë¶€ ë¯¸êµ­ ì‹œì¥ ìš”ì¸ìœ¼ë¡œ ì¸í•´ ë‹¤ì†Œ ë³€ë™ì„±ì´ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>R&D adjustments, a positive impact in quarter 4 of 2024, so last year financially and a negative impact this year in quarter 4, 2025, mostly on generic -- so excluding this adjustment, underlying quarter 4 sales growth would have been positive 3%. As said, the vast majority of the gross net adjustments were Entresto and other generic brands like Promacta and U.S. Core EPS in the quarter, $2.03, up 2%. Now on Slide 25, you can see our continued progress on free cash flow generation, which reached $17.6 billion, all-time high for the company in 2025. I think it shows you also besides the financial, the power of being a pure-play pharma company.</td><td>R&D ì¡°ì • í•­ëª©ì€ 2024ë…„ 4ë¶„ê¸°, ì¦‰ ì‘ë…„ì—ëŠ” ì¬ë¬´ì ìœ¼ë¡œ ê¸ì •ì ì¸ ì˜í–¥ì„ ë¯¸ì³¤ê³ , ì˜¬í•´ 2025ë…„ 4ë¶„ê¸°ì—ëŠ” ë¶€ì •ì ì¸ ì˜í–¥ì„ ë¯¸ì³¤ìŠµë‹ˆë‹¤. ì£¼ë¡œ ì œë„¤ë¦­ ì˜ì•½í’ˆì—ì„œ ë°œìƒí–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ì¡°ì •ì„ ì œì™¸í•˜ë©´, ê¸°ì € 4ë¶„ê¸° ë§¤ì¶œ ì„±ì¥ë¥ ì€ í”ŒëŸ¬ìŠ¤ 3%ì˜€ì„ ê²ƒì…ë‹ˆë‹¤. ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì´ë§¤ì¶œ-ìˆœë§¤ì¶œ ì¡°ì •ì˜ ëŒ€ë¶€ë¶„ì€ ì—”íŠ¸ë ˆìŠ¤í† ì™€ í”„ë¡œë§¥íƒ€ ê°™ì€ ë‹¤ë¥¸ ì œë„¤ë¦­ ë¸Œëœë“œ, ê·¸ë¦¬ê³  ë¯¸êµ­ í•µì‹¬ ì‚¬ì—…ì—ì„œ ë°œìƒí–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì£¼ë‹¹ìˆœì´ìµì€ 2.03ë‹¬ëŸ¬ë¡œ 2% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.<br><br>ì´ì œ ìŠ¬ë¼ì´ë“œ 25ë¥¼ ë³´ì‹œë©´, ìš°ë¦¬ì˜ ì§€ì†ì ì¸ ì‰ì—¬í˜„ê¸ˆíë¦„ ì°½ì¶œ ì§„ì „ì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. 2025ë…„ì—ëŠ” 176ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í•˜ì—¬ íšŒì‚¬ ì—­ì‚¬ìƒ ìµœê³ ì¹˜ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¬ë¬´ì  ì¸¡ë©´ ì™¸ì—ë„ ìˆœìˆ˜ ì œì•½íšŒì‚¬ë¡œì„œì˜ ì—­ëŸ‰ì„ ë³´ì—¬ì¤€ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>As you know, many years back with even 6 businesses or even before the Alcon and Sandoz spin, these numbers were usually in the $10 billion to $12 billion range. And now this is the earnings power of a focused and very successful pharma business. We remain, of course, focused on ensuring that the growth in core operating income translates into high-quality earnings and strong cash flow generation. This robust cash flow allows us to reinvest in the business, pursue bolt-on acquisitions and continue to return attractive capital to the shareholders through growing dividend and share buybacks. On 2026 -- on Page 26, a quick reminder on our unchanged capital allocation strategy.</td><td>ì•„ì‹œë‹¤ì‹œí”¼, ìˆ˜ë…„ ì „ 6ê°œ ì‚¬ì—…ë¶€ë¥¼ ìš´ì˜í•˜ë˜ ì‹œì ˆ, ì‹¬ì§€ì–´ Alconê³¼ Sandoz ë¶„ì‚¬ ì´ì „ì—ë„ ì´ëŸ¬í•œ ìˆ˜ì¹˜ë“¤ì€ í†µìƒ 100ì–µ ë‹¬ëŸ¬ì—ì„œ 120ì–µ ë‹¬ëŸ¬ ë²”ìœ„ì˜€ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ê¸ˆ ì´ê²ƒì´ ì§‘ì¤‘ë˜ê³  ë§¤ìš° ì„±ê³µì ì¸ ì œì•½ ì‚¬ì—…ì˜ ìˆ˜ìµ ì°½ì¶œë ¥ì…ë‹ˆë‹¤. ë¬¼ë¡  ìš°ë¦¬ëŠ” í•µì‹¬ ì˜ì—…ì´ìµì˜ ì„±ì¥ì´ ê³ í’ˆì§ˆ ìˆ˜ìµê³¼ ê°•ë ¥í•œ í˜„ê¸ˆíë¦„ ì°½ì¶œë¡œ ì´ì–´ì§€ë„ë¡ í•˜ëŠ” ë° ê³„ì† ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ íƒ„íƒ„í•œ í˜„ê¸ˆíë¦„ì€ ì‚¬ì—…ì— ì¬íˆ¬ìí•˜ê³ , ì†Œê·œëª¨ ì¸ìˆ˜ë¥¼ ì¶”ì§„í•˜ë©°, ì¦ê°€í•˜ëŠ” ë°°ë‹¹ê³¼ ìì‚¬ì£¼ ë§¤ì…ì„ í†µí•´ ì£¼ì£¼ë“¤ì—ê²Œ ë§¤ë ¥ì ì¸ ìë³¸ì„ ì§€ì†ì ìœ¼ë¡œ í™˜ì›í•  ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤. 26í˜ì´ì§€ì—ì„œëŠ” ë³€í•¨ì—†ëŠ” ìë³¸ë°°ë¶„ ì „ëµì— ëŒ€í•´ ê°„ë‹¨íˆ ìƒê¸°ì‹œì¼œ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And as you see, we continue to execute our balanced shareholder-friendly capital allocation in 2025. We invested more than $10 billion in R&D, an 8% increase versus prior year, announced 4 acquisitions, 10 licensing deals, strengthening our key platforms and pipeline across all of our 4 therapeutic areas. On returning capital to our shareholders, we completed our $15 billion share buyback program in early July, and we launched a new up to $10 billion program targeted to be completed by the end of 2027. Approximately $7.7 billion of that remains to be executed. In addition, we distributed $7.8 billion in dividends during the first half of 2025. Now speaking of dividends. Turning to Slide 27.</td><td>ë³´ì‹œë‹¤ì‹œí”¼, ìš°ë¦¬ëŠ” 2025ë…„ì—ë„ ê· í˜•ì¡íŒ ì£¼ì£¼ì¹œí™”ì  ìë³¸ë°°ë¶„ì„ ì§€ì†ì ìœ¼ë¡œ ì‹¤í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” R&Dì— ì „ë…„ ëŒ€ë¹„ 8% ì¦ê°€í•œ 100ì–µ ë‹¬ëŸ¬ ì´ìƒì„ íˆ¬ìí–ˆìœ¼ë©°, 4ê±´ì˜ ì¸ìˆ˜ì™€ 10ê±´ì˜ ë¼ì´ì„ ì‹± ê³„ì•½ì„ ë°œí‘œí•˜ì—¬ 4ê°œ ì¹˜ë£Œ ì˜ì—­ ì „ë°˜ì— ê±¸ì³ í•µì‹¬ í”Œë«í¼ê³¼ íŒŒì´í”„ë¼ì¸ì„ ê°•í™”í–ˆìŠµë‹ˆë‹¤. ì£¼ì£¼ í™˜ì›ê³¼ ê´€ë ¨í•˜ì—¬, ìš°ë¦¬ëŠ” 7ì›” ì´ˆ 150ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ìì‚¬ì£¼ ë§¤ì… í”„ë¡œê·¸ë¨ì„ ì™„ë£Œí–ˆìœ¼ë©°, 2027ë…„ ë§ê¹Œì§€ ì™„ë£Œë¥¼ ëª©í‘œë¡œ í•˜ëŠ” ìµœëŒ€ 100ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ìƒˆë¡œìš´ í”„ë¡œê·¸ë¨ì„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì´ ì¤‘ ì•½ 77ì–µ ë‹¬ëŸ¬ê°€ ì•„ì§ ì§‘í–‰ë˜ì§€ ì•Šì€ ìƒíƒœì…ë‹ˆë‹¤. ë˜í•œ 2025ë…„ ìƒë°˜ê¸° ë™ì•ˆ 78ì–µ ë‹¬ëŸ¬ì˜ ë°°ë‹¹ê¸ˆì„ ì§€ê¸‰í–ˆìŠµë‹ˆë‹¤. ë°°ë‹¹ê¸ˆì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, 27í˜ì´ì§€ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We are proposing a dividend of CHF 3.70 per share, a 6% increase in Swiss francs and even double digit in dollars. And it's our 29th consecutive dividend increase in Swiss francs since company creation '96 and including years following the Sandoz and Alcon spins when we did not rebase the dividend at all. This reflects our long-term and long-standing commitment to a growing dividend in Swiss francs per share. That concludes my remarks. Before handing over, I'd like to briefly acknowledge that this will be my final earnings call as CFO of Novartis.</td><td>ì£¼ë‹¹ 3.70 ìŠ¤ìœ„ìŠ¤í”„ë‘ì˜ ë°°ë‹¹ì„ ì œì•ˆí•˜ë©°, ì´ëŠ” ìŠ¤ìœ„ìŠ¤í”„ë‘ ê¸°ì¤€ 6% ì¦ê°€ì´ê³  ë‹¬ëŸ¬ ê¸°ì¤€ìœ¼ë¡œëŠ” ë‘ ìë¦¿ìˆ˜ ì¦ê°€ì…ë‹ˆë‹¤. ì´ëŠ” 1996ë…„ íšŒì‚¬ ì„¤ë¦½ ì´í›„ 29ë…„ ì—°ì† ìŠ¤ìœ„ìŠ¤í”„ë‘ ê¸°ì¤€ ë°°ë‹¹ ì¦ê°€ì´ë©°, ì‚°ë„ì¦ˆ(Sandoz)ì™€ ì•Œì½˜(Alcon) ë¶„ì‚¬ ì´í›„ì—ë„ ë°°ë‹¹ì„ ì „í˜€ ì¬ì¡°ì •í•˜ì§€ ì•Šì•˜ë˜ í•´ë“¤ì„ í¬í•¨í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ëŠ” ì£¼ë‹¹ ìŠ¤ìœ„ìŠ¤í”„ë‘ ê¸°ì¤€ ë°°ë‹¹ ì„±ì¥ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì¥ê¸°ì ì´ê³  í™•ê³ í•œ ì•½ì†ì„ ë°˜ì˜í•©ë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ì œ ë°œì–¸ì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ë§ˆë¬´ë¦¬í•˜ê¸° ì „ì—, ì´ë²ˆì´ ë…¸ë°”í‹°ìŠ¤ CFOë¡œì„œ ì œ ë§ˆì§€ë§‰ ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì´ ë  ê²ƒì„ì„ ê°„ëµíˆ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤.</td></tr>
<tr><td>It has been a privilege to serve in this role in the last 13 years and to work alongside Vas and so many other great colleagues to help guide the company through a period of significant transformation and performance improvement. I'm very pleased to hand over to Mukul, a long-time colleague. In fact, we both started maybe at different stages of our career in 2003 at Novartis and very intensively worked together, especially in the last 10 years. So with that, I turn it over to Mukul to take you through 2026 guidance. Mukul Mehta<br><br>Yes. A big thank you to you, Harry, for everything.</td><td>ì´ ì—­í• ì„ ì§€ë‚œ 13ë…„ê°„ ìˆ˜í–‰í•˜ê³ , Vasì™€ ë‹¤ë¥¸ ë§ì€ í›Œë¥­í•œ ë™ë£Œë“¤ê³¼ í•¨ê»˜ íšŒì‚¬ê°€ ì¤‘ìš”í•œ ë³€í˜ê³¼ ì‹¤ì  ê°œì„ ì˜ ì‹œê¸°ë¥¼ í—¤ì³ë‚˜ê°€ë„ë¡ ë•ëŠ” ê²ƒì€ íŠ¹ê¶Œì´ì—ˆìŠµë‹ˆë‹¤. ì˜¤ëœ ë™ë£Œì¸ Mukulì—ê²Œ ì´ ì—­í• ì„ ë„˜ê¸°ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤. ì‚¬ì‹¤ ìš°ë¦¬ ë‘˜ ë‹¤ 2003ë…„ Novartisì—ì„œ ê²½ë ¥ì˜ ë‹¤ë¥¸ ë‹¨ê³„ì—ì„œ ì‹œì‘í–ˆê³ , íŠ¹íˆ ì§€ë‚œ 10ë…„ê°„ ë§¤ìš° ê¸´ë°€í•˜ê²Œ í˜‘ë ¥í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Mukulì—ê²Œ ë„˜ê²¨ 2026ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ì„¤ëª…í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. <br><br>Mukul Mehta<br><br>ë„¤. Harry, ëª¨ë“  ê²ƒì— ëŒ€í•´ ì§„ì‹¬ìœ¼ë¡œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>It's been -- it is an honor to step into the role that you're leaving me with, and I look forward to getting to know everybody on the line in the months to come. So if you can go on Slide #29, please. For 2026, we expect sales to grow low single digit and core operating income to decline low single digits. And this reflects the 1 to 2 percent points of core margin dilution related to the Avidity deal that we had previously indicated. Importantly, in 2026, we will be growing top line through a period of highest GX impact in our company's history. At the same time, we will make sure that we continue to invest in R&D.</td><td>ì œê°€ ë§¡ê²Œ ë  ì—­í• ì„ ë¬¼ë ¤ì£¼ì…”ì„œ ì˜ê´‘ì…ë‹ˆë‹¤. ì•ìœ¼ë¡œ ëª‡ ë‹¬ ë™ì•ˆ ì „í™” ì°¸ì„í•˜ì‹  ëª¨ë“  ë¶„ë“¤ì„ ì•Œì•„ê°€ê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 29ë²ˆìœ¼ë¡œ ë„˜ì–´ê°€ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. 2026ë…„ì—ëŠ” ë§¤ì¶œì´ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥í•˜ê³  í•µì‹¬ ì˜ì—…ì´ìµì€ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ëŠ” ì´ì „ì— ì–¸ê¸‰í–ˆë˜ Avidity ê±°ë˜ì™€ ê´€ë ¨í•˜ì—¬ 1~2%í¬ì¸íŠ¸ì˜ í•µì‹¬ ë§ˆì§„ í¬ì„ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€, 2026ë…„ì— ìš°ë¦¬ íšŒì‚¬ ì—­ì‚¬ìƒ ê°€ì¥ í° ì œë„¤ë¦­ ì˜ì•½í’ˆ(GX) ì˜í–¥ì„ ë°›ëŠ” ê¸°ê°„ ë™ì•ˆì—ë„ ë§¤ì¶œ ì„±ì¥ì„ ì´ë£° ê²ƒì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ë™ì‹œì— ìš°ë¦¬ëŠ” R&Dì— ëŒ€í•œ íˆ¬ìë¥¼ ì§€ì†ì ìœ¼ë¡œ ì´ì–´ê°ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We fund our launches appropriately while driving forward with the productivity improvement plans that the company has. As previously noted, we expect to close the Avidity deal in the first half of 2026. Looking ahead, we remain very confident in our 5% to 6% sales CAGR in the '25, '30 period, and we expect to return to 40% plus core margin in 2029 as laid out in our Capital Markets Day. For 2026, we expect core net financial income expenses to be around $1.7 billion. This is higher than the '25 levels, and this is largely due to the anticipated funding costs related to the Avidity deal, which we have previously indicated is primarily going to be debt funded.</td><td>ìš°ë¦¬ëŠ” íšŒì‚¬ê°€ ì¶”ì§„í•˜ê³  ìˆëŠ” ìƒì‚°ì„± ê°œì„  ê³„íšì„ ì§„í–‰í•˜ë©´ì„œ ì‹ ì œí’ˆ ì¶œì‹œì— ì ì ˆí•˜ê²Œ ìê¸ˆì„ íˆ¬ì…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ì„œ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´, Avidity ê±°ë˜ëŠ” 2026ë…„ ìƒë°˜ê¸°ì— ë§ˆë¬´ë¦¬ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì•ìœ¼ë¡œë„ ìš°ë¦¬ëŠ” 2025ë…„ë¶€í„° 2030ë…„ê¹Œì§€ ì—°í‰ê·  5~6%ì˜ ë§¤ì¶œ ì„±ì¥ë¥ ì— ëŒ€í•´ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìœ¼ë©°, ìë³¸ì‹œì¥ì˜ ë‚ (Capital Markets Day)ì—ì„œ ì œì‹œí•œ ëŒ€ë¡œ 2029ë…„ì—ëŠ” í•µì‹¬ ë§ˆì§„ 40% ì´ìƒìœ¼ë¡œ ë³µê·€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. 2026ë…„ì˜ ê²½ìš°, í•µì‹¬ ìˆœê¸ˆìœµìˆ˜ìµ ë¹„ìš©ì´ ì•½ 17ì–µ ë‹¬ëŸ¬ ìˆ˜ì¤€ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ëŠ” 2025ë…„ ìˆ˜ì¤€ë³´ë‹¤ ë†’ì€ ê²ƒìœ¼ë¡œ, ì£¼ë¡œ Avidity ê±°ë˜ì™€ ê´€ë ¨ëœ ì˜ˆìƒ ìê¸ˆì¡°ë‹¬ ë¹„ìš© ë•Œë¬¸ì…ë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ì´ ê±°ë˜ëŠ” ì£¼ë¡œ ë¶€ì±„ë¡œ ì¡°ë‹¬ë  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>We also expect core tax rate to remain around 16.5%. Moving to Slide 30, please. As we have previously indicated as well, 2026 is going to be a year of 2 halves. We expect -- we continue to expect strong volume growth from our priority brands throughout 2026. But we have to understand that for the first half of the year, we will have a tough prior year base with Entresto, Promacta and Tasigna generics having entered the U.S. market mid-2025. With that, we expect the first half of the year sales to decline low single digit and core operating income to decline low double digit.</td><td>ìŠ¬ë¼ì´ë“œ 30ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì´ì „ì—ë„ ë§ì”€ë“œë ¸ë“¯ì´, 2026ë…„ì€ ìƒë°˜ê¸°ì™€ í•˜ë°˜ê¸°ë¡œ ë‚˜ë‰˜ëŠ” í•œ í•´ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2026ë…„ ë‚´ë‚´ ìš°ì„ ìˆœìœ„ ë¸Œëœë“œë“¤ì˜ ê°•ë ¥í•œ ë¬¼ëŸ‰ ì„±ì¥ì„ ê³„ì†í•´ì„œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ìƒë°˜ê¸°ì˜ ê²½ìš°, Entresto, Promacta, Tasignaì˜ ì œë„¤ë¦­ ì˜ì•½í’ˆë“¤ì´ 2025ë…„ ì¤‘ë°˜ì— ë¯¸êµ­ ì‹œì¥ì— ì§„ì…í•¨ì— ë”°ë¼ ì „ë…„ë„ ê¸°ì €íš¨ê³¼ê°€ ë†’ë‹¤ëŠ” ì ì„ ì´í•´í•´ì•¼ í•©ë‹ˆë‹¤. ì´ì— ë”°ë¼ ìƒë°˜ê¸° ë§¤ì¶œì€ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œ(low single digit decline)ë¥¼, í•µì‹¬ ì˜ì—…ì´ìµ(core operating income)ì€ ë‚®ì€ ë‘ ìë¦¿ìˆ˜ ê°ì†Œ(low double digit decline)ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Additionally, Q1 will be impacted by the 2% positive gross to net impact that we had in the base Q1 '25, which will weigh on the quarter-on-quarter growth rate in Q1. That said, in the second half of the year, we expect a clear improvement with sales growing mid-single digit and core operating income growing mid- to high single digit. This takes us to our full year guidance of low single digit on top line. So moving to Slide 31, please. If exchange rates remain as at their late January levels, we expect a positive 2 to 3 percentage point impact on our full year sales and a positive 1% point impact on core operating income.</td><td>ì¶”ê°€ë¡œ, 1ë¶„ê¸°ëŠ” 2025ë…„ 1ë¶„ê¸° ê¸°ì¤€ì— ìˆì—ˆë˜ 2% ê¸ì •ì ì¸ ì´ë§¤ì¶œ ëŒ€ë¹„ ìˆœë§¤ì¶œ ì˜í–¥ìœ¼ë¡œ ì¸í•´ ì˜í–¥ì„ ë°›ì„ ê²ƒì´ë©°, ì´ëŠ” 1ë¶„ê¸° ì „ë¶„ê¸° ëŒ€ë¹„ ì„±ì¥ë¥ ì— ë¶€ë‹´ìœ¼ë¡œ ì‘ìš©í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ í•˜ë°˜ê¸°ì—ëŠ” ë§¤ì¶œì´ ì¤‘ê°„ í•œìë¦¿ìˆ˜ ì„±ì¥í•˜ê³  í•µì‹¬ ì˜ì—…ì´ìµì´ ì¤‘ê°„ì—ì„œ ë†’ì€ í•œìë¦¿ìˆ˜ ì„±ì¥í•˜ëŠ” ë“± ëª…í™•í•œ ê°œì„ ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì—°ê°„ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ëŠ” ë‚®ì€ í•œìë¦¿ìˆ˜ ì„±ì¥ì´ ë©ë‹ˆë‹¤. ê·¸ëŸ¼ 31í˜ì´ì§€ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. í™˜ìœ¨ì´ 1ì›” ë§ ìˆ˜ì¤€ìœ¼ë¡œ ìœ ì§€ëœë‹¤ë©´, ì—°ê°„ ë§¤ì¶œì— 2~3%í¬ì¸íŠ¸ì˜ ê¸ì •ì  ì˜í–¥ê³¼ í•µì‹¬ ì˜ì—…ì´ìµì— 1%í¬ì¸íŠ¸ì˜ ê¸ì •ì  ì˜í–¥ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And as a reminder, which Harry has conveyed previously, we published updated FX estimates monthly on our website. So that concludes my remarks, and I hand it over back to Vas. Vasant Narasimhan<br>Chief Executive Officer<br><br>Yes. Thank you, Mukul. I want to take a moment as well to acknowledge Harry Kirsch's incredible contributions to Novartis over 23 years. Over my tenure as CEO, now entering my ninth year, Harry has been by my side as we've transformed the company into a pure play and I think unlocked really outstanding shareholder returns, outstanding financial performance.</td><td>ê·¸ë¦¬ê³  Harryê°€ ì´ì „ì— ì „ë‹¬í•œ ë°”ì™€ ê°™ì´, ì €í¬ëŠ” ë§¤ì›” ì›¹ì‚¬ì´íŠ¸ì— ì—…ë°ì´íŠ¸ëœ í™˜ìœ¨ ì¶”ì •ì¹˜ë¥¼ ê²Œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ì œ ë°œì–¸ì„ ë§ˆì¹˜ê³ , ë‹¤ì‹œ Vasì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Vasant Narasimhan<br>ìµœê³ ê²½ì˜ì<br><br>ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Mukul. ì €ëŠ” ì ì‹œ ì‹œê°„ì„ ë‚´ì–´ 23ë…„ê°„ ë…¸ë°”í‹°ìŠ¤ì— ëŒ€í•œ Harry Kirschì˜ ë†€ë¼ìš´ ê³µí—Œì„ ì¸ì •í•˜ê³ ì í•©ë‹ˆë‹¤. ì´ì œ 9ë…„ì°¨ì— ì ‘ì–´ë“  ì œ CEO ì¬ì„ ê¸°ê°„ ë™ì•ˆ, HarryëŠ” ì €ì™€ í•¨ê»˜ íšŒì‚¬ë¥¼ ìˆœìˆ˜ ì‚¬ì—…ì²´(pure play)ë¡œ ì „í™˜í•˜ëŠ” ê³¼ì •ì—ì„œ ì œ ê³ì„ ì§€ì¼œì™”ìœ¼ë©°, ì •ë§ íƒì›”í•œ ì£¼ì£¼ ìˆ˜ìµë¥ ê³¼ ë›°ì–´ë‚œ ì¬ë¬´ ì„±ê³¼ë¥¼ ì°½ì¶œí–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>But probably less visible is the strength of the finance organization Harry has built as well as the culture he's created in the company around productivity, financial discipline and operational excellence. He'll surely be missed, but will continue his legacy in the years to come. And a big welcome to Mukul, who I've known for many, many years. It will be a great addition to the team and continue the strong track record of Novartis finance and delivering strong operational execution. Now moving to the next slide. I do want to take a moment to build on Mukul's comments on our confidence in the -- our 5% to 6% sales CAGR to 25% to 30%.</td><td>í•˜ì§€ë§Œ ëœ ëˆˆì— ë„ëŠ” ë¶€ë¶„ì€ Harryê°€ êµ¬ì¶•í•œ ì¬ë¬´ ì¡°ì§ì˜ ê°•ì ê³¼ ê·¸ê°€ íšŒì‚¬ ë‚´ì—ì„œ ìƒì‚°ì„±, ì¬ë¬´ ê·œìœ¨, ìš´ì˜ ìš°ìˆ˜ì„±ì„ ì¤‘ì‹¬ìœ¼ë¡œ ë§Œë“¤ì–´ë‚¸ ë¬¸í™”ì…ë‹ˆë‹¤. ê·¸ê°€ ë– ë‚˜ëŠ” ê²ƒì€ ë¶„ëª… ì•„ì‰½ì§€ë§Œ, ê·¸ì˜ ìœ ì‚°ì€ ì•ìœ¼ë¡œë„ ê³„ì†ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œê°€ ì˜¤ëœ ì„¸ì›” ì•Œê³  ì§€ë‚¸ Mukulì„ ì§„ì‹¬ìœ¼ë¡œ í™˜ì˜í•©ë‹ˆë‹¤. ê·¸ëŠ” íŒ€ì— í›Œë¥­í•œ ë³´íƒ¬ì´ ë  ê²ƒì´ë©°, Novartis ì¬ë¬´ ë¶€ë¬¸ì˜ ê°•ë ¥í•œ ì‹¤ì ê³¼ íƒì›”í•œ ìš´ì˜ ì‹¤í–‰ë ¥ì˜ ì „í†µì„ ì´ì–´ê°ˆ ê²ƒì…ë‹ˆë‹¤. <br><br>ì´ì œ ë‹¤ìŒ ìŠ¬ë¼ì´ë“œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. Mukulì´ ì–¸ê¸‰í•œ ìš°ë¦¬ì˜ ë§¤ì¶œ ì—°í‰ê· ì„±ì¥ë¥ (CAGR) 5%~6%, ê·¸ë¦¬ê³  25%~30%ì— ëŒ€í•œ í™•ì‹ ì— ëŒ€í•´ ì ì‹œ ë¶€ì—° ì„¤ëª…ì„ ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤.</td></tr>
<tr><td>That includes the impact of Entresto in 2026 as well as the U.S. MFN agreement impact. You can see in the chart, we do expect some generic impact. So a lot of that is front-loaded in the first -- early part of the 5-year trajectory here. A number of brands where we believe we can drive dynamic growth in the middle column. And then lastly, a strong set of assets that we probabilized in our pipeline. This ranges from lanalumab, our various Pluvicto and actinium PSMA, pelacarsen as well as the Avidity assets, amongst others, that give us the opportunity to not only hopefully deliver the 5% to 6%, but if we're successful on those pipeline assets, we could even drive higher growth in the period.</td><td>ì´ëŠ” 2026ë…„ ì—”íŠ¸ë ˆìŠ¤í† ì˜ ì˜í–¥ê³¼ ë¯¸êµ­ MFN í˜‘ì •ì˜ ì˜í–¥ì„ í¬í•¨í•œ ê²ƒì…ë‹ˆë‹¤. ì°¨íŠ¸ì—ì„œ ë³´ì‹œë‹¤ì‹œí”¼, ì €í¬ëŠ” ì¼ë¶€ ì œë„¤ë¦­ ì˜í–¥ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ì˜í–¥ì˜ ìƒë‹¹ ë¶€ë¶„ì´ 5ê°œë…„ ê³„íš ì´ˆê¸°ì— ì§‘ì¤‘ë  ê²ƒì…ë‹ˆë‹¤. ì¤‘ê°„ ì—´ì—ëŠ” ì—­ë™ì ì¸ ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆë‹¤ê³  ë¯¿ëŠ” ì—¬ëŸ¬ ë¸Œëœë“œë“¤ì´ ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, íŒŒì´í”„ë¼ì¸ì—ì„œ í™•ë¥ ì„ ë¶€ì—¬í•œ ê°•ë ¥í•œ ìì‚°êµ°ì´ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë¼ë‚ ë£¨ë§™, ë‹¤ì–‘í•œ í”Œë£¨ë¹…í†  ë° ì•…í‹°ëŠ„ PSMA, í ë¼ì¹´ë¥´ì„¼, ê·¸ë¦¬ê³  Avidity ìì‚° ë“±ì´ í¬í•¨ë˜ë©°, ì´ë“¤ì€ 5%~6%ì˜ ì„±ì¥ë¥ ì„ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ì œê³µí•  ë¿ë§Œ ì•„ë‹ˆë¼, ë§Œì•½ ì´ëŸ¬í•œ íŒŒì´í”„ë¼ì¸ ìì‚°ë“¤ì´ ì„±ê³µí•œë‹¤ë©´ í•´ë‹¹ ê¸°ê°„ ë™ì•ˆ ë” ë†’ì€ ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So moving to Slide 34. and in closing, strong performance in 2025. We delivered the guidance that we outlooked and got to our 40% core margin early. Our priority brands continue to outperform, and that's what's going to drive our growth through the second half of '26 and then through the 5 years to come. We're advancing the pipeline meaningfully in 2020 -- we advanced meaningfully in 2025 with 7 pivotal readouts this year. And we're confident in that mid- to long-term growth guidance. So move -- so with that, we can close this section and move to questions. So operator, we could open the line. Thank you.</td><td>ìŠ¬ë¼ì´ë“œ 34ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë§ˆë¬´ë¦¬í•˜ë©´ì„œ, 2025ë…„ ê°•ë ¥í•œ ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì œì‹œí–ˆë˜ ê°€ì´ë˜ìŠ¤ë¥¼ ë‹¬ì„±í–ˆê³  40% í•µì‹¬ ë§ˆì§„ì— ì¡°ê¸°ì— ë„ë‹¬í–ˆìŠµë‹ˆë‹¤. ìš°ì„ ìˆœìœ„ ë¸Œëœë“œë“¤ì´ ê³„ì†í•´ì„œ ìš°ìˆ˜í•œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ '26ë…„ í•˜ë°˜ê¸°ì™€ í–¥í›„ 5ë…„ê°„ ì €í¬ ì„±ì¥ì„ ê²¬ì¸í•  ê²ƒì…ë‹ˆë‹¤. 2025ë…„ì— 7ê±´ì˜ ì¤‘ì¶”ì  ì„ìƒê²°ê³¼ ë°œí‘œë¥¼ í†µí•´ íŒŒì´í”„ë¼ì¸ì„ ì˜ë¯¸ ìˆê²Œ ì§„ì „ì‹œì¼°ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ì¤‘ì¥ê¸° ì„±ì¥ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ì´ ì„¹ì…˜ì„ ë§ˆë¬´ë¦¬í•˜ê³  ì§ˆì˜ì‘ë‹µìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì˜¤í¼ë ˆì´í„°, íšŒì„ ì„ ì—´ì–´ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Novartis AG (NVS) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## ì£¼ìš” ì¬ë¬´ ì„±ê³¼<br>- **2025ë…„ ì—°ê°„ ì‹¤ì **: ë§¤ì¶œ 8% ì„±ì¥, í•µì‹¬ ì˜ì—…ì´ìµ 14% ì¦ê°€, í•µì‹¬ ì˜ì—…ì´ìµë¥  40.1% ë‹¬ì„± (ëª©í‘œ ëŒ€ë¹„ 2ë…„ ì¡°ê¸° ë‹¬ì„±)<br>- **4ë¶„ê¸° ì‹¤ì **: ë§¤ì¶œ 1% ê°ì†Œ (Entresto íŠ¹í—ˆë§Œë£Œ ë° ì´ì•¡-ìˆœì•¡ ì¡°ì • ì˜í–¥), í•µì‹¬ ì˜ì—…ì´ìµ 1% ì¦ê°€<br>- **í˜„ê¸ˆíë¦„**: ì—°ê°„ ì‰ì—¬í˜„ê¸ˆíë¦„ 176ì–µ ë‹¬ëŸ¬ë¡œ ì‚¬ìƒ ìµœê³ ì¹˜ ê¸°ë¡<br>- **2026ë…„ ê°€ì´ë˜ìŠ¤**: ë§¤ì¶œ ì €ë‹¨ìœ„ í•œìë¦¿ìˆ˜ ì„±ì¥, í•µì‹¬ ì˜ì—…ì´ìµ ì €ë‹¨ìœ„ í•œìë¦¿ìˆ˜ ê°ì†Œ ì „ë§ (Avidity ì¸ìˆ˜ë¡œ ì¸í•œ ë§ˆì§„ í¬ì„ 1-2%p ë°˜ì˜)<br><br>## í•µì‹¬ ì„±ì¥ ë™ë ¥<br>- **Kisqali**: ì—°ê°„ 57% ì„±ì¥í•˜ì—¬ 48ì–µ ë‹¬ëŸ¬ ë‹¬ì„±, ë¯¸êµ­ ì¡°ê¸°ìœ ë°©ì•” ì‹œì¥ NBRx ì ìœ ìœ¨ 60% ì´ˆê³¼, ìµœëŒ€ 100ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ ëª©í‘œ ìœ ì§€<br>- **Kesimpta**: 36% ì„±ì¥í•˜ì—¬ 44ì–µ ë‹¬ëŸ¬, ë¯¸êµ­ ì‹ ê·œ ì²˜ë°©ì˜ 50%ê°€ 1ì°¨ ì¹˜ë£Œ, ìµœëŒ€ 60ì–µ ë‹¬ëŸ¬ ì´ìƒ ëª©í‘œ<br>- **Pluvicto**: 42% ì„±ì¥í•˜ì—¬ 20ì–µ ë‹¬ëŸ¬, PSMAfore ì ì‘ì¦ ì¶œì‹œë¡œ ë¯¸êµ­ ì‹œì¥ ì ìœ ìœ¨ 16% ë‹¬ì„±, í˜¸ë¥´ëª¬ ë¯¼ê°ì„±</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] We'll start with our first question, and this is from Sachin Jain from Bank of America.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ì˜ Sachin Jain ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Sachin Jain: BofA Securities, Research Division Perhaps I'll just kick off with thanking Harry for support and insight over the years. The question, I guess, for that on remi. You talked about avoiding liver monitoring in MS given no high law. Competition recently has been vocal avoiding monitoring in the label when monitoring has been involved in the studies could be difficult. So I wonder if you could just give us any color on FDA conversations around this topic and whether monitoring in the studies picked up events that required dose changes? And then a quick follow-on on efficacy. Any color on what you're targeting on relapse or progression given we have no Phase II to go here.</td><td>**Sachin Jain:** ì§€ë‚œ ëª‡ ë…„ê°„ Harryì˜ ì§€ì›ê³¼ í†µì°°ë ¥ì— ê°ì‚¬ë“œë¦°ë‹¤ëŠ” ë§ì”€ì„ ë¨¼ì € ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë ˆë¯¸(remi)ì— ëŒ€í•œ ì§ˆë¬¸ì…ë‹ˆë‹¤. ê°„ ìˆ˜ì¹˜ ìƒìŠ¹ì´ ë†’ì§€ ì•Šì•„ ë‹¤ë°œì„±ê²½í™”ì¦(MS)ì—ì„œ ê°„ ëª¨ë‹ˆí„°ë§ì„ í”¼í•  ìˆ˜ ìˆë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ìµœê·¼ ê²½ìŸì‚¬ë“¤ì€ ì„ìƒì‹œí—˜ì—ì„œ ëª¨ë‹ˆí„°ë§ì´ í¬í•¨ë˜ì—ˆì„ ë•Œ ë¼ë²¨ì—ì„œ ëª¨ë‹ˆí„°ë§ì„ í”¼í•˜ëŠ” ê²ƒì´ ì–´ë ¤ìš¸ ìˆ˜ ìˆë‹¤ê³  ëª©ì†Œë¦¬ë¥¼ ë†’ì—¬ì™”ìŠµë‹ˆë‹¤. ì´ ì£¼ì œì™€ ê´€ë ¨í•˜ì—¬ FDAì™€ì˜ ë…¼ì˜ ë‚´ìš©ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ì„ìƒì‹œí—˜ì—ì„œì˜ ëª¨ë‹ˆí„°ë§ì„ í†µí•´ ìš©ëŸ‰ ì¡°ì ˆì´ í•„ìš”í•œ ì‚¬ë¡€ë“¤ì´ ë°œê²¬ë˜ì—ˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  íš¨ëŠ¥ì— ëŒ€í•œ ê°„ë‹¨í•œ í›„ì† ì§ˆë¬¸ì…ë‹ˆë‹¤. 2ìƒ ì„ìƒ ë°ì´í„°ê°€ ì—†ëŠ” ìƒí™©ì—ì„œ ì¬ë°œë¥ ì´ë‚˜ ì§„í–‰ ê´€ë ¨í•˜ì—¬ ëª©í‘œë¡œ í•˜ì‹œëŠ” ìˆ˜ì¹˜ê°€ ìˆìœ¼ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Chief Executive Officer: Yes. Thanks, Sachin. So I think first on liver, I think we should first take a step back and note that we already have an approval and an approved label without any liver safety discussion in the label, which just points to the fact that remibrutinib structurally does not have the off-target toxicities we believe that the structures of some of the other molecules do. And so that we didn't have any of that in the existing TSU label. I think I have an abundance of caution given the findings of the other competitors, FDA asked us for a limited liver monitoring to our understanding that's more limited than the liver monitoring that our competitors have had to add to their programs. And our full plan is assuming that we -- and as we've seen to date, no liver signals in our study, we fully plan to advocate to FDA that we should stick to the current label in the absence of any information to really -- any data to really change the current label with respect to that. I'd also note that for -- in general, for competitors, when there is a Hy's law case, at least to our understanding, whether it's 1, 2, 3 cases, that generally leads to REMS programs, leads to monitoring, does lead to warnings and precautions, just given the safety risk that these -- that creates for patients who have alternative therapies. And in RRMS, there's numerous alternative therapies. So safety is absolutely paramount. So I think that's our overall perspective on the safety. We're very confident in overall remi's safety and assuming 2 positive Phase III trials this summer, the potential for this to be a very significant medicine. Now with respect to efficacy, I think it's very fair to point out, we don't have Phase II data. We went to Phase III based on the findings that we saw from competitors. So -- but I think given that we know that we hit the target very well at 25 milligrams BID and we move up to 100 milligrams BID in the study, we think we'll definitely have strong target saturation. We think the molecule is very well designed when we look at the PK and the PD of the molecule. So that gives us confidence that assuming the class is effective against RRMS, we will have a compelling profile from an efficacy standpoint and with the safety profile and with the fact that we're established now in the market having already launched should give us a strong value proposition.</td><td>**Chief Executive Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € ê°„ ì•ˆì „ì„± ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, í•œ ë°œ ë¬¼ëŸ¬ì„œì„œ ìƒê°í•´ë³¼ í•„ìš”ê°€ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë¯¸ ìŠ¹ì¸ì„ ë°›ì•˜ê³ , ìŠ¹ì¸ëœ ë¼ë²¨ì— ê°„ ì•ˆì „ì„± ê´€ë ¨ ë‚´ìš©ì´ ì „í˜€ í¬í•¨ë˜ì–´ ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ëŠ” ë ˆë¯¸ë¸Œë£¨í‹°ë‹™ì´ êµ¬ì¡°ì ìœ¼ë¡œ ë‹¤ë¥¸ ê²½ìŸ ë¬¼ì§ˆë“¤ì´ ê°€ì§€ê³  ìˆë‹¤ê³  ìƒê°ë˜ëŠ” ë¹„í‘œì  ë…ì„±(off-target toxicity)ì„ ê°€ì§€ê³  ìˆì§€ ì•Šë‹¤ëŠ” ì ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ê·¸ë˜ì„œ ê¸°ì¡´ TSU ë¼ë²¨ì—ëŠ” ê·¸ëŸ¬í•œ ë‚´ìš©ì´ ì „í˜€ ì—†ì—ˆìŠµë‹ˆë‹¤. <br><br>ë‹¤ë§Œ ê²½ìŸì‚¬ë“¤ì˜ ì—°êµ¬ ê²°ê³¼ë¥¼ ê³ ë ¤í•˜ì—¬, FDAê°€ ì‹ ì¤‘ì„ ê¸°í•´ ì œí•œì ì¸ ê°„ ëª¨ë‹ˆí„°ë§ì„ ìš”ì²­í–ˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ì´í•´í•˜ê¸°ë¡œëŠ” ì´ê²ƒì´ ê²½ìŸì‚¬ë“¤ì´ í”„ë¡œê·¸ë¨ì— ì¶”ê°€í•´ì•¼ í–ˆë˜ ê°„ ëª¨ë‹ˆí„°ë§ë³´ë‹¤ í›¨ì”¬ ì œí•œì ì¸ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì €í¬ì˜ ì „ì²´ ê³„íšì€ í˜„ì¬ê¹Œì§€ ì—°êµ¬ì—ì„œ ê°„ ê´€ë ¨ ì‹ í˜¸ê°€ ë‚˜íƒ€ë‚˜ì§€ ì•Šì•˜ë‹¤ëŠ” ì ì„ ì „ì œë¡œ í•˜ê³  ìˆìœ¼ë©°, í˜„í–‰ ë¼ë²¨ì„ ë³€ê²½í•  ë§Œí•œ ì‹¤ì§ˆì ì¸ ì •ë³´ë‚˜ ë°ì´í„°ê°€ ì—†ëŠ” ìƒí™©ì—ì„œ FDAì— í˜„í–‰ ë¼ë²¨ì„ ìœ ì§€í•´ì•¼ í•œë‹¤ê³  ì ê·¹ ì£¼ì¥í•  ê³„íšì…ë‹ˆë‹¤. ë˜í•œ ì¼ë°˜ì ìœ¼ë¡œ ê²½ìŸì‚¬ë“¤ì˜ ê²½ìš°, ì €í¬ê°€ ì´í•´í•˜ê¸°ë¡œëŠ” Hy's law ì‚¬ë¡€ê°€ 1ê±´ì´ë“  2ê±´ì´ë“  3ê±´ì´ë“  ë°œìƒí•˜ë©´, ì´ëŠ” ëŒ€ì²´ ì¹˜ë£Œì œê°€ ìˆëŠ” í™˜ìë“¤ì—ê²Œ ë°œìƒì‹œí‚¤ëŠ” ì•ˆì „ì„± ìœ„í—˜ì„ ê³ ë ¤í•  ë•Œ ì¼ë°˜ì ìœ¼ë¡œ REMS í”„ë¡œê·¸ë¨ìœ¼ë¡œ ì´ì–´ì§€ê³ , ëª¨ë‹ˆí„°ë§ì´ í•„ìš”í•˜ê²Œ ë˜ë©°, ê²½ê³  ë° ì£¼ì˜ì‚¬í•­ì´ ì¶”ê°€ë˜ê²Œ ë©ë‹ˆë‹¤. RRMSì˜ ê²½ìš° ìˆ˜ë§ì€ ëŒ€ì²´ ì¹˜ë£Œì œë“¤ì´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì•ˆì „ì„±ì´ ì ˆëŒ€ì ìœ¼ë¡œ ìµœìš°ì„ ì…ë‹ˆë‹¤. ì´ê²ƒì´ ì•ˆì „ì„±ì— ëŒ€í•œ ì €í¬ì˜ ì „ë°˜ì ì¸ ê´€ì ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì „ë°˜ì ì¸ ë ˆë¯¸ì˜ ì•ˆì „ì„±ì— ëŒ€í•´ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìœ¼ë©°, ì˜¬ ì—¬ë¦„ 2ê±´ì˜ 3ìƒ ì„ìƒì‹œí—˜ì—ì„œ ê¸ì •ì ì¸ ê²°ê³¼ê°€ ë‚˜ì˜¨ë‹¤ë©´ ì´ ì•½ë¬¼ì´ ë§¤ìš° ì¤‘ìš”í•œ ì˜ì•½í’ˆì´ ë  ì ì¬ë ¥ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ìœ íš¨ì„±ê³¼ ê´€ë ¨í•´ì„œëŠ”, ì €í¬ê°€ 2ìƒ ë°ì´í„°ë¥¼ ë³´ìœ í•˜ê³  ìˆì§€ ì•Šë‹¤ëŠ” ì ì„ ì§€ì í•˜ì‹œëŠ” ê²ƒì´ íƒ€ë‹¹í•©ë‹ˆë‹¤. ì €í¬ëŠ” ê²½ìŸì‚¬ë“¤ì˜ ì—°êµ¬ ê²°ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ 3ìƒìœ¼ë¡œ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 25mg BID ìš©ëŸ‰ì—ì„œ íƒ€ê²Ÿì„ ë§¤ìš° ì˜ ì ì¤‘ì‹œì¼°ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆê³ , ì„ìƒì‹œí—˜ì—ì„œ 100mg BIDê¹Œì§€ ìš©ëŸ‰ì„ ë†’ì˜€ê¸° ë•Œë¬¸ì—, í™•ì‹¤íˆ ê°•ë ¥í•œ íƒ€ê²Ÿ í¬í™”ë„(target saturation)ë¥¼ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ë¶„ìì˜ ì•½ë™í•™(PK)ê³¼ ì•½ë ¥í•™(PD)ì„ ì‚´í´ë´¤ì„ ë•Œ, ì´ ë¶„ìê°€ ë§¤ìš° ì˜ ì„¤ê³„ë˜ì—ˆë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. <budget><br><br>ì‚¬ìš©ëœ í† í°: ì•½ 150 (ì…ë ¥) + 250 (ì¶œë ¥) = 400 í† í°<br>ë‚¨ì€ ì˜ˆì‚°: 199,600 í† í°<br><br></budget><br><br>ë”°ë¼ì„œ ì´ ì•½ë¬¼ ê³„ì—´ì´ ì¬ë°œ-ì™„í™”í˜• ë‹¤ë°œì„± ê²½í™”ì¦(RRMS)ì— íš¨ê³¼ì ì´ë¼ëŠ” ê°€ì • í•˜ì—, ìš°ë¦¬ëŠ” íš¨ëŠ¥ ì¸¡ë©´ì—ì„œ ë§¤ìš° ê²½ìŸë ¥ ìˆëŠ” í”„ë¡œíŒŒì¼ì„ ê°–ì¶”ê²Œ ë  ê²ƒì´ë¼ëŠ” í™•ì‹ ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì— ì•ˆì „ì„± í”„ë¡œíŒŒì¼ê¹Œì§€ ë”í•´ì§€ê³ , ì´ë¯¸ ì¶œì‹œë¥¼ ì™„ë£Œí•˜ì—¬ ì‹œì¥ì—ì„œ ì…ì§€ë¥¼ í™•ë³´í–ˆë‹¤ëŠ” ì ì„ ê³ ë ¤í•˜ë©´, ê°•ë ¥í•œ ê°€ì¹˜ ì œì•ˆì„ ì œì‹œí•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: We'll take our next question today, and this is from Simon Baker, Rothschild & Co Redburn.</td><td>**Operator:** ì˜¤ëŠ˜ ë‹¤ìŒ ì§ˆë¬¸ì€ Rothschild & Co Redburnì˜ Simon Bakerë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Simon Baker: Rothschild & Co Redburn, Research Division Two, if I may, please. Firstly, on -- just continuing on remibrutinib. -- going on from Sachin's question. I just wonder if you could give us your updated thoughts on the commercial opportunities here in MS because it kind of feels like that your enthusiasm for remi in MS has increased over time. A couple of years ago, there was talk of almost MS being playing second fiddle to CSU. So just updated perspectives on your thoughts on the commercial opportunity. And then moving on to pelacarsen. You've now guided to a 2H '26 readout. Given this is an event-based study, could you just give us any thoughts on potential risks and risk mitigation for this what appears to be significantly lower event rate, does this run the risk of creating additional noise in the study? Or is that more than offset by the powering assumptions and the design that you've built in there? Any thoughts on that would be very helpful.</td><td>**Simon Baker:** ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ë ˆë¯¸ë¸Œë£¨í‹°ë‹™ ê´€ë ¨í•´ì„œ Sachinì˜ ì§ˆë¬¸ì— ì´ì–´ì„œ ì—¬ì­™ê² ìŠµë‹ˆë‹¤. MSì—ì„œì˜ ìƒì—…ì  ê¸°íšŒì— ëŒ€í•œ ìµœì‹  ê²¬í•´ë¥¼ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ MSì—ì„œ ë ˆë¯¸ë¸Œë£¨í‹°ë‹™ì— ëŒ€í•œ ê·€ì‚¬ì˜ ê¸°ëŒ€ê°ì´ ë†’ì•„ì§„ ê²ƒì²˜ëŸ¼ ë³´ì…ë‹ˆë‹¤. ëª‡ ë…„ ì „ë§Œ í•´ë„ MSê°€ CSUì— ë¹„í•´ ë¶€ì°¨ì ì¸ ìœ„ì¹˜ë¼ëŠ” ì´ì•¼ê¸°ê°€ ìˆì—ˆëŠ”ë°ìš”. ê·¸ë˜ì„œ ìƒì—…ì  ê¸°íšŒì— ëŒ€í•œ ìµœì‹  ê´€ì ì„ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í ë¼ì¹´ì„¼ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, ì´ì œ 2026ë…„ í•˜ë°˜ê¸° ê²°ê³¼ ë°œí‘œë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ì…¨ëŠ”ë°ìš”. <translation><br><br>ì´ê²ƒì´ ì‚¬ê±´ ê¸°ë°˜(event-based) ì—°êµ¬ë¼ëŠ” ì ì„ ê³ ë ¤í•  ë•Œ, í˜„ì €íˆ ë‚®ì•„ ë³´ì´ëŠ” ì‚¬ê±´ ë°œìƒë¥ ê³¼ ê´€ë ¨ëœ ì ì¬ì  ìœ„í—˜ ìš”ì†Œì™€ ë¦¬ìŠ¤í¬ ì™„í™” ë°©ì•ˆì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì´ë¡œ ì¸í•´ ì—°êµ¬ì— ì¶”ê°€ì ì¸ ë…¸ì´ì¦ˆê°€ ë°œìƒí•  ìœ„í—˜ì´ ìˆëŠ” ê±´ì§€, ì•„ë‹ˆë©´ ê²€ì •ë ¥(powering) ê°€ì •ê³¼ ì„¤ê³„ì— ë°˜ì˜í•˜ì‹  ë¶€ë¶„ë“¤ì´ ê·¸ëŸ¬í•œ ìœ„í—˜ì„ ì¶©ë¶„íˆ ìƒì‡„í•˜ëŠ”ì§€ìš”? ì´ ë¶€ë¶„ì— ëŒ€í•œ ê²¬í•´ë¥¼ ë“¤ë ¤ì£¼ì‹œë©´ í° ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.<br><br></translation></td></tr>
<tr><td>Chief Executive Officer: Yes. Thanks, Simon. So first on the commercial opportunity, I think it's really going to be data-driven. I think our base case assumption is that an oral drug will struggle to have the same level of efficacy as monoclonal antibodies in hitting the B-cell pathways in MS. And because of that, that still B-cell monoclonal antibodies will be the dominant class, but there will be a number -- large number of patients that would want an oral option and who don't want to go through injectable therapy. I mean, as I noted in my slide, still 25% of patients in the U.S. and 65% outside of the U.S. are on DMTs and are not on B-cell injectable B-cell therapy. So there's a large market there on its own. And then I think it will depend if the efficacy and safety profile overall, particularly the efficacy profile in the case of remi in our hand is compelling enough to have a broader market. So I think we'll certainly see based on the data. But even if we take it as a given that there is a large B-cell monoclonal class out there, there is a large market opportunity beyond that, which we think is important. And then, of course, the question is with the brain penetrant properties of our molecule, does that lead to other opportunities either in SPMS or in the control of RRMS that provides another dimension, and that will all be data driven as well. So in this case, I'll exceptionally take the second question, but if everyone could limit themselves to one question. Pelacarsen, so we expect a midyear readout. The study is going to completion in terms of the number of events that we had originally outlined. We had powered up the study, you'll recall, during the process of the Phase III. So we feel like we're adequately powered to demonstrate both at the 70-milligram per DL cutoff and the 90-milligram per DL cutoff, the CVRR that we're targeting. And so I don't think there's necessarily any risk associated with going in full. I think what it does indicate is that the event rates are lower than what we had modeled from the published literature. And I think that's just something that is just the reality now that we found. We suspect it has to do with the fact that we've really optimally managed these patients for all other risk factors, particularly LDL lowering. And I think that, of course, has an impact on event rates as well. So we'll see, and we're excited to see this data and hopefully creating an entire new class of medicines that can help a whole group of patients that have no other option. And so I think with a positive study, we have the opportunity to give these patients a hopeful solution against sudden cardiac death and some of the other things that can happen for patients with elevated Lp(a).</td><td>**Chief Executive Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Simon. ë¨¼ì € ìƒì—…ì  ê¸°íšŒì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, ì´ëŠ” ì •ë§ ë°ì´í„°ì— ê¸°ë°˜í•  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ì €í¬ì˜ ê¸°ë³¸ ì‹œë‚˜ë¦¬ì˜¤ëŠ” ê²½êµ¬ìš© ì•½ë¬¼ì´ ë‹¤ë°œì„± ê²½í™”ì¦ì—ì„œ Bì„¸í¬ ê²½ë¡œë¥¼ íƒ€ê²ŸíŒ…í•˜ëŠ” ë° ìˆì–´ ë‹¨ì¼í´ë¡ í•­ì²´(monoclonal antibodies)ì™€ ë™ì¼í•œ ìˆ˜ì¤€ì˜ íš¨ëŠ¥ì„ ë‹¬ì„±í•˜ê¸° ì–´ë ¤ìš¸ ê²ƒì´ë¼ëŠ” ê°€ì •ì…ë‹ˆë‹¤. ê·¸ë ‡ê¸° ë•Œë¬¸ì— Bì„¸í¬ ë‹¨ì¼í´ë¡ í•­ì²´ê°€ ì—¬ì „íˆ ì§€ë°°ì ì¸ ì¹˜ë£Œì œ í´ë˜ìŠ¤ê°€ ë  ê²ƒì´ì§€ë§Œ, ê²½êµ¬ìš© ì˜µì…˜ì„ ì›í•˜ê³  ì£¼ì‚¬ ì¹˜ë£Œë¥¼ ë°›ê³  ì‹¶ì–´í•˜ì§€ ì•ŠëŠ” í™˜ìë“¤ì´ ìƒë‹¹íˆ ë§ì„ ê²ƒì…ë‹ˆë‹¤. ì œê°€ ìŠ¬ë¼ì´ë“œì—ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ë¯¸êµ­ì—ì„œëŠ” ì—¬ì „íˆ 25%ì˜ í™˜ìë“¤ì´, ê·¸ë¦¬ê³  ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” 65%ì˜ í™˜ìë“¤ì´ ì§ˆë³‘ì¡°ì ˆì¹˜ë£Œì œ(DMTs)ë¥¼ ì‚¬ìš©í•˜ê³  ìˆì§€ë§Œ ì£¼ì‚¬í˜• Bì„¸í¬ ì¹˜ë£Œì œë¥¼ ì‚¬ìš©í•˜ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ ìì²´ë¡œ ì´ë¯¸ í° ì‹œì¥ì´ ì¡´ì¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë ˆë¯¸ì˜ ê²½ìš° ìš°ë¦¬ê°€ í™•ë³´í•œ íš¨ëŠ¥ê³¼ ì•ˆì „ì„± í”„ë¡œíŒŒì¼, íŠ¹íˆ íš¨ëŠ¥ í”„ë¡œíŒŒì¼ì´ ë” ë„“ì€ ì‹œì¥ì„ í™•ë³´í•  ë§Œí¼ ì¶©ë¶„íˆ ì„¤ë“ë ¥ì´ ìˆëŠ”ì§€ì— ë”°ë¼ ë‹¬ë¼ì§ˆ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ë°ì´í„°ë¥¼ ê¸°ë°˜ìœ¼ë¡œ í™•ì‹¤íˆ íŒë‹¨í•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ Bì„¸í¬ ë‹¨í´ë¡ í•­ì²´ ê³„ì—´ì´ í° ì‹œì¥ì„ í˜•ì„±í•˜ê³  ìˆë‹¤ëŠ” ì ì„ ê°ì•ˆí•˜ë”ë¼ë„, ê·¸ ì™¸ì—ë„ ì¤‘ìš”í•œ ëŒ€ê·œëª¨ ì‹œì¥ ê¸°íšŒê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¬¼ë¡  ìš°ë¦¬ ë¬¼ì§ˆì˜ ë‡Œ íˆ¬ê³¼ íŠ¹ì„±ì´ SPMS(ì´ì°¨ì§„í–‰í˜• ë‹¤ë°œì„±ê²½í™”ì¦)ë‚˜ RRMS(ì¬ë°œ-ì™„í™”í˜• ë‹¤ë°œì„±ê²½í™”ì¦) ì¡°ì ˆì—ì„œ ë‹¤ë¥¸ ê¸°íšŒë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆëŠ”ì§€ê°€ ê´€ê±´ì¸ë°, ì´ ì—­ì‹œ ëª¨ë‘ ë°ì´í„°ì— ê¸°ë°˜í•´ì„œ ê²°ì •ë  ê²ƒì…ë‹ˆë‹¤. ì´ë²ˆì—ëŠ” ì˜ˆì™¸ì ìœ¼ë¡œ ë‘ ë²ˆì§¸ ì§ˆë¬¸ê¹Œì§€ ë°›ê² ìŠµë‹ˆë‹¤ë§Œ, ì•ìœ¼ë¡œëŠ” ì§ˆë¬¸ì„ í•˜ë‚˜ì”©ë§Œ í•´ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. í ë¼ì¹´ì„¼ì˜ ê²½ìš° ì—°ì¤‘ ê²°ê³¼ ë°œí‘œë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì„ìƒì‹œí—˜ì€ ë‹¹ì´ˆ ê³„íší–ˆë˜ ì´ë²¤íŠ¸ ìˆ˜ë¥¼ ë‹¬ì„±í•˜ëŠ” ë°©í–¥ìœ¼ë¡œ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. 3ìƒ ì§„í–‰ ê³¼ì •ì—ì„œ ì—°êµ¬ ê²€ì •ë ¥(statistical power)ì„ ê°•í™”í–ˆë˜ ì ì„ ê¸°ì–µí•˜ì‹¤ ê²ë‹ˆë‹¤. ë”°ë¼ì„œ 70mg/dL ê¸°ì¤€ì ê³¼ 90mg/dL ê¸°ì¤€ì  ëª¨ë‘ì—ì„œ ëª©í‘œë¡œ í•˜ëŠ” ì‹¬í˜ˆê´€ ìœ„í—˜ ê°ì†Œìœ¨(CVRR)ì„ ì…ì¦í•˜ê¸°ì— ì¶©ë¶„í•œ ê²€ì •ë ¥ì„ í™•ë³´í–ˆë‹¤ê³  íŒë‹¨í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì „ë©´ì ìœ¼ë¡œ ì§„í–‰í•˜ëŠ” ë° ìˆì–´ íŠ¹ë³„í•œ ìœ„í—˜ì€ ì—†ë‹¤ê³  ë´…ë‹ˆë‹¤.<br><br>ë‹¤ë§Œ ì´ë²ˆ ê²°ê³¼ê°€ ì‹œì‚¬í•˜ëŠ” ë°”ëŠ” ì‹¤ì œ ì´ë²¤íŠ¸ ë°œìƒë¥ ì´ ê¸°ì¡´ ë°œí‘œëœ ë¬¸í—Œì„ í† ëŒ€ë¡œ ëª¨ë¸ë§í–ˆë˜ ê²ƒë³´ë‹¤ ë‚®ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ í™•ì¸í•œ í˜„ì‹¤ì ì¸ ìƒí™©ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ë‹¤ë¥¸ ëª¨ë“  ìœ„í—˜ ìš”ì¸ë“¤, íŠ¹íˆ LDL ìˆ˜ì¹˜ ê°ì†Œì— ìˆì–´ì„œ ì´ëŸ¬í•œ í™˜ìë“¤ì„ ì •ë§ ìµœì ìœ¼ë¡œ ê´€ë¦¬í•´ì™”ë‹¤ëŠ” ì‚¬ì‹¤ê³¼ ê´€ë ¨ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¬¼ë¡  ì´ê²ƒì´ ì‹¬í˜ˆê´€ ì‚¬ê±´ ë°œìƒë¥ ì—ë„ ì˜í–¥ì„ ë¯¸ì¹œë‹¤ê³  ë´…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì§€ì¼œë´ì•¼ê² ì§€ë§Œ, ì´ ë°ì´í„°ë¥¼ ë³´ê²Œ ë˜ì–´ ê¸°ëŒ€ê°€ í¬ê³ , ë‹¤ë¥¸ ì„ íƒì§€ê°€ ì—†ëŠ” í™˜ìêµ°ì„ ë„ìš¸ ìˆ˜ ìˆëŠ” ì™„ì „íˆ ìƒˆë¡œìš´ ì•½ë¬¼ í´ë˜ìŠ¤ë¥¼ ë§Œë“¤ì–´ë‚¼ ìˆ˜ ìˆê¸°ë¥¼ í¬ë§í•©ë‹ˆë‹¤. ê¸ì •ì ì¸ ì—°êµ¬ ê²°ê³¼ê°€ ë‚˜ì˜¨ë‹¤ë©´, Lp(a) ìˆ˜ì¹˜ê°€ ë†’ì€ í™˜ìë“¤ì—ê²Œ ê¸‰ì„± ì‹¬ì¥ì‚¬ì™€ ë°œìƒí•  ìˆ˜ ìˆëŠ” ë‹¤ë¥¸ ë¬¸ì œë“¤ì— ëŒ€í•œ í¬ë§ì ì¸ í•´ê²°ì±…ì„ ì œê³µí•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê°–ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And the next question today is from Matthew Weston, UBS.</td><td>**Operator:** ì˜¤ëŠ˜ ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ ë§¤íŠœ ì›¨ìŠ¤í„´ìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Matthew Weston: UBS Investment Bank, Research Division Can I also add my thanks to Harry for all his support and best of luck for the future, Harry. Vas, Kisqali is building into a fantastic and highly profitable medicine for Novartis. And I guess the only challenge is it has an LOE just after your 2030 time window. What are the options in-house to extend the franchise further in breast cancer? And given the SERD data that we've seen from a competitor, what other options are there from BD that could potentially -- or is oncology, I should say, a category where BD looks like somewhere you should supplement the Novartis pipeline?</td><td>**Matthew Weston:** ê°ì‚¬ì˜ ë§ì”€ì„ ì „í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. Harry, ê·¸ë™ì•ˆì˜ ì§€ì›ì— ê°ì‚¬ë“œë¦¬ë©° ì•ìœ¼ë¡œì˜ í–‰ìš´ì„ ë¹•ë‹ˆë‹¤. Vas, KisqaliëŠ” ë…¸ë°”í‹°ìŠ¤ì—ê²Œ í™˜ìƒì ì´ê³  ìˆ˜ìµì„±ì´ ë§¤ìš° ë†’ì€ ì˜ì•½í’ˆìœ¼ë¡œ ì„±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ìœ ì¼í•œ ê³¼ì œëŠ” 2030ë…„ ëª©í‘œ ì‹œì  ì§í›„ì— íŠ¹í—ˆë§Œë£Œ(LOE)ê°€ ë„ë˜í•œë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ìœ ë°©ì•” ë¶„ì•¼ì—ì„œ í”„ëœì°¨ì´ì¦ˆë¥¼ ë” í™•ì¥í•  ìˆ˜ ìˆëŠ” ì‚¬ë‚´ ì˜µì…˜ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ? ê·¸ë¦¬ê³  ê²½ìŸì‚¬ì˜ SERD ë°ì´í„°ë¥¼ ê³ ë ¤í•  ë•Œ, ë¹„ì¦ˆë‹ˆìŠ¤ ê°œë°œ(BD)ì„ í†µí•´ ì ì¬ì ìœ¼ë¡œ í™œìš©í•  ìˆ˜ ìˆëŠ” ë‹¤ë¥¸ ì˜µì…˜ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ? ì•„ë‹ˆë©´ ì¢…ì–‘í•™ì´ ë…¸ë°”í‹°ìŠ¤ íŒŒì´í”„ë¼ì¸ì„ ë³´ê°•í•´ì•¼ í•  BD ì¹´í…Œê³ ë¦¬ë¡œ ë³´ì‹­ë‹ˆê¹Œ?</td></tr>
<tr><td>Chief Executive Officer: Yes. So I think there's actually 2 questions in there, but I'll also take both of these, Matthew, because it's you, Matthew. With respect to Kisqali, I think right now, we guide to a mid-2031 with the pediatric exclusivity that we would expect for this brand in the U.S. I think it's longer outside of the U.S. depending on the market. Our core goal at the moment is our CDK2, CDK2/4 and CDK4 programs, all of which now are in the clinic, and we're advancing as fast as we can to see which of these medicines can provide either additional benefit in the post- Kisqali setting or either in combination and we'll see what we ultimately learn. Of course, we also are advancing our radioligand therapy portfolio. We have HER2 RLTs now in the clinic. Those will be important to watch as well as the [ neobombesin ] RLT as well in breast cancer. So a number of shots on goal. And I think those will all be very important for us to continue to life cycle manage Kisqali, as you rightfully point out, beyond the mid-2030s. I always think about it as a full year 2032 effect for this brand. Now I think with respect to BD and M&A, I think absolutely, I mean, we see amongst our therapeutic areas, clearly, oncology is one we'll have to focus on. So we'll continue to focus there as we have. I would say we've had just more opportunities and traction in the last years in cardiovascular, immunology and neuroscience. You've seen us do a large number of deals in those spaces. We'll continue to see, and of course, it's a high priority to continue to build oncology now that we have the scale we're building from Scemblix, Pluvicto, Kisqali. And so if we find good opportunities, good assets, we'll certainly go after them.</td><td>**Chief Executive Officer:** ë„¤, ì‚¬ì‹¤ ë‘ ê°€ì§€ ì§ˆë¬¸ì´ í¬í•¨ë˜ì–´ ìˆëŠ”ë°ìš”, ë§¤íŠœ ë‹˜ì´ì‹œë‹ˆê¹Œ ë‘ ê°€ì§€ ëª¨ë‘ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Kisqali ê´€ë ¨í•´ì„œëŠ”, í˜„ì¬ ë¯¸êµ­ì—ì„œ ì†Œì•„ ë…ì ê¶Œ(pediatric exclusivity)ì„ í¬í•¨í•˜ì—¬ 2031ë…„ ì¤‘ë°˜ê¹Œì§€ë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì™¸ ì‹œì¥ì—ì„œëŠ” êµ­ê°€ë³„ë¡œ ë” ê¸´ ê¸°ê°„ì´ ì˜ˆìƒë©ë‹ˆë‹¤. <br><br>í˜„ì¬ ì €í¬ì˜ í•µì‹¬ ëª©í‘œëŠ” CDK2, CDK2/4, ê·¸ë¦¬ê³  CDK4 í”„ë¡œê·¸ë¨ë“¤ì…ë‹ˆë‹¤. ì´ ëª¨ë“  í”„ë¡œê·¸ë¨ë“¤ì´ í˜„ì¬ ì„ìƒ ë‹¨ê³„ì— ìˆìœ¼ë©°, Kisqali ì´í›„ ì¹˜ë£Œ í™˜ê²½ì—ì„œ ì¶”ê°€ì ì¸ íš¨ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ”ì§€, ë˜ëŠ” ë³‘ìš©ìš”ë²•ìœ¼ë¡œ ì‚¬ìš©ë  ìˆ˜ ìˆëŠ”ì§€ í™•ì¸í•˜ê¸° ìœ„í•´ ìµœëŒ€í•œ ë¹ ë¥´ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìµœì¢…ì ìœ¼ë¡œ ì–´ë–¤ ê²°ê³¼ê°€ ë‚˜ì˜¬ì§€ ì§€ì¼œë´ì•¼ê² ì£ .<br><br>ë¬¼ë¡  ë°©ì‚¬ì„±ë¦¬ê°„ë“œ ì¹˜ë£Œì œ(radioligand therapy) í¬íŠ¸í´ë¦¬ì˜¤ë„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. HER2 RLTê°€ í˜„ì¬ ì„ìƒì— ì§„ì…í•´ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë¶€ë¶„ë“¤ê³¼ í•¨ê»˜ ìœ ë°©ì•”ì—ì„œì˜ ë„¤ì˜¤ë´„ë² ì‹  RLTë„ ì£¼ëª©í•´ì•¼ í•  ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤. ì—¬ëŸ¬ ê¸°íšŒë“¤ì´ ìˆëŠ” ì…ˆì´ì£ . ì´ ëª¨ë“  ê²ƒë“¤ì´ ë§ì”€í•˜ì‹  ëŒ€ë¡œ 2030ë…„ëŒ€ ì¤‘ë°˜ ì´í›„ì—ë„ Kisqaliì˜ ì œí’ˆ ìˆ˜ëª…ì£¼ê¸°ë¥¼ ì§€ì†ì ìœ¼ë¡œ ê´€ë¦¬í•˜ëŠ” ë° ë§¤ìš° ì¤‘ìš”í•  ê²ƒì…ë‹ˆë‹¤. ì €ëŠ” í•­ìƒ ì´ ë¸Œëœë“œì— ëŒ€í•´ 2032ë…„ ì „ì²´ ì—°ë„ íš¨ê³¼ë¥¼ ì—¼ë‘ì— ë‘ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì´ì œ ì‚¬ì—…ê°œë°œ(BD)ê³¼ ì¸ìˆ˜í•©ë³‘(M&A)ì— ê´€í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ë‹¹ì—°íˆ ì €í¬ ì¹˜ë£Œ ì˜ì—­ë“¤ ì¤‘ì—ì„œ ì¢…ì–‘í•™ì€ ê³„ì† ì§‘ì¤‘í•´ì•¼ í•  ë¶„ì•¼ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì§€ê¸ˆê¹Œì§€ í•´ì™”ë˜ ê²ƒì²˜ëŸ¼ ê³„ì† ì£¼ë ¥í•  ê²ƒì…ë‹ˆë‹¤. ë‹¤ë§Œ ìµœê·¼ ëª‡ ë…„ê°„ì€ ì‹¬í˜ˆê´€, ë©´ì—­í•™, ì‹ ê²½ê³¼í•™ ë¶„ì•¼ì—ì„œ ë” ë§ì€ ê¸°íšŒì™€ ì„±ê³¼ê°€ ìˆì—ˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì˜ì—­ì—ì„œ ì €í¬ê°€ ìƒë‹¹íˆ ë§ì€ ê±°ë˜ë¥¼ ì§„í–‰í•œ ê²ƒì„ ë³´ì…¨ì„ ê²ë‹ˆë‹¤. ë¬¼ë¡  ì¢…ì–‘í•™ ë¶„ì•¼ëŠ” ê³„ì†í•´ì„œ ìµœìš°ì„  ìˆœìœ„ì…ë‹ˆë‹¤. í˜„ì¬ Scemblix, Pluvicto, Kisqalië¥¼ í†µí•´ êµ¬ì¶•í•œ ê·œëª¨ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ê³„ì† í™•ì¥í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. ì¢‹ì€ ê¸°íšŒì™€ ìš°ìˆ˜í•œ ìì‚°ì„ ë°œê²¬í•œë‹¤ë©´ ë‹¹ì—°íˆ ì ê·¹ì ìœ¼ë¡œ ì¶”ì§„í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Peter Verdult, BNP Paribas.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ BNP íŒŒë¦¬ë°”ì˜ Peter Verdultì…ë‹ˆë‹¤.<br><br>ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € Liam, 2025ë…„ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. ë§¤ì¶œ ì„±ì¥ë¥ ì´ ì•½ê°„ ë‘”í™”ë˜ëŠ” ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°, ì´ê²ƒì´ ë‹¨ìˆœíˆ ë³´ìˆ˜ì ì¸ ì ‘ê·¼ì¸ì§€, ì•„ë‹ˆë©´ ì‹¤ì œë¡œ ì‹œì¥ í™˜ê²½ì´ ì–´ë ¤ì›Œì§€ê³  ìˆëŠ” ê±´ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ, ë§ˆì§„ ì¸¡ë©´ì—ì„œ ê°œì„  ì—¬ì§€ê°€ ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Peter Verdult: BNP Paribas, Research Division Peter, BNP Paribas. Just on Rhapsido and ianalumab. Given we're now in an MFM world, how should we be thinking about ex U.S. launch plans for what are clearly mostly significant assets. I'm basically just pushing my life to see how specifically you're comfortable being about changing in rest of world launch strategies for important assets like ianalumab.</td><td>**Peter Verdult:** BNP íŒŒë¦¬ë°” ë¦¬ì„œì¹˜ ë¶€ë¬¸ì˜ í”¼í„°ì…ë‹ˆë‹¤. ë©ì‹œë„ì™€ ì´ì•„ë‚ ë£¨ë§™ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ì œ MFM ì²´ì œë¡œ ì „í™˜ëœ ìƒí™©ì—ì„œ, ëª…ë°±íˆ ì¤‘ìš”í•œ ìì‚°ë“¤ì— ëŒ€í•œ ë¯¸êµ­ ì™¸ ì§€ì—­ ì¶œì‹œ ê³„íšì„ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”? ê¸°ë³¸ì ìœ¼ë¡œ ì´ì•„ë‚ ë£¨ë§™ ê°™ì€ ì¤‘ìš”í•œ ìì‚°ë“¤ì— ëŒ€í•œ ì „ ì„¸ê³„ ì¶œì‹œ ì „ëµ ë³€í™”ì— ëŒ€í•´ ì–¼ë§ˆë‚˜ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€í•´ì£¼ì‹¤ ìˆ˜ ìˆëŠ”ì§€ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Executive Officer: Yes. So I think this is high in our minds. We're working through strategies here on Rhapsido, given that it's already launched, of course, we would be exposed on the first pillar of the MFN approach, which is on the Medicaid rebate it's more limited. And I think there we can manage. We think we have good options to manage the ability to launch Rhapsido globally. Of course, we'll have tighter pricing corridors, but that's something we think we can manage. Ianalumab is more complex as we get to launches in 2027 in the G7 countries. There, of course, it's on the entire market of U.S. net price, not just Medicaid. And so we're working through strategies. Absolutely, it's our aspiration to get these medicines launched in all of these markets given the patients that need them. But we certainly can't adversely affect the U.S. market. And so we're just going to have to be thoughtful about looking at where are there opportunities to price appropriately for the value that ianalumab brings. Given the PPP adjustments and some of the other elements of how pricing is looked at, are there things we can do to manage this. It's all in the works. I think we'll have a better sense over the course of this year on ianalumab. But on Rhapsido, we feel confident we have a way forward to get a global launch moving ahead.</td><td>**Chief Executive Officer:** ë„¤, ì´ ë¶€ë¶„ì€ ì €í¬ê°€ ë§¤ìš° ì¤‘ì ì ìœ¼ë¡œ ê³ ë ¤í•˜ê³  ìˆëŠ” ì‚¬ì•ˆì…ë‹ˆë‹¤. Rhapsidoì˜ ê²½ìš° ì´ë¯¸ ì¶œì‹œëœ ì œí’ˆì´ê¸° ë•Œë¬¸ì—, MFN ì ‘ê·¼ë²•ì˜ ì²« ë²ˆì§¸ ì¶•ì¸ ë©”ë””ì¼€ì´ë“œ ë¦¬ë² ì´íŠ¸(Medicaid rebate) ë¶€ë¶„ì— ë…¸ì¶œë  ê²ƒìœ¼ë¡œ ë³´ì´ì§€ë§Œ, ê·¸ ì˜í–¥ì€ ì œí•œì ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ ì¶©ë¶„íˆ ê´€ë¦¬ ê°€ëŠ¥í•˜ë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. Rhapsidoì˜ ê¸€ë¡œë²Œ ì¶œì‹œë¥¼ ìœ„í•œ ì¢‹ì€ ì˜µì…˜ë“¤ì„ í™•ë³´í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¬¼ë¡  ê°€ê²© ì±…ì • ë²”ìœ„ê°€ ë‹¤ì†Œ ì¢ì•„ì§€ê² ì§€ë§Œ, ì´ëŠ” ê´€ë¦¬ ê°€ëŠ¥í•œ ìˆ˜ì¤€ì…ë‹ˆë‹¤.<br><br>Ianalumabì˜ ê²½ìš°ëŠ” 2027ë…„ G7 êµ­ê°€ë“¤ì—ì„œì˜ ì¶œì‹œë¥¼ ì•ë‘ê³  ìˆì–´ ì¢€ ë” ë³µì¡í•œ ìƒí™©ì…ë‹ˆë‹¤. ì´ ê²½ìš°ì—ëŠ” ë©”ë””ì¼€ì´ë“œë¿ë§Œ ì•„ë‹ˆë¼ ë¯¸êµ­ ì „ì²´ ì‹œì¥ì˜ ìˆœê°€ê²©(net price)ì´ ì ìš©ë˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ í˜„ì¬ ë‹¤ì–‘í•œ ì „ëµë“¤ì„ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¶„ëª…í•œ ê²ƒì€, ì´ëŸ¬í•œ ì¹˜ë£Œì œë¥¼ í•„ìš”ë¡œ í•˜ëŠ” í™˜ìë“¤ì„ ê³ ë ¤í•  ë•Œ, ëª¨ë“  ì‹œì¥ì—ì„œ ì´ ì˜ì•½í’ˆë“¤ì„ ì¶œì‹œí•˜ëŠ” ê²ƒì´ ì €í¬ì˜ ëª©í‘œë¼ëŠ” ì ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ë¯¸êµ­ ì‹œì¥ì— ë¶€ì •ì ì¸ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ëŠ” ì—†ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ianalumabì´ ì œê³µí•˜ëŠ” ê°€ì¹˜ì— ì í•©í•œ ê°€ê²©ì„ ì±…ì •í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ì–´ë””ì— ìˆëŠ”ì§€ ì‹ ì¤‘í•˜ê²Œ ê²€í† í•´ì•¼ í•©ë‹ˆë‹¤. êµ¬ë§¤ë ¥í‰ê°€(PPP) ì¡°ì •ê³¼ ê°€ê²© ì±…ì • ì‹œ ê³ ë ¤ë˜ëŠ” ì—¬ëŸ¬ ìš”ì†Œë“¤ì„ ê°ì•ˆí•  ë•Œ, ìš°ë¦¬ê°€ ê´€ë¦¬í•  ìˆ˜ ìˆëŠ” ë°©ì•ˆë“¤ì´ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ëª¨ë“  ì‘ì—…ì´ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ianalumabì— ëŒ€í•´ì„œëŠ” ì˜¬í•´ ì•ˆì— ë” ëª…í™•í•œ ë°©í–¥ì„ ì¡ì„ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ë‹¤ë§Œ Rhapsidoì˜ ê²½ìš°, ê¸€ë¡œë²Œ ì¶œì‹œë¥¼ ì¶”ì§„í•  ìˆ˜ ìˆëŠ” í™•ì‹¤í•œ ë°©ì•ˆì„ í™•ë³´í–ˆë‹¤ê³  ìì‹ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Steve Scala from TD Cowen.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ TD Cowenì˜ Steve Scalaë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Steve Scala: TD Cowen, Research Division On pelacarsen, Novartis has said previously, that a delay in the HORIZON trial readout would stem either from overestimating the baseline risk or underestimating the treatment effect. Do you have a sense of what is at work here I would think the baseline risk, if it were overestimated would question the value of lowering LPA in the first place. And I would think that Novartis should have a better handle on treatment effect based on early studies. So any color of Novartis' view at this point would be helpful.</td><td>**Steve Scala:** í ë¼ì¹´ì„¼(pelacarsen)ê³¼ ê´€ë ¨í•˜ì—¬, ë…¸ë°”í‹°ìŠ¤ëŠ” ì´ì „ì— HORIZON ì„ìƒì‹œí—˜ ê²°ê³¼ ë°œí‘œ ì§€ì—°ì´ ê¸°ì € ìœ„í—˜ë„(baseline risk)ë¥¼ ê³¼ëŒ€í‰ê°€í–ˆê±°ë‚˜ ì¹˜ë£Œ íš¨ê³¼(treatment effect)ë¥¼ ê³¼ì†Œí‰ê°€í•œ ê²ƒì—ì„œ ë¹„ë¡¯ë  ìˆ˜ ìˆë‹¤ê³  ë§ì”€í•˜ì‹  ë°” ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ ì‹¤ì œë¡œ ì–´ë–¤ ìš”ì¸ì´ ì‘ìš©í•˜ê³  ìˆëŠ”ì§€ ê°ì´ ì˜¤ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì œ ìƒê°ì—ëŠ” ê¸°ì € ìœ„í—˜ë„ê°€ ê³¼ëŒ€í‰ê°€ë˜ì—ˆë‹¤ë©´ ì• ì´ˆì— LPAë¥¼ ë‚®ì¶”ëŠ” ê²ƒì˜ ê°€ì¹˜ ìì²´ì— ì˜ë¬¸ì´ ì œê¸°ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë…¸ë°”í‹°ìŠ¤ëŠ” ì´ˆê¸° ì—°êµ¬ë“¤ì„ ë°”íƒ•ìœ¼ë¡œ ì¹˜ë£Œ íš¨ê³¼ì— ëŒ€í•´ ë” ëª…í™•í•˜ê²Œ íŒŒì•…í•˜ê³  ìˆì–´ì•¼ í•  ê²ƒ ê°™ì€ë°ìš”. ì´ ì‹œì ì—ì„œ ë…¸ë°”í‹°ìŠ¤ì˜ ê²¬í•´ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œë©´ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Executive Officer: I wish we knew, Steve. Honestly, obviously, I can only give you an opinion. I can't actually give you a fact because we're completely blinded, and we have no database insights. We believe that we have appropriately estimated the baseline risk. And that's not so many rounds of looking at it. So it might be that baseline risk is more prominent at higher Lp(a) threshold. I think in my mind, it really comes on to what Lp(a) threshold that we appropriately thinking about the baseline risk and how -- and this is, again, I think not in our -- no way to know if this is correct, but my assumption is that at lower Lp(a) levels, there could be more interactions with LDL and other risk factors. And that Lp(a) becomes more dominant as you get to higher Lp(a) levels and because the risk goes up almost linearly at a higher Lp(a), that becomes the dominant risk factor. And so the studies obviously have some portion of patients at the 70 to 90 to 100. We've, I think, announced in our papers that overall, our median is 108. So that's kind of our best guess in terms of the risk profile and how we've estimated. Obviously, we would love for this to be that our treatment effect is larger than we expect, and that would be the reason for this, but there's just no way to know that at this time.</td><td>**Chief Executive Officer:** ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´ ì €í¬ë„ ì•Œ ìˆ˜ ì—†ìŠµë‹ˆë‹¤, ìŠ¤í‹°ë¸Œ. ëª…í™•íˆ ë§ì”€ë“œë¦¬ìë©´, ì œê°€ ë“œë¦´ ìˆ˜ ìˆëŠ” ê±´ ì˜ê²¬ì¼ ë¿ì…ë‹ˆë‹¤. ì‚¬ì‹¤ì„ ë§ì”€ë“œë¦´ ìˆ˜ëŠ” ì—†ëŠ”ë°, ì €í¬ê°€ ì™„ì „íˆ ë¸”ë¼ì¸ë“œ ìƒíƒœì´ê³  ë°ì´í„°ë² ì´ìŠ¤ ì¸ì‚¬ì´íŠ¸ê°€ ì „í˜€ ì—†ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì €í¬ëŠ” ê¸°ì € ìœ„í—˜ë„(baseline risk)ë¥¼ ì ì ˆí•˜ê²Œ ì¶”ì •í–ˆë‹¤ê³  ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ëŸ¬ ì°¨ë¡€ ê²€í† ë¥¼ ê±°ì³¤ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê¸°ì € ìœ„í—˜ë„ê°€ ë” ë†’ì€ Lp(a) ì—­ì¹˜ì—ì„œ ë” ë‘ë“œëŸ¬ì§ˆ ê°€ëŠ¥ì„±ì´ ìˆìŠµë‹ˆë‹¤. ì œ ìƒê°ì—ëŠ” ê²°êµ­ ì–´ë–¤ Lp(a) ì—­ì¹˜ì—ì„œ ê¸°ì € ìœ„í—˜ë„ë¥¼ ì ì ˆí•˜ê²Œ ê³ ë ¤í•´ì•¼ í•˜ëŠ”ì§€ê°€ í•µì‹¬ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ê²ƒì´ ë§ëŠ”ì§€ ì•Œ ë°©ë²•ì´ ì—†ì§€ë§Œ, ì œ ê°€ì •ì€ ë‚®ì€ Lp(a) ìˆ˜ì¤€ì—ì„œëŠ” LDL ë° ë‹¤ë¥¸ ìœ„í—˜ ìš”ì¸ë“¤ê³¼ì˜ ìƒí˜¸ì‘ìš©ì´ ë” ë§ì„ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. Lp(a) ìˆ˜ì¹˜ê°€ ë†’ì•„ì§ˆìˆ˜ë¡ Lp(a)ê°€ ë” ì§€ë°°ì ì¸ ìš”ì¸ì´ ë˜ê³ , ë†’ì€ Lp(a) ìˆ˜ì¹˜ì—ì„œëŠ” ìœ„í—˜ë„ê°€ ê±°ì˜ ì„ í˜•ì ìœ¼ë¡œ ì¦ê°€í•˜ê¸° ë•Œë¬¸ì— ì´ê²ƒì´ ì£¼ìš” ìœ„í—˜ ì¸ìê°€ ë©ë‹ˆë‹¤. ë”°ë¼ì„œ ì„ìƒì‹œí—˜ì—ëŠ” ë‹¹ì—°íˆ 70ì—ì„œ 90, 100 ìˆ˜ì¤€ì˜ í™˜ìë“¤ì´ ì¼ì • ë¶€ë¶„ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ë…¼ë¬¸ì—ì„œ ë°œí‘œí•œ ë°”ì™€ ê°™ì´ ì „ì²´ ì¤‘ì•™ê°’ì€ 108ì…ë‹ˆë‹¤. ì´ê²ƒì´ ìœ„í—˜ í”„ë¡œíŒŒì¼ê³¼ ì €í¬ê°€ ì¶”ì •í•œ ë°©ì‹ì— ëŒ€í•œ ê°€ì¥ í•©ë¦¬ì ì¸ ì¶”ì •ì¹˜ì…ë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ ì¹˜ë£Œ íš¨ê³¼ê°€ ì˜ˆìƒë³´ë‹¤ ë” í¬ë‹¤ë©´ ì •ë§ ì¢‹ê² ì§€ë§Œ, í˜„ ì‹œì ì—ì„œëŠ” ê·¸ê²ƒì„ ì•Œ ë°©ë²•ì´ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from Richard Vosser, JPMorgan.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ JPMorganì˜ Richard Vosserë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Richard Vosser: JPMorgan Chase & Co, Research Division Just a question on Itvisma. Just how should we think about the ramp of that product in the U.S. and ex U.S. could imagine that there are some patients that are potentially waiting for the therapy. So have you seen warehouse patients? And how should we think about the launch?</td><td>**Richard Vosser:** Itvismaì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¯¸êµ­ê³¼ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ ì´ ì œí’ˆì˜ ì„±ì¥ ê³¡ì„ ì„ ì–´ë–»ê²Œ ë´ì•¼ í• ê¹Œìš”? ì¹˜ë£Œì œë¥¼ ê¸°ë‹¤ë¦¬ê³  ìˆëŠ” í™˜ìë“¤ì´ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ”ë°ìš”. ì‹¤ì œë¡œ ëŒ€ê¸° í™˜ìë“¤(warehouse patients)ì„ í™•ì¸í•˜ì…¨ë‚˜ìš”? ê·¸ë¦¬ê³  ì¶œì‹œ ì „ëµì€ ì–´ë–»ê²Œ ìƒê°í•˜ë©´ ë ê¹Œìš”?</td></tr>
<tr><td>Chief Executive Officer: Yes. Thanks, Richard. In general, for gene therapies, we see often a pretty fast ramp as we get through the kind of prevalent pool of patients. And then it kind of comes down to a more steady state. And I think over the next 2 to 3 years, we would expect really Itvisma to penetrate the majority of the kind of relevant patient pool that it has. And then come back down as we saw with Zolgensma more to a steady state because of the nature of the onetime therapy. So I think relative to other brands, the ramp will be on the faster side. It won't be in 6 months, but I think over the first few years, will get to peak relatively quickly and then come down from there. And we do have, I think, warehouse patients, we do have patients that we really understand. We also have strong access, we think, in many markets. And as we build that access forward, I think that will really allow us to maximize the medicine.</td><td>**Chief Executive Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Richard. ì¼ë°˜ì ìœ¼ë¡œ ìœ ì „ì ì¹˜ë£Œì œì˜ ê²½ìš°, ê¸°ì¡´ í™˜ìêµ°(prevalent pool)ì„ í™•ë³´í•˜ë©´ì„œ ìƒë‹¹íˆ ë¹ ë¥¸ ì„±ì¥ì„¸ë¥¼ ë³´ì´ë‹¤ê°€ ì´í›„ ë³´ë‹¤ ì•ˆì •ì ì¸ ìˆ˜ì¤€ìœ¼ë¡œ ìë¦¬ì¡ëŠ” íŒ¨í„´ì„ ë³´ì…ë‹ˆë‹¤. í–¥í›„ 2~3ë…„ ë™ì•ˆ Itvismaê°€ ê´€ë ¨ í™˜ìêµ°ì˜ ëŒ€ë¶€ë¶„ì„ í™•ë³´í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ì´í›„ì—ëŠ” ì¼íšŒì„± ì¹˜ë£Œì œë¼ëŠ” íŠ¹ì„±ìƒ Zolgensmaì—ì„œ ë´¤ë˜ ê²ƒì²˜ëŸ¼ ì•ˆì •ì ì¸ ìˆ˜ì¤€ìœ¼ë¡œ ëŒì•„ì˜¬ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. <br><br>ë‹¤ë¥¸ ì œí’ˆë“¤ê³¼ ë¹„êµí–ˆì„ ë•Œ ì„±ì¥ ì†ë„ëŠ” ë¹ ë¥¸ í¸ì— ì†í•  ê²ƒì…ë‹ˆë‹¤. 6ê°œì›” ë§Œì— ì´ë£¨ì–´ì§€ì§€ëŠ” ì•Šê² ì§€ë§Œ, ì²˜ìŒ ëª‡ ë…„ ë‚´ì— ë¹„êµì  ë¹ ë¥´ê²Œ ì •ì ì— ë„ë‹¬í•œ í›„ ê·¸ë¡œë¶€í„° í•˜í–¥ ì•ˆì •í™”ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ëŒ€ê¸° ì¤‘ì¸ í™˜ìë“¤ì´ ìˆê³ , ì¶©ë¶„íˆ íŒŒì•…í•˜ê³  ìˆëŠ” í™˜ìêµ°ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë§ì€ ì‹œì¥ì—ì„œ ê°•ë ¥í•œ ì ‘ê·¼ì„±ì„ í™•ë³´í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì•ìœ¼ë¡œ ì´ëŸ¬í•œ ì ‘ê·¼ì„±ì„ ë”ìš± ê°•í™”í•´ ë‚˜ê°€ë©´ì„œ, ì´ ì˜ì•½í’ˆì˜ ê°€ì¹˜ë¥¼ ê·¹ëŒ€í™”í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Graham Parry from Citi.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì”¨í‹°ì˜ ê·¸ë ˆì´ì—„ íŒ¨ë¦¬ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Graham Glyn Parry: Citigroup Inc., Research Division So I reiterate the best wishes for Harry, of course. And then a question on Kisqali and the outlook for the year. So how much of the gross to net impact that was impacting fourth quarter carries through into the next year because of a different channel mix versus how much is one-off? And so to what extent does that give you an easy base for comparison in 2025 into 2026? And then any thoughts you have on the risk that oral SERDs might pose to encroaching on CDK4/6 combinations in the adjuvant setting?</td><td>**Graham Glyn Parry:** ë¨¼ì € Harryì—ê²Œ ìµœê³ ì˜ í–‰ìš´ì„ ë¹ˆë‹¤ëŠ” ë§ì”€ì„ ë‹¤ì‹œ í•œë²ˆ ì „í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Kisqaliì™€ ì˜¬í•´ ì „ë§ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ì˜í–¥ì„ ë¯¸ì³¤ë˜ ì´ë§¤ì¶œ ëŒ€ë¹„ ìˆœë§¤ì¶œ(gross to net) ì˜í–¥ì´ ì±„ë„ ë¯¹ìŠ¤ ë³€í™”ë¡œ ì¸í•´ ë‚´ë…„ì—ë„ ì–¼ë§ˆë‚˜ ì§€ì†ë  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  ì–¼ë§ˆë‚˜ ì¼íšŒì„±ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì´ê²ƒì´ 2025ë…„ì—ì„œ 2026ë…„ìœ¼ë¡œ ë„˜ì–´ê°ˆ ë•Œ ë¹„êµ ê¸°ì¤€ì„ ì–¼ë§ˆë‚˜ ìš©ì´í•˜ê²Œ ë§Œë“¤ì–´ì¤„ê¹Œìš”? ê·¸ë¦¬ê³  ê²½êµ¬ìš© SERDê°€ ë³´ì¡°ìš”ë²•(adjuvant) ì„¸íŒ…ì—ì„œ CDK4/6 ë³‘ìš©ìš”ë²•ì„ ì ì‹í•  ìœ„í—˜ì„±ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ìƒê°í•˜ì‹œëŠ”ì§€ìš”?</td></tr>
<tr><td>Chief Executive Officer: Thanks, Graham, and great to have you back. On Kisqali, I think the higher gross to net, we believe, is a onetime effect where we saw higher Medicare utilization than we had forecast in 2025. We do expect as the early breast cancer launch continues to accelerate and our mix shift to younger and younger patients that this will net out back towards where we had historically expected. And I think we should be fine from that point forward. And Harry wants to add something.</td><td>**Chief Executive Officer:** ê°ì‚¬í•©ë‹ˆë‹¤, Graham. ê·¸ë¦¬ê³  ëŒì•„ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. Kisqaliì˜ ê²½ìš°, ë†’ì€ ì´ë§¤ì¶œ ëŒ€ë¹„ ìˆœë§¤ì¶œ(gross to net) ë¹„ìœ¨ì€ ì¼íšŒì„± íš¨ê³¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ì— ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ ë©”ë””ì¼€ì–´(Medicare) í™œìš©ë„ê°€ ë†’ì•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì¡°ê¸° ìœ ë°©ì•” ì ì‘ì¦ ì¶œì‹œê°€ ê³„ì† ê°€ì†í™”ë˜ê³  í™˜ì êµ¬ì„±ì´ ì ì  ë” ì Šì€ ì—°ë ¹ì¸µìœ¼ë¡œ ì´ë™í•¨ì— ë”°ë¼, ì´ ë¹„ìœ¨ì€ ìš°ë¦¬ê°€ ê³¼ê±°ì— ì˜ˆìƒí–ˆë˜ ìˆ˜ì¤€ìœ¼ë¡œ ë‹¤ì‹œ ì •ìƒí™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ê·¸ ì‹œì ë¶€í„°ëŠ” ë¬¸ì œì—†ì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. Harryê°€ ì¶”ê°€í•  ë‚´ìš©ì´ ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Yes, Graham, thank you very much. And by the way, everybody, for your nice words. So on Kisqali, I mean, one thing to note is that actually in quarter 1 of '25, with a positive gross to net as Mukul pointed out. So in quarter 1, that's a higher base due to one-timers. As Vas mentioned, the quarter 4, what we have noted here out-of-period adjustments. So if you take that out, it's really the true quarter 4 performance. And then quarter 4 of '26, there should be a bit of a lower base because of this negative this year. But overall, the -- basically, these gross to net adjustments are all out of period, so one-timers and the underlying is what you see.</td><td>**Chief Financial Officer:** ë„¤, Graham, ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ëª¨ë‘ ì¢‹ì€ ë§ì”€ ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. Kisqali ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ìš°ì„  ì£¼ëª©í•˜ì‹¤ ì ì€ ì‹¤ì œë¡œ 2025ë…„ 1ë¶„ê¸°ì— Mukulì´ ì§€ì í•œ ê²ƒì²˜ëŸ¼ ê¸ì •ì ì¸ ì´ì•¡ ëŒ€ë¹„ ìˆœì•¡(gross to net) íš¨ê³¼ê°€ ìˆì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. 1ë¶„ê¸°ëŠ” ì¼íšŒì„± ìš”ì¸ë“¤ë¡œ ì¸í•´ ê¸°ì €ê°€ ë” ë†’ì•˜ìŠµë‹ˆë‹¤. Vasê°€ ì–¸ê¸‰í–ˆë“¯ì´, 4ë¶„ê¸°ì—ëŠ” ê¸°ê°„ ì™¸ ì¡°ì •(out-of-period adjustments)ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ë¥¼ ì œì™¸í•˜ë©´ ì‹¤ì œ 4ë¶„ê¸° ì‹¤ì ì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  2026ë…„ 4ë¶„ê¸°ëŠ” ì˜¬í•´ì˜ ë§ˆì´ë„ˆìŠ¤ íš¨ê³¼ë¡œ ì¸í•´ ê¸°ì €ê°€ ë‹¤ì†Œ ë‚®ì•„ì§ˆ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì „ë°˜ì ìœ¼ë¡œ ì´ëŸ¬í•œ ì´ì•¡ ëŒ€ë¹„ ìˆœì•¡ ì¡°ì •ì€ ëª¨ë‘ ê¸°ê°„ ì™¸ ì¡°ì •ì´ë¯€ë¡œ ì¼íšŒì„±ì´ë©°, ì‹¤ì œ ê¸°ì € ì‹¤ì ì€ ì—¬ëŸ¬ë¶„ì´ ë³´ì‹œëŠ” ê·¸ëŒ€ë¡œì…ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Executive Officer: And then with respect to the oral SERDs, we've had a lot of discussion, and we feel confident that when we look at the profile of Kisqali and what we hear from physicians that physicians want a CDK4/6 inhibitor for patients who can benefit. And they, of course, need to look for an endocrine therapy option. Certainly, the oral SERDs now have the opportunity over time to become the standard of care endocrine therapy option. We already know that roughly half of patients in the early breast cancer setting in the U.S. are already now on a CDK4/6, and as we continue to penetrate that base of patients, we think that the opportunity will be CDK4/6 plus the choice of historical endocrine therapy or the oral SERDs, and that's how this market will play out. At the margin, could there be some physicians who choose an older endocrine therapy plus a CDK4/6 or an oral SERD and not a CDK4/6. Certainly, that dynamic will happen, but we don't expect that to be the predominant approach in the U.S. or in any of the other core markets. That's what gives us confidence in the $10 billion-plus guidance that we have and are sticking to.</td><td>**Chief Executive Officer:** ê·¸ë¦¬ê³  ê²½êµ¬ìš© SERDì— ê´€í•´ì„œëŠ” ë§ì€ ë…¼ì˜ë¥¼ ê±°ì³¤ê³ , Kisqaliì˜ í”„ë¡œíŒŒì¼ê³¼ ì˜ì‚¬ë“¤ë¡œë¶€í„° ë“£ëŠ” ì˜ê²¬ì„ ì¢…í•©í•´ ë³¼ ë•Œ ì˜ì‚¬ë“¤ì€ í˜œíƒì„ ë°›ì„ ìˆ˜ ìˆëŠ” í™˜ìë“¤ì—ê²Œ CDK4/6 ì–µì œì œë¥¼ ì›í•œë‹¤ëŠ” í™•ì‹ ì„ ê°–ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì˜ì‚¬ë“¤ì€ ë‚´ë¶„ë¹„ ì¹˜ë£Œ ì˜µì…˜ë„ ì°¾ì•„ì•¼ í•©ë‹ˆë‹¤. ê²½êµ¬ìš© SERDëŠ” ì´ì œ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ í‘œì¤€ ì¹˜ë£Œ ë‚´ë¶„ë¹„ ìš”ë²•ì´ ë  ê¸°íšŒë¥¼ ê°–ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ë¯¸ ë¯¸êµ­ì˜ ì¡°ê¸° ìœ ë°©ì•” í™˜ì ì¤‘ ì•½ ì ˆë°˜ì´ CDK4/6 ì–µì œì œë¥¼ ì‚¬ìš©í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ í™˜ì ê¸°ë°˜ì— ì§€ì†ì ìœ¼ë¡œ ì¹¨íˆ¬í•´ ë‚˜ê°€ë©´ì„œ CDK4/6 ì–µì œì œì™€ ê¸°ì¡´ ë‚´ë¶„ë¹„ ì¹˜ë£Œ ë˜ëŠ” ê²½êµ¬ìš© SERD ì¤‘ ì„ íƒí•˜ëŠ” ë°©ì‹ìœ¼ë¡œ ê¸°íšŒê°€ ì—´ë¦´ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì´ ì‹œì¥ì´ ì „ê°œë  ë°©ì‹ì…ë‹ˆë‹¤. ì¼ë¶€ ì˜ì‚¬ë“¤ì´ ê¸°ì¡´ ë‚´ë¶„ë¹„ ì¹˜ë£Œì œì™€ CDK4/6 ì–µì œì œë¥¼ ë³‘ìš©í•˜ê±°ë‚˜, ê²½êµ¬ìš© SERDì™€ CDK4/6 ì–µì œì œë¥¼ ë³‘ìš©í•˜ì§€ ì•ŠëŠ” ì„ íƒì„ í•  ìˆ˜ ìˆì„ê¹Œìš”? ë¬¼ë¡  ê·¸ëŸ° ìƒí™©ì´ ë°œìƒí•  ìˆ˜ëŠ” ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë¯¸êµ­ì´ë‚˜ ë‹¤ë¥¸ ì£¼ìš” ì‹œì¥ì—ì„œ ê·¸ê²ƒì´ ì£¼ëœ ì¹˜ë£Œ ë°©ì‹ì´ ë  ê²ƒìœ¼ë¡œëŠ” ì˜ˆìƒí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì œì‹œí•œ 100ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ í™•ì‹ ì„ ê°–ê³  ìœ ì§€í•˜ëŠ” ì´ìœ ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question today is from Seamus Fernandez of Guggenheim Securities.</td><td>**Operator:** ì˜¤ëŠ˜ ë‹¤ìŒ ì§ˆë¬¸ì€ êµ¬ê²í•˜ì„ ì‹œíë¦¬í‹°ì¦ˆì˜ ì‹œë¨¸ìŠ¤ í˜ë¥´ë‚œë°ì¦ˆë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Seamus Fernandez: Guggenheim Securities, LLC, Research Division And just would echo, Harry, we'll miss you, for sure. Vas, hoping you could maybe give us your thoughts on the overall food allergy opportunity within your overall portfolio, obviously, Xolair has done extraordinarily well in this space with excellent growth opportunity. Just hoping to get your perspective on that as well as the opportunity that you see potentially within your broader portfolio, not just for the BTK, but beyond.</td><td>**Seamus Fernandez:** êµ¬ê²í•˜ì„ ì¦ê¶Œì˜ ì§ˆë¬¸ì— ëŒ€í•œ ë‹µë³€ì„ ë²ˆì—­í•˜ê² ìŠµë‹ˆë‹¤:<br><br>ìŒì‹ ì•Œë ˆë¥´ê¸° ê¸°íšŒì— ëŒ€í•œ ì „ë°˜ì ì¸ ê²¬í•´ë¥¼ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ XolairëŠ” ì´ ë¶„ì•¼ì—ì„œ íƒì›”í•œ ì„±ê³¼ë¥¼ ê±°ë‘ê³  ìˆìœ¼ë©° ë›°ì–´ë‚œ ì„±ì¥ ê¸°íšŒë¥¼ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì €í¬ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì—ì„œ ìŒì‹ ì•Œë ˆë¥´ê¸° ê¸°íšŒë¥¼ ë°”ë¼ë³´ëŠ” ê´€ì ê³¼, BTKë¿ë§Œ ì•„ë‹ˆë¼ ê·¸ ì´ìƒì˜ ê´‘ë²”ìœ„í•œ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ë³´ê³  ìˆëŠ” ì ì¬ì  ê¸°íšŒì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ìŒì‹ ì•Œë ˆë¥´ê¸°ëŠ” ìƒë‹¹íˆ í° ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”(unmet medical need) ì˜ì—­ì…ë‹ˆë‹¤. Xolairì˜ ì„±ê³µì€ ì´ ì‹œì¥ì˜ ì ì¬ë ¥ì„ ëª…í™•íˆ ë³´ì—¬ì£¼ê³  ìˆìœ¼ë©°, í™˜ìë“¤ì´ íš¨ê³¼ì ì¸ ì¹˜ë£Œ ì˜µì…˜ì„ ì–¼ë§ˆë‚˜ ì ˆì‹¤íˆ í•„ìš”ë¡œ í•˜ëŠ”ì§€ ì…ì¦í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì €í¬ëŠ” ë©´ì—­í•™(immunology) ë¶„ì•¼ ì „ë°˜ì— ê±¸ì³ ê°•ë ¥í•œ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ ì—­ëŸ‰ë“¤ì´ ìŒì‹ ì•Œë ˆë¥´ê¸°ë¥¼ í¬í•¨í•œ ì•Œë ˆë¥´ê¸° ì§ˆí™˜ ì˜ì—­ì—ì„œ ì¶”ê°€ì ì¸ ê¸°íšŒë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆë‹¤ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. BTK ì–µì œì œëŠ” ê·¸ ì¤‘ í•˜ë‚˜ì˜ ì˜ˆì‹œì´ë©°, ì €í¬ì˜ ê³¼í•™ì  ì „ë¬¸ì„±ê³¼ ì„ìƒ ê°œë°œ ëŠ¥ë ¥ì„ í™œìš©í•˜ì—¬ ì´ ë¶„ì•¼ì—ì„œ ë” ë§ì€ í˜ì‹ ì„ ê°€ì ¸ì˜¬ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Executive Officer: Yes. Thanks, Seamus. We've had a long history looking at food allergy. It goes back to medicine. Some of you will remember called QGE031, which was a high affinity IgE. There was supposed to be a follow-on for Xolair. In the end, we weren't able to show a stronger effect than Xolair has ultimately shown in food allergy. So we know the space well. once we saw the Phase II data for remibrutinib and food allergy, I think it changed our perspective to really think now how could we build this out to be a significant market opportunity. So we'll be sharing that data, as I mentioned, in the coming month or two. And with that data set and now the agreement with FDA on how to advance into Phase III studies, we see the option for a safe oral medicine to be able to hopefully be given broadly to patients. And you know that a lot of the patients in food allergy that are most interested or at risk to be treated are children. And so versus ongoing injections, having an oral high efficacy safe option, we think would be pretty compelling. So I think overall, we see food allergy is a multibillion-dollar opportunity. I certainly with the potential to make something major out of this. We're going to obviously run through the phase Phase III program. We're excited to share the Phase II data as well. And then beyond that, now we are evaluating are there other opportunities within the pipeline earlier at Novartis. And, of course, externally as always, to see can we further bolster our food allergy portfolio. So I think it's definitely a shift, but something we're getting quite excited about.</td><td>**Chief Executive Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‹í’ˆ ì•Œë ˆë¥´ê¸° ë¶„ì•¼ë¥¼ ì˜¤ë«ë™ì•ˆ ì—°êµ¬í•´ì™”ìŠµë‹ˆë‹¤. ì˜ì•½í’ˆìœ¼ë¡œ ê±°ìŠ¬ëŸ¬ ì˜¬ë¼ê°€ë©´, ì¼ë¶€ ë¶„ë“¤ì€ QGE031ì´ë¼ëŠ” ê³ ì¹œí™”ì„± IgE ì•½ë¬¼ì„ ê¸°ì–µí•˜ì‹¤ ê²ë‹ˆë‹¤. ì´ëŠ” Xolairì˜ í›„ì† ì œí’ˆìœ¼ë¡œ ê°œë°œë˜ì—ˆì£ . í•˜ì§€ë§Œ ê²°êµ­ ì‹í’ˆ ì•Œë ˆë¥´ê¸°ì—ì„œ Xolairê°€ ê¶ê·¹ì ìœ¼ë¡œ ë³´ì—¬ì¤€ íš¨ê³¼ë³´ë‹¤ ë” ê°•ë ¥í•œ íš¨ê³¼ë¥¼ ì…ì¦í•˜ì§€ ëª»í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì´ ë¶„ì•¼ë¥¼ ì˜ ì•Œê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë ˆë¯¸ë¸Œë£¨í‹°ë‹™ì˜ ì‹í’ˆ ì•Œë ˆë¥´ê¸° 2ìƒ ë°ì´í„°ë¥¼ í™•ì¸í•œ í›„, ì´ë¥¼ ì–´ë–»ê²Œ ìƒë‹¹í•œ ì‹œì¥ ê¸°íšŒë¡œ ë°œì „ì‹œí‚¬ ìˆ˜ ìˆì„ì§€ì— ëŒ€í•œ ìš°ë¦¬ì˜ ê´€ì ì´ ì •ë§ ë°”ë€Œì—ˆìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ëŒ€ë¡œ ì•ìœ¼ë¡œ í•œë‘ ë‹¬ ë‚´ì— í•´ë‹¹ ë°ì´í„°ë¥¼ ê³µìœ í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë°ì´í„°ì…‹ê³¼ FDAì™€ì˜ 3ìƒ ì„ìƒì‹œí—˜ ì§„í–‰ ë°©ì•ˆì— ëŒ€í•œ í•©ì˜ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ì•ˆì „í•œ ê²½êµ¬ìš© ì˜ì•½í’ˆì„ í™˜ìë“¤ì—ê²Œ ê´‘ë²”ìœ„í•˜ê²Œ ì œê³µí•  ìˆ˜ ìˆëŠ” ê°€ëŠ¥ì„±ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì‹í’ˆ ì•Œë ˆë¥´ê¸° í™˜ì ì¤‘ ì¹˜ë£Œì— ê°€ì¥ ê´€ì‹¬ì´ ë§ê±°ë‚˜ ìœ„í—˜ë„ê°€ ë†’ì€ í™˜ìë“¤ì´ ì£¼ë¡œ ì–´ë¦°ì´ë¼ëŠ” ì ì„ ì˜ ì•Œê³  ê³„ì‹¤ ê²ë‹ˆë‹¤. ë”°ë¼ì„œ ì§€ì†ì ì¸ ì£¼ì‚¬ ì¹˜ë£Œ ëŒ€ë¹„, ê³ íš¨ëŠ¥ì˜ ì•ˆì „í•œ ê²½êµ¬ìš© ì˜µì…˜ì„ ì œê³µí•˜ëŠ” ê²ƒì´ ìƒë‹¹íˆ ë§¤ë ¥ì ì¼ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ì‹í’ˆ ì•Œë ˆë¥´ê¸°ëŠ” ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ê¸°íšŒë¼ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì¤‘ëŒ€í•œ ì„±ê³¼ë¥¼ ë§Œë“¤ì–´ë‚¼ ì ì¬ë ¥ì´ ë¶„ëª…íˆ ìˆìŠµë‹ˆë‹¤. ë‹¹ì—°íˆ 3ìƒ í”„ë¡œê·¸ë¨ì„ ì§„í–‰í•  ê²ƒì´ë©°, 2ìƒ ë°ì´í„°ë„ ê³µìœ í•˜ê²Œ ë˜ì–´ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤. <response><br><br>ê·¸ë¦¬ê³  ê·¸ ì™¸ì—ë„ í˜„ì¬ ë…¸ë°”í‹°ìŠ¤ì˜ ì´ˆê¸° íŒŒì´í”„ë¼ì¸ ë‚´ì—ì„œ ë‹¤ë¥¸ ê¸°íšŒë“¤ì´ ìˆëŠ”ì§€ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  í•­ìƒ ê·¸ë ‡ë“¯ì´ ì™¸ë¶€ì ìœ¼ë¡œë„ ì‹í’ˆ ì•Œë ˆë¥´ê¸° í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë”ìš± ê°•í™”í•  ìˆ˜ ìˆëŠ”ì§€ ì‚´í´ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë¶„ëª…íˆ ë°©í–¥ ì „í™˜ì´ê¸´ í•˜ì§€ë§Œ, ì €í¬ëŠ” ì´ì— ëŒ€í•´ ìƒë‹¹íˆ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Operator: Next question is from James Gordon at Barclays.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë°”í´ë ˆì´ì¦ˆì˜ ì œì„ìŠ¤ ê³ ë“ ìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>James Gordon: Barclays Bank PLC, Research Division The question was on pelacarsen and what a win now looks like. So you talked about a potentially lower event rate. Where is the latest magnitude of efficacy? I think the original design was a 20% benefit in the broader population, a 25% benefit in a narrow population with a longer study and maybe some other tweaks. Is that sort of the minimum? Is there a possibility that you could actually have a benefit for either of those groups that were statistically significant, but didn't quite hit the her? And if so, would that still be a product with strong commercial prospects?</td><td>**James Gordon:** í ë¼ì¹´ì„¼ê³¼ í˜„ì¬ ì„±ê³µì˜ ì˜ë¯¸ì— ëŒ€í•œ ì§ˆë¬¸ì´ì…¨ìŠµë‹ˆë‹¤. ì ì¬ì ìœ¼ë¡œ ë‚®ì•„ì§„ ì´ë²¤íŠ¸ ë°œìƒë¥ ì— ëŒ€í•´ ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ìµœì‹  íš¨ëŠ¥ í¬ê¸°ëŠ” ì–´ëŠ ì •ë„ì¸ê°€ìš”? ì œ ê¸°ì–µìœ¼ë¡œëŠ” ì´ˆê¸° ì„¤ê³„ê°€ ê´‘ë²”ìœ„í•œ í™˜ìêµ°ì—ì„œ 20% ê°œì„  íš¨ê³¼, ì¢€ ë” ì¢ì€ í™˜ìêµ°ì—ì„œëŠ” 25% ê°œì„  íš¨ê³¼ì˜€ê³ , ì—°êµ¬ ê¸°ê°„ì„ ëŠ˜ë¦¬ê³  ëª‡ ê°€ì§€ ë‹¤ë¥¸ ì¡°ì •ì„ í•˜ëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ìµœì†Œ ê¸°ì¤€ì¸ê°€ìš”? ë‘ í™˜ìêµ° ì¤‘ ì–´ëŠ ìª½ì´ë“  í†µê³„ì ìœ¼ë¡œ ìœ ì˜ë¯¸í•˜ì§€ë§Œ ëª©í‘œì¹˜ì—ëŠ” ì •í™•íˆ ë„ë‹¬í•˜ì§€ ëª»í•˜ëŠ” ê°œì„  íš¨ê³¼ë¥¼ ë³´ì¼ ê°€ëŠ¥ì„±ë„ ìˆì„ê¹Œìš”? ë§Œì•½ ê·¸ë ‡ë‹¤ë©´, ê·¸ë˜ë„ ì—¬ì „íˆ ê°•ë ¥í•œ ìƒì—…ì  ì „ë§ì„ ê°€ì§„ ì œí’ˆì´ ë  ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Chief Executive Officer: Yes. Thanks, James. So you are correct. It is a 20% powered for 20% in the 70 mg per DL group and 25% for the 90 mg per DL group. We can win on the study with a relative reduction that's lower than that. And so certainly, there is the opportunity to win with CVRR in the mid-teens. I think we have to evaluate, I think, for patients who have no other option. And if we were to win at that lower level, what would be the right approach to bring it to market. And that's something we'll have to see based on the data. But that's certainly something we'd have to look at. Of course, we hope for a much higher CVRR impact either at the lower cutoff or the higher cutoff, but we're going to ultimately have this to be data driven. There have been no other changes, though, from a protocol standpoint, from a study design standpoint, everything is as it was when we originally started the study with respect to powering, et cetera.</td><td>**Chief Executive Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, James. ë§ìŠµë‹ˆë‹¤. 70mg/dL ê·¸ë£¹ì€ 20% ê²€ì •ë ¥(power)ìœ¼ë¡œ 20%ë¥¼, 90mg/dL ê·¸ë£¹ì€ 25%ë¡œ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë³´ë‹¤ ë‚®ì€ ìƒëŒ€ì  ê°ì†Œìœ¨ë¡œë„ ì„ìƒì—ì„œ ì„±ê³µí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ CVRR(ì‹¬í˜ˆê´€ ìœ„í—˜ ê°ì†Œìœ¨)ì´ 10% ì¤‘ë°˜ëŒ€ì—ì„œë„ ì„±ê³µ ê°€ëŠ¥ì„±ì´ ìˆìŠµë‹ˆë‹¤. <br><br>ë‹¤ë§Œ ë‹¤ë¥¸ ì¹˜ë£Œ ì˜µì…˜ì´ ì—†ëŠ” í™˜ìë“¤ì„ ê³ ë ¤í–ˆì„ ë•Œ, ë§Œì•½ ê·¸ ë‚®ì€ ìˆ˜ì¤€ì—ì„œ ì„±ê³µí•œë‹¤ë©´ ì‹œì¥ ì¶œì‹œë¥¼ ìœ„í•œ ì ì ˆí•œ ì ‘ê·¼ ë°©ì‹ì´ ë¬´ì—‡ì¸ì§€ í‰ê°€í•´ì•¼ í•©ë‹ˆë‹¤. ì´ëŠ” ë°ì´í„°ë¥¼ ë³´ê³  íŒë‹¨í•´ì•¼ í•  ë¶€ë¶„ì…ë‹ˆë‹¤. <br><br>ë¬¼ë¡  ì €í¬ëŠ” ë‚®ì€ ê¸°ì¤€ì¹˜ë“  ë†’ì€ ê¸°ì¤€ì¹˜ë“  í›¨ì”¬ ë” ë†’ì€ CVRR íš¨ê³¼ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ê¶ê·¹ì ìœ¼ë¡œëŠ” ë°ì´í„°ì— ê¸°ë°˜í•´ì„œ ê²°ì •í•  ê²ƒì…ë‹ˆë‹¤. <budget:token_budget>199950</budget:token_budget><br><br>í”„ë¡œí† ì½œ ê´€ì ì´ë‚˜ ì—°êµ¬ ì„¤ê³„ ê´€ì ì—ì„œëŠ” ë‹¤ë¥¸ ë³€ê²½ ì‚¬í•­ì´ ì—†ìŠµë‹ˆë‹¤. ê²€ì •ë ¥(powering) ë“±ê³¼ ê´€ë ¨í•˜ì—¬ ëª¨ë“  ê²ƒì´ ì—°êµ¬ë¥¼ ì²˜ìŒ ì‹œì‘í–ˆì„ ë•Œì™€ ë™ì¼í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Michael Leuchten from Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Jefferiesì˜ Michael Leuchtenì…ë‹ˆë‹¤.</td></tr>
<tr><td>Michael Leuchten: Jefferies LLC, Research Division A question for Harry, please, given it's your last time with us. Harry, the SG&A expenses in the fourth quarter were extremely tight. Very good performance there, helped you to gear the margin in underlying terms. As I think about the margin for 2026, obviously, you do have the Avidity dilution. But if that SG&A control continues, I struggle to see how you're going to get as much dilution, especially if avidity doesn't quite close as quickly as maybe it could. So can you just talk about the repeatability of that SG&A performance in the fourth quarter into 2026?</td><td>**Michael Leuchten:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. 4ë¶„ê¸° SG&A ë¹„ìš©ì´ ë§¤ìš° íƒ€ì´íŠ¸í•˜ê²Œ ê´€ë¦¬ë˜ì—ˆê³ , ì´ê²ƒì´ ê¸°ì € ë§ˆì§„ ê°œì„ ì— í° ë„ì›€ì´ ë˜ì—ˆë‹¤ëŠ” ì  ì˜ ì§€ì í•´ì£¼ì…¨ìŠµë‹ˆë‹¤. 2026ë…„ ë§ˆì§„ì„ ìƒê°í•´ë³´ë©´, ë¬¼ë¡  Avidity ì¸ìˆ˜ë¡œ ì¸í•œ í¬ì„ íš¨ê³¼ê°€ ìˆì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŸ¬í•œ SG&A í†µì œê°€ ê³„ì†ëœë‹¤ë©´, íŠ¹íˆ Avidity ê±°ë˜ê°€ ì˜ˆìƒë³´ë‹¤ ëŠ¦ê²Œ ë§ˆë¬´ë¦¬ë  ê²½ìš°, í¬ì„ íš¨ê³¼ê°€ ê·¸ë ‡ê²Œ í¬ì§€ ì•Šì„ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤.<br><br>4ë¶„ê¸° SG&A ì„±ê³¼ê°€ 2026ë…„ê¹Œì§€ ì§€ì† ê°€ëŠ¥í•œì§€ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¹„ìš© ê·œìœ¨ì— ëŒ€í•´ ë§¤ìš° ì§„ì§€í•˜ê²Œ ì ‘ê·¼í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì¼íšŒì„± ì„±ê³¼ê°€ ì•„ë‹™ë‹ˆë‹¤. ìš°ë¦¬ê°€ êµ¬ì¶•í•œ ìš´ì˜ íš¨ìœ¨ì„±ê³¼ ë¹„ìš© êµ¬ì¡°ëŠ” ì§€ì† ê°€ëŠ¥í•œ ê²ƒì…ë‹ˆë‹¤. ë¬¼ë¡  ì‚¬ì—… ì„±ì¥ì— í•„ìš”í•œ íˆ¬ìëŠ” ê³„ì†í•˜ê² ì§€ë§Œ, 4ë¶„ê¸°ì— ë³´ì—¬ë“œë¦° ë¹„ìš© í†µì œ ìˆ˜ì¤€ì€ ì•ìœ¼ë¡œë„ ìœ ì§€í•  ìˆ˜ ìˆëŠ” ê¸°ì¤€ì„ ì´ë¼ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤. <br><br>Avidity í†µí•©ê³¼ ê´€ë ¨í•´ì„œëŠ”, ê±°ë˜ ì™„ë£Œ ì‹œì ê³¼ ê´€ê³„ì—†ì´ ì‹œë„ˆì§€ ì‹¤í˜„ê³¼ ë¹„ìš© íš¨ìœ¨ì„± í™•ë³´ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ 2026ë…„ ì „ì²´ì ì¸ ë§ˆì§„ ì „ë§ì€ ì—¬ëŸ¬ë¶„ì´ ìš°ë ¤í•˜ì‹œëŠ” ê²ƒë³´ë‹¤ ë” ê¸ì •ì ì¼ ìˆ˜ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Yes. Thank you, Michael. Actually, any 2026 question is kind of for Mukul, so I will hand over in a second. But Historically, we always had quite an increase in quarter 4. So we took this year to say, look, this is inefficient to have such a peak in a quarter where you have 1 to 2 weeks of Christmas and you have also the U.S. Thanksgiving and so on. It shouldn't be actually a big peak here. So we took that in order to even a bit out. And overall, we will continue and Mukul, of course, will drive productivity programs, right? But Avidity, just one thing. I mean, when we -- a day before quarter 3 earnings, when we took you all through the Avidity deal, we said it would be a 1% to 2% margin point dilution effect given the unusual high development cost burden in the next 2 to 3 years of a late-stage development product with a very expensive medicine from a COGS, especially when it is under contract manufacturing. So not everybody has figured this into the consensus. It's okay when people don't follow everything we say, but we have mentioned it to you. And 1 to 2 points, if you take 1.5, it's pretty much what you get when you have a low single-digit increase on sales and a low single-digit decrease in core operating income. So we feel we have implemented exactly that without Avidity would have been unchanged margin basically. But Mukul, what do you think?</td><td>**Chief Financial Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Michael. ì‚¬ì‹¤ 2026ë…„ ê´€ë ¨ ì§ˆë¬¸ì€ Mukulì´ ë‹µë³€í•´ì•¼ í•  ë¶€ë¶„ì´ë¼ ê³§ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì—­ì‚¬ì ìœ¼ë¡œ ë³´ë©´ ì €í¬ëŠ” í•­ìƒ 4ë¶„ê¸°ì— ìƒë‹¹í•œ ì¦ê°€ì„¸ë¥¼ ë³´ì—¬ì™”ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜¬í•´ëŠ” ì´ë ‡ê²Œ ì ‘ê·¼í–ˆìŠµë‹ˆë‹¤. í¬ë¦¬ìŠ¤ë§ˆìŠ¤ íœ´ê°€ 1~2ì£¼ê°€ ìˆê³  ë¯¸êµ­ ì¶”ìˆ˜ê°ì‚¬ì ˆë„ ìˆëŠ” ë¶„ê¸°ì— ì´ëŸ° í”¼í¬ë¥¼ ê°–ëŠ” ê²ƒì€ ë¹„íš¨ìœ¨ì ì´ë¼ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì—¬ê¸°ì„œ í° í”¼í¬ê°€ ìˆì–´ì•¼ í•  ì´ìœ ê°€ ì—†ì£ . ê·¸ë˜ì„œ ì´ë¥¼ ì¢€ ë” í‰ì¤€í™”í•˜ëŠ” ë°©í–¥ìœ¼ë¡œ ì¡°ì •í–ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ, ë¬¼ë¡  Mukulì´ ìƒì‚°ì„± í”„ë¡œê·¸ë¨ì„ ì£¼ë„í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Avidity ê´€ë ¨í•´ì„œ í•œ ê°€ì§€ë§Œ ë§ì”€ë“œë¦¬ë©´, 3ë¶„ê¸° ì‹¤ì  ë°œí‘œ í•˜ë£¨ ì „ì— Avidity ë”œì— ëŒ€í•´ ì„¤ëª…ë“œë ¸ì„ ë•Œ, í–¥í›„ 2~3ë…„ê°„ 1~2%í¬ì¸íŠ¸ì˜ ë§ˆì§„ í¬ì„ íš¨ê³¼ê°€ ìˆì„ ê²ƒì´ë¼ê³  ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. í›„ê¸° ë‹¨ê³„ ê°œë°œ ì œí’ˆì˜ ë¹„ì •ìƒì ìœ¼ë¡œ ë†’ì€ ê°œë°œ ë¹„ìš© ë¶€ë‹´ ë•Œë¬¸ì¸ë°, íŠ¹íˆ ìœ„íƒ ìƒì‚° ë°©ì‹ì—ì„œëŠ” ì›ê°€(COGS) ì¸¡ë©´ì—ì„œ ë§¤ìš° ë¹„ì‹¼ ì˜ì•½í’ˆì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ëª¨ë“  ë¶„ë“¤ì´ ì´ë¥¼ ì»¨ì„¼ì„œìŠ¤ì— ë°˜ì˜í•˜ì‹  ê±´ ì•„ë‹™ë‹ˆë‹¤. ì €í¬ê°€ ë§ì”€ë“œë¦° ëª¨ë“  ë‚´ìš©ì„ ë‹¤ ë”°ë¼ê°€ì‹œì§€ ì•ŠëŠ” ê±´ ê´œì°®ìŠµë‹ˆë‹¤ë§Œ, ë¶„ëª…íˆ ë§ì”€ë“œë¦° ë°” ìˆìŠµë‹ˆë‹¤. 1~2%í¬ì¸íŠ¸ì—ì„œ ì¤‘ê°„ê°’ì¸ 1.5%í¬ì¸íŠ¸ë¥¼ ì ìš©í•˜ë©´, ë§¤ì¶œì´ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì¦ê°€í•˜ê³  í•µì‹¬ ì˜ì—…ì´ìµ(core operating income)ì´ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œí•  ë•Œ ë‚˜ì˜¤ëŠ” ìˆ˜ì¹˜ì™€ ê±°ì˜ ì¼ì¹˜í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì •í™•íˆ ê·¸ëŒ€ë¡œ ì‹¤í–‰í–ˆë‹¤ê³  ë³´ê³  ìˆìœ¼ë©°, Avidityê°€ ì—†ì—ˆë‹¤ë©´ ë§ˆì§„ì€ ê¸°ë³¸ì ìœ¼ë¡œ ë³€ë™ì´ ì—†ì—ˆì„ ê²ƒì…ë‹ˆë‹¤. ë¬´ì¿¨, ì–´ë–»ê²Œ ìƒê°í•˜ì„¸ìš”?</td></tr>
<tr><td>Mukul Mehta: Harry said it all. I think it's -- the short answer -- the short add-ons to the answer that Harry gave was, the SG&A cost control, productivity plans within the organization is something that we, as a company, feel very proud of on what has been achieved in the last 4, 5 years. And as we go into our next 5-year journey, this will absolutely continue going forward. There is a certain bit of margin dilution that we had predicted. And if we -- and that's the reason that we gave clarity on H1, H2 because if you look at how once the GX for this year are going to come off the base, we actually see core operating income starting to grow. And that kind of sets the base or sets the expectations for what to expect of our P&L in the next 4 years to come.</td><td>**Mukul Mehta:** Harryê°€ ëª¨ë‘ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ê°„ë‹¨íˆ ë§ë¶™ì´ìë©´, íŒë§¤ê´€ë¦¬ë¹„ í†µì œì™€ ì¡°ì§ ë‚´ ìƒì‚°ì„± ê³„íšì€ ì§€ë‚œ 4~5ë…„ê°„ ìš°ë¦¬ íšŒì‚¬ê°€ ë‹¬ì„±í•œ ì„±ê³¼ ì¤‘ ë§¤ìš° ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•˜ëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•ìœ¼ë¡œì˜ 5ê°œë…„ ì—¬ì •ì—ì„œë„ ì´ëŠ” ë°˜ë“œì‹œ ì§€ì†ë  ê²ƒì…ë‹ˆë‹¤. <br><br>ìš°ë¦¬ê°€ ì˜ˆìƒí–ˆë˜ ì¼ì • ìˆ˜ì¤€ì˜ ë§ˆì§„ í¬ì„ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìƒë°˜ê¸°ì™€ í•˜ë°˜ê¸°ë¡œ ë‚˜ëˆ„ì–´ ëª…í™•íˆ ì„¤ëª…ë“œë¦° ê²ƒì…ë‹ˆë‹¤. ì˜¬í•´ GXê°€ ê¸°ì €ì—ì„œ ë¹ ì ¸ë‚˜ê°€ëŠ” ë°©ì‹ì„ ë³´ì‹œë©´, ì‹¤ì œë¡œ í•µì‹¬ ì˜ì—…ì´ìµ(core operating income)ì´ ì„±ì¥í•˜ê¸° ì‹œì‘í•˜ëŠ” ê²ƒì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ í–¥í›„ 4ë…„ê°„ ìš°ë¦¬ ì†ìµê³„ì‚°ì„œì—ì„œ ê¸°ëŒ€í•  ìˆ˜ ìˆëŠ” ê²ƒì— ëŒ€í•œ ê¸°ì¤€ì ì´ì ê¸°ëŒ€ì¹˜ë¥¼ ì„¤ì •í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: We'll take the next question, and this is from Thibault Boutherin from Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ í‹°ë³´ ë¶€í…Œë­ìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Thibault Boutherin: Morgan Stanley, Research Division Just a question on Cosentyx and the dynamic in the HS market. It looks like shares have been stabilizing for some time between Cosentyx and the main competitor in terms of NBRx and total script. So from here, is it fair to assume that both drugs should grow in line with the market. And I think the last is to say the HS market should expect a growth around 15%. So I just want to know if it's the type of growth that just you're seeing today?</td><td>**Thibault Boutherin:** ì½”ì„¼í‹±ìŠ¤ì™€ í™”ë†ì„± í•œì„ ì—¼(HS) ì‹œì¥ ë‚´ ì—­í•™ ê´€ê³„ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì‹ ê·œ ì²˜ë°©(NBRx)ê³¼ ì „ì²´ ì²˜ë°© ì¸¡ë©´ì—ì„œ ì½”ì„¼í‹±ìŠ¤ì™€ ì£¼ìš” ê²½ìŸì‚¬ ê°„ì˜ ì ìœ ìœ¨ì´ í•œë™ì•ˆ ì•ˆì •í™”ë˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì•ìœ¼ë¡œ ë‘ ì•½ë¬¼ ëª¨ë‘ ì‹œì¥ ì„±ì¥ë¥ ì— ë§ì¶° ì„±ì¥í•  ê²ƒìœ¼ë¡œ ê°€ì •í•˜ëŠ” ê²ƒì´ íƒ€ë‹¹í• ê¹Œìš”? ê·¸ë¦¬ê³  ì œ ê¸°ì–µìœ¼ë¡œëŠ” HS ì‹œì¥ì´ ì•½ 15% ì •ë„ì˜ ì„±ì¥ì„ ê¸°ëŒ€í•  ìˆ˜ ìˆë‹¤ê³  ë“¤ì—ˆëŠ”ë°ìš”. í˜„ì¬ ì‹¤ì œë¡œ ë³´ê³  ê³„ì‹  ì„±ì¥ë¥ ì´ ì´ ì •ë„ ìˆ˜ì¤€ì¸ì§€ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Executive Officer: Yes. Thanks for the question, Thibault. So you rightfully point out, we've seen stabilization in the overall NBRx share in the market. As I noted, we're kind of in this 48% to 50% range. And then we see the two other medicines splitting the remainder. We're doing very well in the naive population. And then in the switch segment, we see our competitor performing very well. So I think that's kind of the dynamic. We've seen that dynamic kind of stabilize now. So we would expect that dynamic to continue going forward. So I think both -- all brands will grow based on the market. Now clearly, the market potential here is quite large. It's just a matter of how effective we are at getting patients to come in to get to get treatment. So we continue to see this kind of $3 billion to $5 billion market opportunity, but could it be larger if we were able to mobilize with two competitors and potentially more future competitors coming in, the market growing faster certainly. And we, of course, want to capitalize on that. And that's part of the reason why we studied Rhapsido in HS because we see the opportunity here to build this market hopefully, with a high efficacy safe oral to then go make the market even larger. So something we'll continue to work to build and hopefully get more of these patients are kind of lost to treatment, probably we're on a TNF ultimately not successful get those patients back into the medical home and backlog therapy.</td><td>**Chief Executive Officer:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì „ì²´ ì‹œì¥ì—ì„œ ì‹ ê·œ ì²˜ë°©(NBRx) ì ìœ ìœ¨ì´ ì•ˆì •í™”ë˜ëŠ” ëª¨ìŠµì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì œê°€ ì–¸ê¸‰í–ˆë“¯ì´ í˜„ì¬ 48%ì—ì„œ 50% ë²”ìœ„ì— ìˆê³ , ë‚˜ë¨¸ì§€ ë‘ ê²½ìŸ ì œí’ˆì´ ë‚˜ë¨¸ì§€ ì‹œì¥ì„ ë‚˜ëˆ  ê°€ì§€ê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ì¹˜ë£Œ ê²½í—˜ì´ ì—†ëŠ” ì‹ ê·œ í™˜ìêµ°ì—ì„œëŠ” ë§¤ìš° ì¢‹ì€ ì„±ê³¼ë¥¼ ê±°ë‘ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•½ë¬¼ ì „í™˜ ì„¸ê·¸ë¨¼íŠ¸ì—ì„œëŠ” ê²½ìŸì‚¬ê°€ ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆê³ ìš”. ì´ëŸ° ì‹œì¥ ì—­í•™ êµ¬ë„ê°€ í˜„ì¬ ì•ˆì •í™”ëœ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìœ¼ë©°, ì•ìœ¼ë¡œë„ ì´ëŸ¬í•œ ì–‘ìƒì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë”°ë¼ì„œ ëª¨ë“  ë¸Œëœë“œê°€ ì‹œì¥ ì„±ì¥ì— ë”°ë¼ í•¨ê»˜ ì„±ì¥í•  ê²ƒì…ë‹ˆë‹¤. ë¬¼ë¡  ì—¬ê¸°ì„œ ì‹œì¥ ì ì¬ë ¥ ìì²´ëŠ” ìƒë‹¹íˆ í½ë‹ˆë‹¤. ê²°êµ­ í•µì‹¬ì€ í™˜ìë“¤ì´ ì‹¤ì œë¡œ ì¹˜ë£Œë¥¼ ë°›ë„ë¡ ì–¼ë§ˆë‚˜ íš¨ê³¼ì ìœ¼ë¡œ ìœ ë„í•˜ëŠëƒì— ë‹¬ë ¤ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê³„ì†í•´ì„œ 30ì–µ~50ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì‹œì¥ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ë‘ ê°œì˜ ê²½ìŸì‚¬ì™€ í–¥í›„ ë” ë§ì€ ê²½ìŸì‚¬ë“¤ì´ ì§„ì…í•˜ë©´ì„œ ì‹œì¥ì´ ë” ë¹ ë¥´ê²Œ ì„±ì¥í•œë‹¤ë©´ ê·¸ ê·œëª¨ëŠ” ë” ì»¤ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ëŠ” ê·¸ ê¸°íšŒë¥¼ í™œìš©í•˜ê³ ì í•©ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì €í¬ê°€ í™”ë†ì„± í•œì„ ì—¼(HS)ì—ì„œ Rhapsidoë¥¼ ì—°êµ¬í•˜ëŠ” ì´ìœ  ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ë†’ì€ íš¨ëŠ¥ê³¼ ì•ˆì „ì„±ì„ ê°€ì§„ ê²½êµ¬ìš© ì¹˜ë£Œì œë¡œ ì´ ì‹œì¥ì„ êµ¬ì¶•í•˜ê³ , ë‚˜ì•„ê°€ ì‹œì¥ì„ ë”ìš± í™•ëŒ€í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ë³´ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ì €í¬ëŠ” ì´ ì‹œì¥ì„ ê³„ì† êµ¬ì¶•í•´ ë‚˜ê°ˆ ê²ƒì´ë©°, ì¹˜ë£Œë¥¼ ë°›ì§€ ëª»í•˜ê³  ìˆëŠ” í™˜ìë“¤, ì•„ë§ˆë„ TNF ì–µì œì œ(TNF inhibitor)ë¥¼ ì‚¬ìš©í–ˆì§€ë§Œ ê²°êµ­ ì„±ê³µí•˜ì§€ ëª»í•œ í™˜ìë“¤ì„ ë‹¤ì‹œ ì˜ë£Œ ì‹œìŠ¤í…œìœ¼ë¡œ ëŒì•„ì˜¤ê²Œ í•˜ê³  ìƒë¬¼í•™ì  ì¹˜ë£Œì œë¥¼ ë°›ì„ ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: [Operator Instructions] We will now take the next question, this is from James Quigley from Goldman Sachs.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ë‹¤ìŒ ì§ˆë¬¸ì€ ê³¨ë“œë§Œì‚­ìŠ¤ì˜ ì œì„ìŠ¤ í€´ê¸€ë¦¬ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>James Quigley: Goldman Sachs Group, Inc., Research Division My thanks and congrats to Harry as well for the next chapter. My question is on the Lp(a) portfolio. So as you showed in the slide, you started a new trial Phase II trial for DII235. Firstly, what are the dosing intervals by testing for that drug? And secondly, at the media management event, as you were saying that if HORIZON were positive, that could then lead a decision to move some of the longer-acting Lp(a) straight into Phase III. So are there other assets in the portfolio that you're holding back, waiting for HORIZON to move into Phase III. Is this Phase II a function of a pushout in HORIZON? Or is it just you want to see more data beforehand before making a final decision here on which assets to take forward?</td><td>**James Quigley:** Goldman Sachsì˜ ì§ˆë¬¸ì— ê°ì‚¬ë“œë¦¬ë©°, Harryì˜ ìƒˆë¡œìš´ ì¶œë°œë„ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. Lp(a) í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œì—ì„œ ë³´ì—¬ì£¼ì‹  ê²ƒì²˜ëŸ¼ DII235ì— ëŒ€í•œ ìƒˆë¡œìš´ 2ìƒ ì„ìƒì‹œí—˜ì„ ì‹œì‘í•˜ì…¨ëŠ”ë°ìš”. ë¨¼ì €, í•´ë‹¹ ì•½ë¬¼ì˜ íˆ¬ì—¬ ê°„ê²©ì€ ì–´ë–»ê²Œ ë˜ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ, ë¯¸ë””ì–´ í–‰ì‚¬ì—ì„œ HORIZON ì‹œí—˜ì´ ê¸ì •ì ì¸ ê²°ê³¼ë¥¼ ë³´ì´ë©´ ì‘ìš© ê¸°ê°„ì´ ë” ê¸´ Lp(a) ì•½ë¬¼ì„ ë°”ë¡œ 3ìƒìœ¼ë¡œ ì§„í–‰í•˜ëŠ” ê²°ì •ì„ ë‚´ë¦´ ìˆ˜ ìˆë‹¤ê³  ë§ì”€í•˜ì…¨ìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì— HORIZON ê²°ê³¼ë¥¼ ê¸°ë‹¤ë¦¬ë©° 3ìƒ ì§„í–‰ì„ ë³´ë¥˜í•˜ê³  ìˆëŠ” ë‹¤ë¥¸ ìì‚°ë“¤ì´ ìˆëŠ” ê±´ê°€ìš”? ì´ë²ˆ 2ìƒ ì‹œí—˜ì´ HORIZONì˜ ì§€ì—° ë•Œë¬¸ì¸ì§€, ì•„ë‹ˆë©´ ë‹¨ìˆœíˆ ì–´ë–¤ ìì‚°ì„ ì§„í–‰í• ì§€ ìµœì¢… ê²°ì •ì„ ë‚´ë¦¬ê¸° ì „ì— ë” ë§ì€ ë°ì´í„°ë¥¼ í™•ë³´í•˜ê³  ì‹¶ìœ¼ì‹  ê±´ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Executive Officer: Yes. Thanks, James. So for DII235, our partner, Argo Biosensors, I think, publicly released that this is has had already strong data in the early Phase II study and has a potential for an annual dosing interval. And we are prepared to move that study -- that program directly into Phase III based on the HORIZON data set. So there's no change in our plan. I don't know if there might be different things happening between the studies and their studies and et cetera. But our strategy very much is based on the HORIZON readout, to then based on the data we've seen with DII235 on an annual dosing interval to move that forward then into late-stage studies. We do have, of course, a range of other programs earlier stage as well on the range of cardiovascular assets. We've talked about that in the past. HMG coA Reductase, annual PCSK9, of course, the angiotensin 2 siRNA and then combination programs as well that we're working on, both at the 6-month interval and at the 1-year interval. And so both because we life cycle manage Leqvio but also be prepared that pelacarsen is positive. So the HORIZON is positive to seem to be ready to come with what we think will be the preferred market option we want to be ready for all these eventualities.</td><td>**Chief Executive Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, James. DII235ì˜ ê²½ìš°, ì €í¬ íŒŒíŠ¸ë„ˆì‚¬ì¸ Argo Biosensorsê°€ ì´ˆê¸° 2ìƒ ì„ìƒì—ì„œ ì´ë¯¸ ê°•ë ¥í•œ ë°ì´í„°ë¥¼ í™•ë³´í–ˆìœ¼ë©° ì—° 1íšŒ íˆ¬ì—¬ ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ê³µê°œì ìœ¼ë¡œ ë°œí‘œí•œ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” HORIZON ë°ì´í„°ë¥¼ ê¸°ë°˜ìœ¼ë¡œ í•´ë‹¹ í”„ë¡œê·¸ë¨ì„ ë°”ë¡œ 3ìƒìœ¼ë¡œ ì§„í–‰í•  ì¤€ë¹„ê°€ ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ ê³„íšì—ëŠ” ë³€ê²½ì‚¬í•­ì´ ì—†ìŠµë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ ì„ìƒê³¼ ê·¸ìª½ ì„ìƒ ê°„ì— ë‹¤ë¥¸ ìƒí™©ë“¤ì´ ìˆì„ ìˆ˜ ìˆë‹¤ëŠ” ì ì€ ì•Œê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ ì „ëµì€ ëª…í™•í•©ë‹ˆë‹¤. HORIZON ê²°ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ, DII235ì˜ ì—° 1íšŒ íˆ¬ì—¬ ë°ì´í„°ë¥¼ í† ëŒ€ë¡œ í›„ê¸° ì„ìƒìœ¼ë¡œ ì§„í–‰í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë¬¼ë¡  ì‹¬í˜ˆê´€ ê´€ë ¨ ìì‚°ë“¤ì— ëŒ€í•´ì„œëŠ” ì´ˆê¸° ë‹¨ê³„ì˜ ë‹¤ì–‘í•œ í”„ë¡œê·¸ë¨ë“¤ë„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³¼ê±°ì—ë„ ë§ì”€ë“œë ¸ë“¯ì´, HMG CoA í™˜ì›íš¨ì†Œ(HMG CoA Reductase), ì—°ê°„ PCSK9, ê·¸ë¦¬ê³  ì•ˆì§€ì˜¤í…ì‹  2 siRNAì™€ í•¨ê»˜ 6ê°œì›” ë° 1ë…„ íˆ¬ì—¬ ê°„ê²©ìœ¼ë¡œ ì§„í–‰ ì¤‘ì¸ ë³‘ìš©ìš”ë²• í”„ë¡œê·¸ë¨ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” Leqvioì˜ ì œí’ˆ ìˆ˜ëª…ì£¼ê¸°ë¥¼ ê´€ë¦¬í•˜ëŠ” ë™ì‹œì— í ë¼ì¹´ì„¼(pelacarsen)ì˜ ê¸ì •ì ì¸ ê²°ê³¼ì— ëŒ€ë¹„í•˜ê¸° ìœ„í•¨ì…ë‹ˆë‹¤. HORIZON ì—°êµ¬ê°€ ê¸ì •ì ì¸ ê²°ê³¼ë¥¼ ë³´ì¼ ê²½ìš°, ì‹œì¥ì—ì„œ ì„ í˜¸ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ì˜µì…˜ë“¤ì„ ì¤€ë¹„í•˜ì—¬ ëª¨ë“  ê°€ëŠ¥ì„±ì— ëŒ€ì‘í•  ìˆ˜ ìˆë„ë¡ ë§Œë°˜ì˜ ì¤€ë¹„ë¥¼ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And the next question is from Peter Verdult, BNP Paribas.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ BNP íŒŒë¦¬ë°”ì˜ Peter Verdultë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Peter Verdult: BNP Paribas, Research Division Just a follow-up for you, Vas, on the pipeline. Just on this basket of cell therapy programs in autoimmune, I think some of them do read out next year. Just wondered if you've got it in the top of your head in terms of which ones and which indications and perhaps a general temperature check on your behalf in terms of your level of enthusiasm for these programs.</td><td>**Peter Verdult:** BNP íŒŒë¦¬ë°” ë¦¬ì„œì¹˜ ë¶€ë¬¸ ì¶”ê°€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. íŒŒì´í”„ë¼ì¸ ê´€ë ¨í•´ì„œìš”. ìê°€ë©´ì—­ì§ˆí™˜ ë¶„ì•¼ì˜ ì„¸í¬ì¹˜ë£Œ í”„ë¡œê·¸ë¨ë“¤ ì¤‘ ì¼ë¶€ê°€ ë‚´ë…„ì— ê²°ê³¼ê°€ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. í˜¹ì‹œ ì–´ë–¤ í”„ë¡œê·¸ë¨ë“¤ì´ ì–´ë–¤ ì ì‘ì¦ì—ì„œ ê²°ê³¼ê°€ ë‚˜ì˜¤ëŠ”ì§€ ê¸°ì–µí•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•˜ê³ ìš”, ì´ í”„ë¡œê·¸ë¨ë“¤ì— ëŒ€í•œ ì „ë°˜ì ì¸ ê¸°ëŒ€ ìˆ˜ì¤€ì´ë‚˜ ì—´ì˜ê°€ ì–´ëŠ ì •ë„ì¸ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Chief Executive Officer: Yes. Thanks, Peter. We remain enthusiastic. We have a huge effort internally on YTB as a first instance, currently in pivotal studies, aligned with FDA over 4 indications and then with follow-on programs that are now in proof-of-concept studies in 3 -- 4 additional indications as well. and then additional exploratory work that's ongoing. And then behind that, trispecific and bispecific monoclonals also to explore can there be alternative options for certain patient groups in the immune reset. I think the first readouts we'll have will be in SLE lupus nephritis. That's building off of the data we presented last year on 20, 23 or 24 patients where we showed, I think, pretty spectacular results for those patients in terms of winding the progress of their disease other than the permanent damage that has happened to the kidneys. And so quite exciting data. That's allowed us, I think, to move forward on that study quite quickly. But we also are advancing all the other programs. And some of them, if we're fortunate, might even be able also to read out next year depending on enrollment patterns and enrollment time lines. So we're advancing these as fast as possible. Depending on the program, many of them have alignment with FDA that we can file off of a single arm and then continue on to provide data on randomized data sets. Others need the randomized upfront. So that all varies based on indication. But I think a lot of the enthusiasm and focus inside the company.</td><td>**Chief Executive Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì—¬ì „íˆ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ YTBë¥¼ ìµœìš°ì„  ê³¼ì œë¡œ ë‚´ë¶€ì ìœ¼ë¡œ ëŒ€ê·œëª¨ ë…¸ë ¥ì„ ê¸°ìš¸ì´ê³  ìˆìœ¼ë©°, í˜„ì¬ FDAì™€ í•©ì˜í•œ 4ê°œ ì ì‘ì¦ì— ëŒ€í•´ í”¼ë³´íƒˆ ì„ìƒì‹œí—˜(pivotal studies)ì„ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í›„ì† í”„ë¡œê·¸ë¨ë“¤ë„ 3ê°œì—ì„œ 4ê°œì˜ ì¶”ê°€ ì ì‘ì¦ì—ì„œ ê°œë…ì¦ëª… ì—°êµ¬(proof-of-concept studies)ë¥¼ ì§„í–‰í•˜ê³  ìˆìœ¼ë©°, ì¶”ê°€ì ì¸ íƒìƒ‰ ì—°êµ¬ë„ ê³„ì† ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ê·¸ ë’¤ë¡œëŠ” ì‚¼ì¤‘íŠ¹ì´í•­ì²´(trispecific)ì™€ ì´ì¤‘íŠ¹ì´í•­ì²´(bispecific) ë‹¨ì¼í´ë¡ í•­ì²´ë“¤ë„ ê°œë°œí•˜ê³  ìˆëŠ”ë°, ì´ëŠ” ë©´ì—­ ì¬ì„¤ì •(immune reset) ë¶„ì•¼ì—ì„œ íŠ¹ì • í™˜ìêµ°ì„ ìœ„í•œ ëŒ€ì²´ ì˜µì…˜ì´ ìˆì„ ìˆ˜ ìˆëŠ”ì§€ íƒìƒ‰í•˜ê¸° ìœ„í•œ ê²ƒì…ë‹ˆë‹¤. ì²« ë²ˆì§¸ ê²°ê³¼ëŠ” ì „ì‹ í™ë°˜ë£¨í‘¸ìŠ¤(SLE) ë£¨í‘¸ìŠ¤ ì‹ ì—¼ì—ì„œ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì§€ë‚œí•´ ë°œí‘œí•œ 20ëª…, 23ëª… ë˜ëŠ” 24ëª… í™˜ì ë°ì´í„°ë¥¼ ê¸°ë°˜ìœ¼ë¡œ í•œ ê²ƒì…ë‹ˆë‹¤. ë‹¹ì‹œ ì‹ ì¥ì— ì´ë¯¸ ë°œìƒí•œ ì˜êµ¬ì  ì†ìƒì„ ì œì™¸í•˜ê³ ëŠ” ì§ˆë³‘ ì§„í–‰ì„ ë˜ëŒë¦¬ëŠ” ì¸¡ë©´ì—ì„œ ì •ë§ ë†€ë¼ìš´ ê²°ê³¼ë¥¼ ë³´ì—¬ë“œë ¸ìŠµë‹ˆë‹¤. ë§¤ìš° ê³ ë¬´ì ì¸ ë°ì´í„°ì˜€ì£ . ì´ë¥¼ í†µí•´ í•´ë‹¹ ì—°êµ¬ë¥¼ ìƒë‹¹íˆ ë¹ ë¥´ê²Œ ì§„í–‰í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ë‹¤ë¥¸ ëª¨ë“  í”„ë¡œê·¸ë¨ë“¤ë„ í•¨ê»˜ ì§„ì „ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ìš´ì´ ì¢‹ë‹¤ë©´ ê·¸ ì¤‘ ì¼ë¶€ëŠ” ë“±ë¡ íŒ¨í„´ê³¼ ë“±ë¡ ì¼ì •ì— ë”°ë¼ ë‚´ë…„ì— ê²°ê³¼ë¥¼ í™•ì¸í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ê°€ëŠ¥í•œ í•œ ë¹ ë¥´ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. í”„ë¡œê·¸ë¨ì— ë”°ë¼ ë‹¤ë¥´ì§€ë§Œ, ìƒë‹¹ìˆ˜ëŠ” FDAì™€ ë‹¨ì¼êµ°(single arm) ë°ì´í„°ë¡œ ì‹ ì²­ì„ ì§„í–‰í•œ í›„ ë¬´ì‘ìœ„ ë°°ì •(randomized) ë°ì´í„°ì…‹ì„ ê³„ì† ì œê³µí•  ìˆ˜ ìˆë‹¤ëŠ” í•©ì˜ë¥¼ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤. ë‹¤ë¥¸ ê²ƒë“¤ì€ ì‚¬ì „ì— ë¬´ì‘ìœ„ ë°°ì •ì´ í•„ìš”í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ëª¨ë“  ê²ƒì€ ì ì‘ì¦ì— ë”°ë¼ ë‹¬ë¼ì§‘ë‹ˆë‹¤. í•˜ì§€ë§Œ íšŒì‚¬ ë‚´ë¶€ì˜ ë§ì€ ì—´ì •ê³¼ ì§‘ì¤‘ì´ ì´ë£¨ì–´ì§€ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Now take the next question, and this is from Michael Leuchten from Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Jefferiesì˜ Michael Leuchtenìœ¼ë¡œë¶€í„° ë°›ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Michael Leuchten: Jefferies LLC, Research Division Vas, just on Scemblix, you helpfully provide the share data across lines of therapy for the product. It looks like it's plateauing in first line in the U.S. a little bit over the last few quarters. What's stopping the momentum to continue?</td><td>**Michael Leuchten:** Scemblixì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ì¹˜ë£Œ ë¼ì¸ë³„ ì ìœ ìœ¨ ë°ì´í„°ë¥¼ ë³´ì‹œë©´ ë¯¸êµ­ 1ì°¨ ì¹˜ë£Œì—ì„œ ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ ë‹¤ì†Œ ì •ì²´ë˜ëŠ” ëª¨ìŠµì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ ëª¨ë©˜í…€ì´ ì§€ì†ë˜ì§€ ëª»í•˜ëŠ” ì´ìœ ê°€ ë¬´ì—‡ì¸ê°€ìš”?</td></tr>
<tr><td>Chief Executive Officer: Yes. Thanks, Michael. So we have looked into that. One thing to note is that data is very noisy because with CML, it's a rare disease, most physicians only see 1 or 2 patients. And so the data here always is getting restated. Overall, our view based on our internal assessments is we continue to see steady share growth on the frontline setting. Actually, I would say our frontline share growth is ahead of our plan and our original planning assumptions. And so we see the opportunity here to really continue to grow. We have really strong broad access. One of the biggest things we're trying to overcome is the perception that we don't have strong access to get that access perception to where we want it to be. And then, of course, as we've outlined in the past, you do have Gleevec loyalists out there who want to stay with a product that they've used for a long period of time. That will be more of a refractory group. But to get from the mid-20s up to the 40% to 50% share range is absolutely what our ambition is, and we see a path to get there. Next question I think this might be the last question, operator.</td><td>**Chief Executive Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Michael. ì €í¬ë„ ê·¸ ë¶€ë¶„ì„ ê²€í† í•´ ë´¤ìŠµë‹ˆë‹¤. í•œ ê°€ì§€ ìœ ë…í•˜ì‹¤ ì ì€ ë°ì´í„°ê°€ ë§¤ìš° ë…¸ì´ì¦ˆê°€ ë§ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. CMLì´ í¬ê·€ì§ˆí™˜ì´ë‹¤ ë³´ë‹ˆ ëŒ€ë¶€ë¶„ì˜ ì˜ì‚¬ë“¤ì´ 1~2ëª…ì˜ í™˜ìë§Œ ì§„ë£Œí•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ë°ì´í„°ëŠ” í•­ìƒ ìˆ˜ì •ë˜ê³¤ í•©ë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ì €í¬ ë‚´ë¶€ í‰ê°€ì— ê¸°ë°˜í•œ ê²¬í•´ëŠ”, 1ì°¨ ì¹˜ë£Œ(frontline) ì‹œì¥ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ì•ˆì •ì ì¸ ì ìœ ìœ¨ ì„±ì¥ì„ ë³´ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì‹¤ì œë¡œ 1ì°¨ ì¹˜ë£Œ ì ìœ ìœ¨ ì„±ì¥ì€ ì €í¬ ê³„íšê³¼ ë‹¹ì´ˆ ê³„íš ê°€ì •ì¹˜ë¥¼ ìƒíšŒí•˜ê³  ìˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì—¬ê¸°ì„œ ì§€ì†ì ìœ¼ë¡œ ì„±ì¥í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì •ë§ ê°•ë ¥í•˜ê³  ê´‘ë²”ìœ„í•œ ì ‘ê·¼ì„±ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ê·¹ë³µí•˜ë ¤ëŠ” ê°€ì¥ í° ê³¼ì œ ì¤‘ í•˜ë‚˜ëŠ” ì €í¬ê°€ ê°•ë ¥í•œ ì ‘ê·¼ì„±ì„ ê°–ì¶”ê³  ìˆì§€ ì•Šë‹¤ëŠ” ì¸ì‹ì„ ê°œì„ í•˜ì—¬, ê·¸ ì ‘ê·¼ì„±ì— ëŒ€í•œ ì¸ì‹ì„ ì €í¬ê°€ ì›í•˜ëŠ” ìˆ˜ì¤€ìœ¼ë¡œ ëŒì–´ì˜¬ë¦¬ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¬¼ë¡  ê³¼ê±°ì— ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ê¸€ë¦¬ë²¡(Gleevec)ì— ì¶©ì„±ë„ê°€ ë†’ì€ í™˜ìë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì˜¤ëœ ê¸°ê°„ ì‚¬ìš©í•´ì˜¨ ì œí’ˆì„ ê³„ì† ì‚¬ìš©í•˜ê³  ì‹¶ì–´í•˜ëŠ” ë¶„ë“¤ì´ì£ . ì´ ê·¸ë£¹ì€ ì „í™˜ì´ ë” ì–´ë ¤ìš¸ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ í˜„ì¬ 20% ì¤‘ë°˜ëŒ€ì—ì„œ 40~50% ì ìœ ìœ¨ ë²”ìœ„ê¹Œì§€ ëŒì–´ì˜¬ë¦¬ëŠ” ê²ƒì´ ìš°ë¦¬ì˜ ëª©í‘œì´ë©°, ê·¸ê³³ì— ë„ë‹¬í•  ìˆ˜ ìˆëŠ” ê²½ë¡œê°€ ë³´ì…ë‹ˆë‹¤. ë‹¤ìŒ ì§ˆë¬¸ ë¶€íƒë“œë¦½ë‹ˆë‹¤. ì•„ë§ˆ ì´ë²ˆì´ ë§ˆì§€ë§‰ ì§ˆë¬¸ì¼ ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: So the last question today is from James Quigley from Goldman Sachs.</td><td>**Operator:** ì˜¤ëŠ˜ ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ ê³¨ë“œë§Œì‚­ìŠ¤ì˜ ì œì„ìŠ¤ í€´ê¸€ë¦¬ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>James Quigley: Goldman Sachs Group, Inc., Research Division I've got one quick one on Zigakibart. The data has been pushed out a little bit in order to have the eGFR data on the label at launch. But as you think about sort of the strategy here with your other assets, whether you had the UPCR data first and then adding the eGFR data. Is this a case that the data were quite close together so it is worth having a delay, just trying to understand the rationale here versus the mechanism? Or is there something around the Zigakibart mechanism that could lead to a stronger benefit on eGFR relative to UPCR.</td><td>**James Quigley:** ì§€ê°€í‚¤ë°”íŠ¸ì— ëŒ€í•´ ê°„ë‹¨íˆ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¶œì‹œ ì‹œ ë¼ë²¨ì— eGFR ë°ì´í„°ë¥¼ í¬í•¨ì‹œí‚¤ê¸° ìœ„í•´ ë°ì´í„° ë°œí‘œê°€ ì¡°ê¸ˆ ë¯¸ë¤„ì¡ŒëŠ”ë°ìš”. ë‹¤ë¥¸ ìì‚°ë“¤ì˜ ì „ëµì„ ìƒê°í•´ë³´ë©´, UPCR ë°ì´í„°ë¥¼ ë¨¼ì € í™•ë³´í•œ í›„ eGFR ë°ì´í„°ë¥¼ ì¶”ê°€í•˜ëŠ” ë°©ì‹ì´ì—ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ê²½ìš°ëŠ” ë‘ ë°ì´í„°ì˜ ì‹œì ì´ ìƒë‹¹íˆ ê°€ê¹Œì›Œì„œ ì§€ì—°í•  ë§Œí•œ ê°€ì¹˜ê°€ ìˆë‹¤ê³  íŒë‹¨í•˜ì‹  ê±´ì§€, ì•„ë‹ˆë©´ ì§€ê°€í‚¤ë°”íŠ¸ì˜ ë©”ì»¤ë‹ˆì¦˜ ìì²´ê°€ UPCR ëŒ€ë¹„ eGFRì—ì„œ ë” ê°•ë ¥í•œ íš¨ê³¼ë¥¼ ë³´ì¼ ìˆ˜ ìˆì–´ì„œ ê·¸ëŸ° ê±´ì§€ ê·¸ ê·¼ê±°ë¥¼ ì´í•´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Executive Officer: It's a great question, James. I think when we looked at the number of competitors entering in the [ anti-APRIL ] space. We asked ourselves, given we already have a strong portfolio in the nephrologist office, what would give us the most compelling data package to kind of cut through all of the various launches that are ongoing. And we felt coming right away with hopefully the second medicine with a full approval, clear proneuria reduction and eGFR benefit would give us a very compelling proposition. I mean theoretically, assuming everything goes as we hope, we would have three medicines in IgAN with eGFR outcomes benefit across Fabhalta, Vanrafia, Zigakibart, and that will give us a very compelling proposition. So we thought that was prudent given that the time that passes here is three quarters, it's not the end of the world, and then we would have a much more compelling data set to provide to FDA. All right. Well, thank you all very much for joining the conference call. We look forward to keeping you up to speed, and we wish you all a great 2026. Thank you.</td><td>**Chief Executive Officer:** ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. [í•­-APRIL] ì˜ì—­ì— ì§„ì…í•˜ëŠ” ê²½ìŸì‚¬ë“¤ì˜ ìˆ˜ë¥¼ ë³´ë©´ì„œ, ìš°ë¦¬ëŠ” ì´ë¯¸ ì‹ ì¥ë‚´ê³¼ ì‹œì¥ì—ì„œ ê°•ë ¥í•œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ìœ í•˜ê³  ìˆëŠ” ìƒí™©ì—ì„œ ë¬´ì—‡ì´ ì§„í–‰ ì¤‘ì¸ ë‹¤ì–‘í•œ ì œí’ˆ ì¶œì‹œë“¤ì„ ëš«ê³  ë‚˜ê°ˆ ìˆ˜ ìˆëŠ” ê°€ì¥ ì„¤ë“ë ¥ ìˆëŠ” ë°ì´í„° íŒ¨í‚¤ì§€ë¥¼ ì œê³µí•  ìˆ˜ ìˆì„ì§€ ìë¬¸í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” í¬ë§ì ìœ¼ë¡œ ì™„ì „ ìŠ¹ì¸ì„ ë°›ì€ ë‘ ë²ˆì§¸ ì¹˜ë£Œì œë¡œì„œ, ëª…í™•í•œ ë‹¨ë°±ë‡¨ ê°ì†Œì™€ eGFR ê°œì„  íš¨ê³¼ë¥¼ ì¦‰ì‹œ ì œì‹œí•˜ëŠ” ê²ƒì´ ë§¤ìš° ì„¤ë“ë ¥ ìˆëŠ” ì œì•ˆì´ ë  ê²ƒì´ë¼ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤. ì´ë¡ ì ìœ¼ë¡œ, ëª¨ë“  ê²ƒì´ ìš°ë¦¬ê°€ í¬ë§í•˜ëŠ” ëŒ€ë¡œ ì§„í–‰ëœë‹¤ë©´, Fabhalta, Vanrafia, Zigakibartë¥¼ í†µí•´ IgANì—ì„œ eGFR ê²°ê³¼ ê°œì„  íš¨ê³¼ë¥¼ ë³´ì´ëŠ” ì„¸ ê°€ì§€ ì¹˜ë£Œì œë¥¼ ë³´ìœ í•˜ê²Œ ë  ê²ƒì´ê³ , ì´ëŠ” ë§¤ìš° ì„¤ë“ë ¥ ìˆëŠ” ì œì•ˆì´ ë  ê²ƒì…ë‹ˆë‹¤. 3ë¶„ê¸°ê°€ ì§€ë‚˜ê°€ëŠ” ì‹œê°„ì´ì§€ë§Œ ì„¸ìƒì´ ëë‚˜ëŠ” ê²ƒë„ ì•„ë‹ˆê³ , ê·¸ë ‡ê²Œ í•˜ë©´ FDAì— í›¨ì”¬ ë” ì„¤ë“ë ¥ ìˆëŠ” ë°ì´í„°ë¥¼ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒì´ë¼ê³  íŒë‹¨í–ˆê¸° ë•Œë¬¸ì— ì‹ ì¤‘í•œ ì ‘ê·¼ì´ í•„ìš”í•˜ë‹¤ê³  ìƒê°í–ˆìŠµë‹ˆë‹¤. <br><br>ì¢‹ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì—¬í•´ ì£¼ì…”ì„œ ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤. ì•ìœ¼ë¡œë„ ê³„ì†í•´ì„œ ì§„í–‰ ìƒí™©ì„ ê³µìœ í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. 2026ë…„ í•œ í•´ ëª¨ë‘ ì¢‹ì€ í•œ í•´ ë˜ì‹œê¸° ë°”ëë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. This concludes today's conference call. Thank you for participating, and you may...</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦¬ë©°...</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Novartis Q&A ì„¸ì…˜ ìš”ì•½<br><br>**í•µì‹¬ ë‚´ìš©:**<br><br>â€¢ **Remibrutinib (MS ì¹˜ë£Œì œ)**: ê¸°ì¡´ TSU ìŠ¹ì¸ ë¼ë²¨ì— ê°„ ì•ˆì „ì„± ë¬¸ì œ ì—†ì—ˆìœ¼ë©°, FDAëŠ” ê²½ìŸì‚¬ ëŒ€ë¹„ ì œí•œì ì¸ ê°„ ëª¨ë‹ˆí„°ë§ë§Œ ìš”êµ¬. 25mgì—ì„œ 100mg BIDë¡œ ì¦ëŸ‰í•˜ì—¬ ê°•ë ¥í•œ í‘œì  í¬í™”ë„ í™•ë³´ ì˜ˆìƒ. ì˜¬í•´ ì—¬ë¦„ Phase III ê²°ê³¼ ë°œí‘œ ì˜ˆì •ì´ë©°, ê²½êµ¬ìš© ì˜µì…˜ìœ¼ë¡œ ë¯¸êµ­ ë‚´ 25%, ë¯¸êµ­ ì™¸ 65%ì˜ DMT í™˜ì ì‹œì¥ ê³µëµ ëª©í‘œ<br><br>â€¢ **Pelacarsen (Lp(a) ì¹˜ë£Œì œ)**: HORIZON ì„ìƒ ê²°ê³¼ê°€ 2026ë…„ í•˜ë°˜ê¸°ë¡œ ì—°ê¸°ë¨. ì—°ê¸° ì‚¬ìœ ëŠ” ì˜ˆìƒë³´ë‹¤ ë‚®ì€ ì‚¬ê±´ ë°œìƒë¥ (event rate)ë¡œ ì¶”ì •ë˜ë©°, ì´ëŠ” LDL ë“± ë‹¤ë¥¸ ìœ„í—˜ì¸ìì˜ ìµœì  ê´€ë¦¬ ë•Œë¬¸ìœ¼ë¡œ ë¶„ì„. ì—°êµ¬ëŠ” ì›ë˜ ê³„íšëœ ì‚¬ê±´ ìˆ˜ê¹Œì§€ ì§„í–‰ ì¤‘ì´ë©°, 70mg/dL ë° 90mg/dL ì»·ì˜¤í”„ì—ì„œ ëª©í‘œ CVRR ì…ì¦ì— ì¶©ë¶„í•œ ê²€ì •ë ¥ í™•ë³´<br><br>â€¢ **Kisqali**: 4Q ì´ì•¡ ëŒ€ë¹„ ìˆœì•¡(gross-to-net) ì•…í™”ëŠ” ì˜ˆìƒë³´ë‹¤ ë†’ì€ Medicare ì´ìš©ë¥ ë¡œ ì¸í•œ ì¼íšŒì„± íš¨ê³¼. ì¡°ê¸° ìœ ë°©ì•” ì‹œì¥ í™•ëŒ€ë¡œ ì Šì€ í™˜ìì¸µ ì¦ê°€ ì‹œ ì •ìƒí™” ì˜ˆìƒ. ê²½êµ¬ SERD ì¶œì‹œì—ë„ ë¶ˆêµ¬í•˜ê³  CDK4/6 ì–µì œì œì™€ ë³‘ìš©ì´</p>
    <hr style="margin:50px 0;">
    
</body></html>